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ABSTRACT
Adenosine is a potent inhibitor o f inflammatory responses, and the A%A adenosine receptor 
(A2aAR) plays a key role in this process in vivo. This thesis has demonstrated that A2aAR 
gene expression in human umbilical vein endothelial cells (HUVECs) and in C6 glioma 
cells could inhibit multiple inflammatory responses in vitro even in the absence of agonist. 
This is indicated by the reduced induction of the adhesion molecule E-selectin, by over 
70% in HUVECs in response to either TN Fa or LPS isolated from E.coli. In addition, the 
induction of inducible nitric oxide synthase (iNOS) was abolished in C6 glioma cells 
following treatment with interferon-y (IFNy) in combination with LPS or TNFa. This 
suggests that A2aAR expression inhibits a common step in the induction of each o f these 
pro-inflammatory genes. In agreement with this, A2aAR expression was found to inhibit 
the activity of NF-kB, a key transcription factor in the expression o f these pro- 
inflammatory genes. NF-kB binding to target DNA was severely inhibited in both cell 
types however, the mechanisms that mediated this were distinct. A2aAR expression in 
HUVECs inhibited NF-icB translocation to the nucleus independent of any effect on the 
degradation o f hcBa. In contrast, receptor expression in C6  glioma cells could block 
phosphorylation o f IicBa resulting in its reduced degradation. In addition, receptor 
expression could also increase IFNy-mediated degradation of STATl, which may 
contribute to the complete loss o f iNOS expression. Together, these results indicate that 
adenosine acting via the A2aAR can inhibit pro-inflammatory responses by specifically 
inhibiting activation o f the NF-icB and JAK-STAT signalling cascades at multiple steps.
Chapter 1 
Introduction
1.1 General Inflammation
Inflammation is defined as “..a defensive response mediated by the immune system that 
begins after cellular injury to the vasculature” (Villarreal et al., 2001). Many different pro- 
inflammatory stimuli lead to cellular injuiy; microbes, e.g. bacteria and viruses, physical 
agents, e.g. a burn or cut, chemicals, e.g. strong acids or alkalis and/or inappropriate 
immunological reactions to inflammatory stimuli or to self-antigens (auto-antigen; Sullivan 
et al, 2000). This variety of causes mean that inflammation plays a key role in the 
pathogenesis of several different disease states including, septic shock (Van Amersfoort et 
a l,  2003), ischaemia-reperfusion injury (Sullivan et al, 2000), atherosclerosis (Greaves 
and Channon, 2002), rheumatoid arthritis (Firestein, 2003), inflammatory bowel disease 
(IBS; Barbara et a l ,  2002; Carty and Rampton 2003), asthma (Halayko and Amrani, 2003) 
and in neuro-inflammatory diseases such as multiple sclerosis (Bradl and Hohlfeld, 2003), 
stroke (Price et a l ,  2003) and Alzheimer’s disease (Akiyama et a l ,  2000). Consequently, 
intensive research centres on the inflammatory process as effective anti-inflammatory 
therapeutic strategies may provide a wide-ranging solution to several different disease 
states.
Inflammatory processes can be divided into two types: acute or chronic, based on the 
duration of the response. This classification is quite arbitrary as the appearance of the 
lesion, if  accessible, can often give a clearer indication o f the type of inflammation 
(Villarreal et a l ,  2001). Important differences that exist between acute and chronic 
inflammation are described in Table 1.
1.2 Acute Inflammation
Classical symptoms of acute inflammation include redness, heat, oedema and pain, which 
reflect a wide range o f underlying cellular responses (Tortora and Grabowski, 2003). 
These include coagulation (Monroe and Hoffman, 2002; Weyrich et a l,  2003), 
vasodilatory increases in blood flow, increased vascular permeability at the site o f 
infection (Suzuki et a l,  2003; Yuan, 2002), release of fluid (exudate) from the infected 
site, migration and accumulation o f inflammatory leukocytes from blood vessels into the 
tissue (Muller, 2003), formation of granulomatous tissue and ultimately, tissue repair 
(Davis et a l ,  2003). A comprehensive review of all aspects of inflammation is beyond the 
scope of this thesis, consequently, it will focus on the trafficking o f leukocytes and the 
signalling pathways stimulated in response to pro-inflammatory mediators.
The recruitment of leukocytes to sites of inflammation comprises o f three separate stages 
(Figure 1.1), 1) initial recognition and recruitment of leukocytes, 2) firm adhesion between 
leukocytes and the endothelium, and lastly 3) migration o f leukocytes from the blood 
vessel to the inflamed area. Cell types involved in this process include platelets, 
neutrophils, monocytes and macrophages (Weyrich et al., 2003). In addition, non- 
haematopoietic cells such as fibroblasts, smooth muscle cells and endothelial cells also 
play a key role in the inflammatory response. To provide an effective, appropriate 
response, a paracrine and autocrine conmuinication network exists between these different 
cell types. This is mediated via soluble inflammatory mediators such as cytokines e.g. 
tumour necrosis factor a  (TNFa) and interleukin-1 (IL-1), chcmokines e.g. monocyte 
chemoattractant protein (MCP-1) and interleukin-8  (IL-8 ), and growth factors e.g. platelet- 
derived growth factor (PDGF) which will be discussed in Sections 1.4, 1.5 and 1.6 
(Figarella-Branger et al., 2003; Ulbrich et al., 2003). The precise expression and secretion 
o f these pro-inflammatory mediators is essential to all stages of the initial recognition and 
recruitment of leukocytes.
The expression and secretion o f pro-inflammatory mediators is stimulated by the 
recognition of different pathogenic stimuli by receptors expressed at the cell surface. This 
leads predominately to the recruitment of neutrophils to the site of injury. Upon arrival, 
neutrophils roll along the endothelial cell boundary due to weak adhesive interactions 
between adhesion molecules present on both neutrophils and endothelial cells. Effective 
neutrophil recruitment requires the expression o f P- and E-selectin, as Imockout mice show 
impairment in neutrophil adhesion to the endothelium (Jung and Ley, 1999; Robinson et 
al, 1999). This demonstrates the key role selectins play in the adhesion of neutrophils and 
monocytes to the endothelium.
1.2.1 Selectins
Selectins are a family of three type 1 glycoproteins: E-, P-, and L-selectin (Figure 1.1). 
They range in size from 138-212 amino acids long and all have a similar domain structure. 
They consist of an N-temiinal lectin-like domain, an epidermal growth factor (EGF) 
domain, 2 - 9  short consensus repeat domains, a short transmembrane region and a short 
cytoplasmic tail (Ley, 2003). The expression of each selectin is cell type-specific. Thus,
Table 1 Acute versus Chronic Inflammation
This table outlines the key differences between acute and chronic 
inflammation.
Table 1
Acute Inflammation Chronic Inflammation
Duration of 
response
Within seconds or minutes or 
at most hours.
Results after 6  weeks; Can 
last for months, years.
Possible
Symptoms
Redness, Heat, Oedema, 
Pain.
Fever, Tiredness, Systemic 
wasting.
Predominant 
cell type
Neutrophil Macrophage, Lymphocytes
L-selectin is constitutively expressed on leukocytes, some B and T lymphocytes and some 
natural killer (NK) cells, while P-selectin is stored in a-granules of platelets and in Weibel- 
Palade bodies o f endothelial cells and is rapidly transferred to the cell surface upon cellular 
activation. In contrast, E-selectin is inducibly expressed in endothelial cells upon exposure 
to inflammatory stimuli. All selectins bind to fucosylated and sialylated glycoproteins, e.g. 
sialyl Lewis(x), which are expressed on inflammatory target cells. P-selectin weakly binds 
to P-selectin glycoprotein ligand (PSGL) which is found on infiltrating leukocytes (Ulbrich 
et al., 2003). It has been reported that the weak interaction of P-selectin and PSGL-1, can 
be strengthened by its dimérisation with other P-selectin-PSGL-1 pairings (Zimmerman, 
2001). PSGL-1 is also the major ligand for L-selectin in inflammation although L-selectin 
is more important in the homing of T lymphocytes to peripheral lymph nodes. This is 
mediated by L-selectin ligands such as peripheral node addressin molecules expressed on 
high endothelial venules o f secondary lymph organs (Lowe, 2002). E-selectin binds to E- 
selectin-ligand-1 (ESL-1), a ISOlcDa high affinity sialoglycoprotein expressed on the 
surface of infiltrating leukocytes (Mourelatos et al., 1996). LAD-11, a rare leukocyte 
deficiency disease is caused by a mutation in the gene that encodes a fucose transporter. 
This demonstrates the importance of fucosylation in the generation of selectin ligands, 
which are required for effective leukocyte adhesion. As a result, patients suffer from 
bacterial infections of the mucosal membranes and skin (Luhn et al., 2001). The 
interaction of selectins on both the neutrophil and endothelial cell, in addition to the 
presence of cytokines and chemokines, leads to the expression of other types of adhesion 
molecule, which mediate the firm adhesion o f the neutrophil to the endothelium. These are 
members o f the immunoglobulin-like cell adhesion molecule (Ig-CAM) family and 
integrin adhesion molecules.
1,2.2 Immimoglobiilin-like adhesion molecules (Ig-CAM)
Ig-CAMs are transmembrane glycoproteins that are characterised by the presence of 
several Ig-like binding extracellular domains (Figure 1.1). While there are many Ig- 
domain-containing proteins, those important in leukocyte-endothelial interactions are 
intercellular adhesion molecule-1 (lCAM-1), intercellular adhesion molecule-2 (lCAM-2), 
vascular cell adhesion molecule (VCAM) and platelet endothelial cell adhesion molecule 
(PECAM; Bevilacqua et al, 1994). 1C A M -1 contains five Ig-like domains and is expressed 
solely in leukocytes, fibroblasts, and epithelial cells in response to pro-inflammatory 
signals. Once expressed at the surface, lCAM-1 is able to bind to its cognate integrin-
binding partner LFA-1 (aLp2) expressed on infiltrating leukocytes. By contrast, ICAM-2 
which is constitutively expressed by endothelial cells, contains only two Ig-like domains, 
which share 35% amino acid identity with the last two ligand-binding domains of ICAM-1 
(Lehmann et al, 2003). This results in a degree of redundancy between the two ligands, 
however, upon induction, ICAM-1 is predominately expressed in excess of ICAM-2. 
There are also family members ICAM-3-5 but although only ICAM-3 is minimally 
expressed in endothelial cells, it is thought not to be involved in leukocyte interactions 
(Patey et ah, 1996).
There are two isoforms o f VC AM-1, which are generated by alternative splicing. This 
results in either a full-length protein that contains seven Ig-like domains in the N-temiinus 
or a protein that consists of all the domains except domain 4, which results in an adhesion 
molecule with reduced affinity (Figure 1.1; Cybulsky et a l,  1991). Full length VCAM-1 is 
predominately expressed on endothelial cells in response to pro-inflammatory stimuli 
similar to ICAM-1, and will bind to the aivPi integrin expressed on infiltrating leukocytes. 
VCAM-1 ligand binding stimulates NADPH oxidase-dependent production o f reactive 
oxygen species (ROS) by endothelial cells, which are essential for lymphocyte migration 
into inflamed tissue (Matheny et al., 2000).
The primary transcript for PECAM is also subject to alternative splicing resulting in 
several domain-deficient proteins (Wang et al, 2003). These are constitutively expressed 
on endothelial cells, platelets, monocytes, neutrophils and specific subsets of T 
lymphocytes. Possibly because o f its many isoforms, PECAM is able to bind several 
substrates: these include homophillic (Sun et al., 1996) as well as heterophillic interactions 
with proteoglycans (DeLisser et a l, 1993) and integrins (avPs; Buckley., et al., 1996).
1.2.3 Integrins
Integrins each consist o f a non-covalently associated heterodimer of a  and (3 subunits 
comprising large ligand binding domains and short cytoplasmic domains (Figure 1.1). 
Binding of integrins to cognate ligands expressed on infiltrating leukocytes and to 
components o f the ECM, cause changes in the cell cytoskeleton via a domain in their C- 
terminus. There are 19 different a  and 8 different p subunits reported in vertebrates 
leading to many different possible integrin combinations (Shimaoka et a l,  2002). The 
integrins involved in leukocyte-endothelial interactions are those that bind to the Ig-like
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Figure 1.1 Adhesion molecules involved in leukocyte recruitment to inflammatory 
sites
Different adhesion molecules are involved in the recruitment o f leukocytes 
to inflammatory sites. The left panel indicates the predominance of 
selectin-mediated adhesion during the Tolling’ phase of recruitment 
(Section 1.2.1). The right panel indicates the switch to Ig-like cell adhesion 
molecule-integrin interactions during the arrest and transendothelial 
migration of leukocytes (Section 1.2.2 & 1.2.3). (Taken from Ulbrich et al., 
2003)
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cell adhesion molecules. This includes the aL^2 integrin for ICAM-1 and 2, aivPi for 
VCAM-1 and the avPs for PECAM. It is important to note that receptor activation by the 
binding of integrin and Ig-like domain of the cognate CAM, can trigger several signalling 
cascades including the JAK-STAT and MAPK pathways. In addition, integrins can also 
transmit signals out of the cell in a process known as ‘inside-out’ signalling (Miranti and 
Brugge, 2002).
Acute inflammation stimulates induetion o f adhesion molecule expression in a defined 
manner in response to pro-inflammatory stimuli. Firstly, selectin adhesion molecules are 
expressed at the surface within seconds. This is a transient response designed to recruit 
infiltrating neutrophils from peak luminal blood flow to the vascular wall, sometimes 
referred to as ‘rolling’. Cytokine and chemokine-stimulated endothelial cells then express 
Ig-CAMs, which recognise and bind to integrins present on the neutrophil surface. This is 
a fimier adhesive interaction, which prevents further rolling and arrests the neutrophil at 
endothelial cell-eell junctions. Finally the sustained interaction of Ig-CAMs and integrins, 
in addition to the action of cytokines and chemokines, is required to ensure efficient 
neutrophil migration across the endothelial barrier. In this model of acute inflammation, 
the temporal nature of adhesion moleeule expression is important to the effective 
recruitment o f neutrophils. In contrast, this process occurs simultaneously in chronic 
inflammation leading to a much more complex lesion.
1.2.4 Other pro-inflammatory responses
In addition to effects on adhesion molecule expression, pro-inflammatory mediators 
(Seetion 1.4) can also lead to an increase in the generation o f nitric oxide (NO), a potent 
vasodilatory molecule first identified as endothelium-derived relaxing factor (Furchgott 
and Zawadzki, 1980; Janssens et al., 1992). NO is enzymatically generated from the 
eonversion of L-arginine to L-citrulline, by nitric oxide synthase (NOS) o f which there are 
three isoforms: eNOS, nNOS and iNOS. eNOS is eonstitutively expressed on endothelial 
eells, platelets, and some astrocytes, and releases small amounts o f NO that regulate 
vaseular tone (Palmer et al., 1987), inhibit platelet aggregation (Radomski et al., 1987) and 
neuro-transmission (Garthwaite, 1991). nNOS is also constitutively expressed throughout 
the CNS and on nitrergic nerves in the PNS and is also important in neuro-transmission. 
iNOS, in eontrast, is an inducible form of NOS and is expressed in many tissues in 
response to ischaemic, traumatic, neurotoxic, endotoxic or inflammatory insults (Lee et a i,
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2003). iNOS is known to be regulated at the level of transcription by several transcription 
factors including NF-kB, AP-1, and STAT proteins (Nishiya et al., 2000; Ganster et a l,
2001), and their upstream signalling cascades (Nishiya et al., 2000; Xu and Malave, 2000; 
DelPAlbani et a l ,  2001). iNOS also produces 1000-fold excess of NO in response to 
inflammatory mediators compared with eNOS and nNOS, which contributes to the anti- 
mierobial effects in infections and tumour cells. The precise anti-microbial mechanism of 
NO is unclear although, in addition to the aetivation of soluble guanylyl cyclase leading to 
the generation of cGMP, NO can also inhibit cellular respiration via the inhibition of 
mitochondrial cytochrome c complex. At higher concentrations, it can also interact with 
superoxide anions (O2 ) to form peroxynitrite, a strong oxidant that can promote lipid 
peroxidation and nitration of tyrosine residues on target proteins leading to cellular injury 
(Coeroli et al., 1998; Moncada and Higgs, 2001). The production o f reactive oxygen 
species (ROS) and reactive nitrogen species (RNS), can also have non-cytotoxic effects, 
including the modulation of cytokine responses in lymphocytes and the regulation of 
immune cell apoptosis (Bogdan et al., 2000; Garg and Aggarwal, 2002). The regulation of 
NO synthesis, and the subsequent generation of ROS/RNS is critical, as the cytotoxic 
effects o f ROS/RNS, can lead to respiratory, neurodegenerative and chronic inflammatory 
diseases (Moncada and Higgs, 2001; Nevin and Bradley, 2002).
Failure of the acute inflammatory response to deal effectively with the pathogenic stimuli, 
leads to an inappropriately prolonged immune response temied chronic inflammation. 
This is also governed by the aiTay o f pro-inflammatoiy mediators released by the acute 
inflammatory response. Consequently, the accurate expression and seeretion o f these 
inflammatory mediators is essential to the resolution of inflammation and the restoration of 
normal tissue homeostasis.
1.3 Chronic inflammation
Chronic inflammation can be divided into two types dependent upon the degree of 
granuloma tissue fonned within the lesion. Granuloma tissue consists of a localised 
collection o f infiltrating leukocytes and networks of fibroblasts, which continue to grow 
and develop due to the continued presence o f cytokines, chemokines and growth factors. It 
generally has systemie symptoms such as fatigue, weight loss and generalised wasting, 
examples of which are rheumatoid arthritis, and multiple sclerosis (Wakefield and Kumar,
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2001), In contrast atherosclerosis, which exhibits none of these symptoms, is also an 
example o f chronic inflammation because o f the persistent low-level inflammatory 
response following injury to the endothelium, which is a prelude to atherosclerotic plaque 
formation and plaque rupture. This releases a wide array o f thrombogenic agents including 
pro-inflammatory mediators that increase the inflammatory response. This systemic 
leakage also leads to a greater immune response by both the innate and adaptive immune 
system (Greaves and Channon, 2002), The variety of chronic inflammatory diseases is 
attributed to differences in recruited cells of the immune system, the cell-specific 
expression o f pro-inflammatory mediators and the cellular responses generated. This 
underlies the importance o f pro-inflammatory cytokines, chemokines and growth factors in 
chronic inflammation.
1.4 Cytokines
Cytokines are speeific inflammatory mediators that are differentially regulated during 
inflammatory conditions. They have multiple functions and are released from several 
different sources, which act locally to control the inflammatory response. Key examples of 
cytokines involved in the inflammatory process are TN Fa, IL-1 and interferon-y (IFNy), 
which will be explored in more detail.
1.4,1 Tumour Necrosis Factor a  (TNFa)
TN Fa is a homotrimer that is generated by the proteolytic cleavage o f transmembrane 
TN Fa by a metalloprotease TNFa-converting enzyme (TACE; Moss et al., 1997). First 
recognised as a soluble factor responsible for the necrosis o f tumours in mice, it is now 
known to be part of a wider TNF superfamily, members of whieh are ubiquitously 
expressed throughout the vasculature. Each TNF family member binds to a cognate 
receptor found expressed on its target cells, which mediates the downstream effects. There 
are two receptors that are selective for TNFa, namely TNFRl (751cDa) and TNFR2 
(551cDa). TNFRl has been widely studied and comprises o f an N-terminal TN Fa binding 
domain, a short transmembrane region and an intracellular death domain (DD) in its C- 
terminus (Figure 1.2). TN Fa binding results in receptor trimérisation causing the release 
o f the protein, silencer of death domains (SODD; Chen and Goeddel, 2002). This exposes 
the DD of the receptor, which acts as a scaffold for other DD-containing proteins including 
the adaptor protein, TN Fa receptor-associated death domain (TRADD). TRADD binds to
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the receptor and is able to recruit other downstream signalling proteins to the receptor e.g. 
reeeptor-interacting protein (RIP) and TN Fa reeeptor-associated faetors (TRAFs). TRAFs 
are a family of six adaptor proteins (TRA Fl-6 ), which are important in the downstream 
signalling pathways generated by pro-inflammatory receptors belonging to the TNF family 
and IL-1 receptor family. They consist of a C-terminal TRAF domain that is responsible 
for reeeptor recognition, five Zn binding domains and an N-terminal RING finger motif 
(Except TRAF-1), which mediates the signalling properties o f TRAFs (Dempsey et a i,  
2003). The TRAF domain is also required for the formation of homo- or hetero-trimers 
among spécifié TRAF family members (Pullen et al., 1998; Park et al., 1999). T N FR l- 
TRADD interactions lead to the recruitment of TRAF-2. This interacts with several other 
downstream signalling proteins including IkB kinase (IKK; Section 1.8), mitogen- 
activated protein kinase/extracellular-signal-regulated kinase kinase kinase -1 (M EKKl; 
Baud et a l,  1999), apoptosis signal-regulating kinase-1 (ASK-1; Nishitoh et a l,  1998), 
germinal centre kinase (Yuasa et a l,  1998) and the gemiinal centre kinase-related kinase 
(Shi and Kehrl, 2003), which leads to the activation o f nuclear factor-icB (NF-kB; Section 
1.8), c-Jun-N-terminal kinase (JNK) and p38 MAPK (Song et a l ,  1997; Saccani et a l ,  
2002; Platanias, 2003). Activation of JNK and p38 lead to the phosphorylation and 
activation of AP-1 heterodimers, which are important immuno-regulatory transcription 
factors. In addition to the activation of N F-kB, JNK and p38 MAPK, TN Fa can also lead 
to the recmitment o f the protein Fas-associated death domain (FADD). This protein can 
bind to TRADD and to the TNF receptor via its death domain. In contrast to TRADD, it 
also has a death effector domain (DED), which is a binding site for other DED containing 
proteins like proeaspase-8 . Upon recruitment to FADD, pro-caspase 8 undergoes 
proteolytic cleavage, which allows it to target other effector caspases such as caspase-3 and 
caspase-9 leading to apoptosis.
1.4.2 Iiiterleiikin-1
Two forms of interleukin-1 (a  & (3) were first cloned by March et a l,  (1985) and were 
shown to act in concert with TN Fa as a pro-inflammatory eytokine. IL-1 a  and IL -ip  are 
synthesised as pro-IL-1 isoforms and are proteolytic cleaved by IL-1 converting enzyme to 
generate mature proteins o f 17 kDa (Black et a l,  1989). IL-1 is synthesised and released 
by activated macrophages, monocytes and endothelial eells to act on target cells expressing 
interlekin-1 receptors (IL-IR; Figure 1.3; Sims et a l,  1988). The IL-1 receptor eomprises
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Figure 1.2 TN Fa receptor signalling
TN Fa binding induces receptor trimérisation leading to the. release of 
SODD allowing the interaction o f the receptor death domains. Receptor 
trimérisation generates a scaffold for the recruitment o f adaptor proteins 
such as TRADD, FADD, TRAF2 and RIP, which are essential for 
downstream signalling. Recruitment o f TRAF2 and RIP is necessary to 
activate the IKK complex leading to the phosphorylation-dependent 
polyubiquitination of IkB. This results in its degradation by the 268 
proteosome, which allows NF-KB to translocate to the nucleus and activate 
transcription (Section 1.4.1). In addition, TRAF2 is also required for the 
TNF receptor-dependent activation of JNK. Recruitment o f FADD to the 
TNFR causes the recruitment and activation o f Caspase-8  leading to 
downstream signalling events that trigger apoptosis.
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of a single transmembrane protein containing an N-terminal Ig-like domain and a C- 
terminal Toll-like/interleukin-1 (TIR) domain, which interacts with the transmembrane IL- 
IR  aecessory protein (IL-lRAc-P), upon ligand activation. This interaction recruits the 
adapter protein Myd88  via a distinct domain in the C-terminus. This domain is common to 
other inflammatoiy receptors o f the Toll family (Section 1.4.4). Recruitment o f Myd88  
allows the subsequent reeruitment of IL-1 reeeptor associated kinase (IRAK) whose 
subsequent phosphorylation, leads to the recruitment of TRAF 6 . This protein acts as a 
scaffold for the recruitment of several kinases which signal to different downstream targets 
such as NF-kB and JNK. Several additional adapter proteins have recently been 
discovered whose role is as yet unclear including other IRAKs (Wesche et al., 1999), Toll- 
interacting protein (Tollip; Burns et al., 2000), TRAF 6 binding protein (T6BP; Ling and 
Goeddel, 2000), TIR-domain-containing-adapter-protein (TIRP; Bin et a l,  2003), TGF(3- 
activated kinase (TAK) and the accessory proteins TABl (TAK-binding protein) and 
TAB-2 (Takaesu et al., 2000) and evolutionarily conserved signalling intermediate in Toll 
pathways (ECSIT; Kopp et ah, 1999). Activation o f IL-1 signalling leads to the 
transcription of many pro-inflammatory genes such as adhesion molecules, TNF, Cyclo- 
oxygenase (COX-2), inducible nitric oxide synthase (iNOS) and collagenases which all 
participate in the immune response
1.4.3 Interferon gamma (IFNy)
The potent anti-viral properties o f interferons were first identified because of their ability 
to interfere with viral replication (Isaacs and Lindenmann, 1987). In addition, they now 
have several other physiological roles including a role in mierobial defence (Shtrichman 
and Samuel, 2001). They are divided into two types; I and II, with IFNy constituting the 
sole family member of the type II class. It is synthesised and released from natural killer 
(NK) cells, helper T lymphocytes (ThI cells) and cytotoxic T lymphocytes (Tc) (Young, 
1996; Bach et al., 1997), in response to other pro-inflammatory stimuli such as interleukin- 
12 (IL-12; Lammas et al., 2000), IL-18 (Akira, 2000) and TN Fa. IFNy is 17kDa in size 
and functions as a dimer, which binds to the IFNy receptor (IFNyR) expressed on nearly all 
cell surfaces (Ramana et al., 2002). The IFNyR is composed o f two heterologous subunits, 
the IFNyR-a and ~p subunits. Receptor activation leads to heterologous dimérisation and 
the subsequent activation of Janus activated kinase (JAK) signal transduction pathway 
(Darnell et al., 1994). JAKl is recmited to IFNyR-a while JAK2 is recruited to IFNyR-(3
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Figure 1.3 IL-1 receptor signalling
IL-1-mediated binding to the IL-lR-IL-lRA cP complex recruits the adaptor 
protein MyD88  thus recruiting IRAK to the receptor. Autophosphorylation 
of IRAK leads to dissociation from the receptor and the activation of 
TRAF6 . This leads to the formation o f an 
IRAK7TRAF6/TAK1/TAB1/TAB2 complex leading to phosphorylation- 
dependent ubiquitination o f TAKl and TRAF 6 . Active TAKl can then 
phosphorylate further downstream kinases such as the IKK complex and 
MAP kinase, leading to the activation of NF-KB-and AP-1-dependent 
transcription.
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(Shtrictmann and Samuel, 2001). JAK activation leads to tyrosine phosphorylation 
o f signal transducers and activators of transcription (STAT) proteins. 
Phosphorylation of STAT 1 induces homologous dimérisation and translocation to the 
nucleus, where it binds to target genes containing the gamma activation sequence 
(GAS; TTCN3GAA) to initiate transcription. Target genes include interferon 
regulatory faetor (IRF)-l, iNOS and suppressors o f cytokine signalling-1 (SOCS-1). 
This simplistic model of JAK-STAT signalling is regulated in a complex manner by 
the antagonistic interactions of specific STAT family members. For example in 
endothelial cells, STAT3 can antagonise STATl activity. This interaction can be 
frirther regulated by the expression of SOCS-1 (Samuel, 2001).
1.4,4 Lipopolysaeeharide (LPS)
LPS is not a member o f the cytokine family however it is a potent pro-inflammatory 
stimulus. It is a major structural component of the outer wall in Gram-negative 
bacteria and can activate monocytes, macrophages and endothelial cells to produce 
many pro-inflammatoiy eytokines, including TNFa, IL-1, IL-6 , IL-8  and IL-12 
(Cohen, 2002). LPS can initiate effects by binding to a cell-surface receptor-binding 
complex (Figure 1.4). This complex consists of CD 14 (Schumann et aL, 1990; 
Fujihara et al., 2003), a 55kDa transmembrane glycoprotein. Toll-like receptor-4 
(TLR-4; Poltorak et a l,  1998a; Poltorak et a l,  1998b), a member of the Toll-like 
receptor family and myeloid differentiation protein-2 (MD-2), a co-receptor protein 
necessary for efficient TLR-4 expression and LPS recognition (Shimazu et a l ,  1999; 
Silva Correia et al., 2001).
1.4.4.1 Activation of LPS signalling
LPS binding protein (LBP) present in serum, transfers LPS to either membrane- 
bound or soluble CD 14, as studies indicate that endothelial cells and epithelial cells 
lacking membrane-bound CD 14, are still LPS-responsive (Pugin et al., 1994). This 
complex then binds to the TLR-4-MD-2 receptor to initiate LPS responsive signal 
transduction pathways. TLR-4 is a member of the wider Toll-like receptor family, 
which were first characterised in Drosophila, and are important in mediating dorsal- 
ventral polarity in embryonic development (Morisato and Anderson, 1994) and in 
generating the anti-fungal response in Drosophila (Lemaitre et al., 1996). There are 
ten human TLRs which all share a common (Toll-like/Interleukin-1 Receptor (TIR)-
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Figure 1.4 LPS signalling via TLR-4
Activation of the TLR-4 receptor complex leads to the recruitment of 
MyD88  via the TIR domain. This leads to the phosphorylation o f IRAK by 
IRAK-4, which recruits TRAF 6 to the complex. Upon activation, TRAF6 
can interact with the TAK1/TAB1/TAB2 complex that also contains U evlA  
and U bcl3, This leads to the polyubiquitination of TRAF6 and TA K l, 
which activates downstream signalling to IKK and JNK. Taken from 
Takeda and Akira, 2004.
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m otif which generates the downstream signalling from TLRs. This m otif is also 
common to the IL -IR  family o f receptors and consequently, downstream signalling 
events between TLR and IL-IR  can share a eonimon pathway (Imler and Hoffmann, 
2001; Janeway and Medzhitov, 2002; Dunne and O ’Neill, 2003; Takeda et a i ,  2003).
Upon LPS binding to TLR-4, a multiprotein complex is recruited to and assembled at 
the cytoplasmic tail o f the receptor mediated by the Toll-like/IL-1 receptor (TIR) 
domain o f the TLR (Figure 1.4; Takeda et al., 2003). Several different proteins have 
been identified as adaptor molecules for TLR-4. Myeloid differentiation gene 88 
(MyD8 8 ) is a TIR containing TLR adaptor protein, which is recruited to and binds to 
the TIR domains o f TLR-4 (Wesche et al., 1997; Medzhitov et al., 1998). It is also 
reported recently that a M yD8 8 -adaptor like protein Mal/TIRAP can also bind to the 
TIR domain o f TLR-4 (Horng et al., 2001; Fitzgerald et al., 2001), In addition to 
MyD8 8 and Mai, a fiirther TIR interacting protein (Toll interacting protein) Tollip 
can also interact with TLRs 2 , 4 and 6 (Bulut et al., 2001). This interaction is 
reported to negatively regulate TLR signalling, as Tollip overexpression can block 
NF-kB activation in response to TLR-4 agonists (Zhang and Ghosh, 2002). The 
precise detail regarding the complex interactions between TLR-4 and MyD8 8 , Mai 
and Tollip remain to be fully elucidated.
Following M yd88  recruitment to TLR-4, IL-1 receptor associated kinase (IRAK) is 
recruited to the receptor via an interaction between the DD present on both proteins, 
where it becomes phosphorylated by IRAK-4 (Suzuki et al., 2002). The IRAK 
family consists of four members to date, IRAK-1, IRAK-2, IRAK-4 and IRAK-M 
which contain a conserved DD and kinase domain: (Li et al., 2002). Each kinase is 
reported to interact with TLR-4 although the variety of upstream adaptor molecules 
may explain the non-specific nature of these interactions (Janssens and Beyaert, 
(2003). IRAK-4 has been reported as the most significant interaction as IRAK-4 
deficient mice show almost no inflammatory responses to LPS or IL-1 (Suzuki et al.,
2002). Activated IRAK will then interact with TRAF6  a member of the TNF 
receptor associated factor family leading to the downstream activation o f NF-kB and 
JNK. Activation of TLR-4 signalling leads to the transcription o f many pro- 
inflammatory genes such as adhesion molecules, TN Fa, cyclo-oxygenase (COX-2),
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inducible nitric oxide synthase (iNOS) and collagenases which all participate in the 
anti-inflammatory response.
1.5 Chemokines
Chemokines are a large family o f small (7-14 kDa) cysteine rich chemoattractant 
proteins that are central to the inflammatory response (Homk, 2001). Secreted by 
leukocytes and other haematopoetlc cells they are classified into four different 
groups according to the position of conserved cysteine residues within the N- 
terminus: C, CC, CXC, CX3C. Each chemokine binds to cognate receptors which 
belong to the G-protein coupled receptor (GPCR) family, a large family of 
transmembrane glycoproteins which will be discussed in detail later (Section 1.11). 
All chemokines contain a heparin-binding site defined by a highly basic helical 
region toward the C-tenninal end o f the protein. It is thought that 
glycosaminoglycans (GAGs) expressed on the surface o f endothelial cells, bind to 
chemokines through an interaction with the heparin-binding site, a highly basic 
helical region located close to the C-terminal end o f the chemokine. Experimental 
evidence for the formation o f solid phase chemokine gradients was provided by 
Tanaka et al. (1993), who showed that macrophage inflammatory protein (MIP-1) 
could be immobilized by binding to proteoglycan, and that the immobilized 
chemokine could induce the binding o f T cells to VCAM-1 in vitro. This can 
therefore generate a stable gradient for the effective reeruitment o f leukocytes. Two 
of the most important chemokines in leukocyte recruitment are MCP-1 (CCL2) and 
IL-8  (CXCL8 ) (Gerszten et al., 1999).
1.5.1 Monocyte chemoattractant protein-1 (MCP-1)
MCP-1 is prototypical CC family chemokine that was first isolated from LPS- 
stimulated human monocyte supernatants by Matsushima e? a/., (1989). It conforms 
to a general chemokine structure comprising a flexible N-terniinus, three anti-parallel 
p-sheets arranged in a ‘Greek key’ formation and an a-helix in the C-terminus 
(Mukaida et al., 1998). It is secreted primarily by endothelial cells, which recruits 
monocytes and basophils to sites of inflammation. In addition to its chemotactic 
role, it can also stimulate respiratory burst, increases in p2-integrin adhesion
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Table 2 Toll-like receptors and their ligands
The table describes the array o f ligands for members of the Toll-like 
receptor family.
TLR Family member Some TLR Ligands
TLR-1 Tri-acyl lipoproteins,
TLR-2 Peptidoglycan, Bacterial lipoproteins
TLR-3 Double-stranded RNA
TLR-4 LPS (Gram negative)
TLR-5 Flagellin
TLR -6 Di-acyl lipoproteins
TLR-7 Imidazoquinoline (synthetic compound)
TLR -8 ?
TLR-9 Unmethylated CpG DNA
TLR-10 ?
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molecule expression and the secretion o f IL-1 and IL -6  (Rollins et ah, 1989; Jiang et 
ah, 1992). In basophils it can also stimulate leukotriene and histamine release. 
These effects are mediated by the CCR2 chemokine receptor, which is expressed by 
monocytes, B and T lymphocytes and is modulated by pro-inflammatory mediators 
LPS, TNFa, IL-1 and IL-6  (David and Mortari, 2000).
1.5.2 Interleukin-8 (IL-8)
IL -8  is a potent CXC chemokine, required for the recruitment of neutrophils to sites 
of inflammation. Produced in vitro by a wide variety o f cell types including 
monocytes, neutrophils and vascular endothelial cells, in response to pro- 
inflammatory cytokines and LPS, IL -8  binds to two different receptors CXCRl and 
CXCR2 expressed on neutrophils (Matsushima et ah, 1989; Baggiolini et ah, 1994). 
Different pro-inflammatory stimuli can also regulate receptor expression, for 
example, unlike CXCRl, CXCR2 expression is increased by neutrophil exposure to 
TN Fa (Asagoe et ah, 1998). The active form of IL-8  is 79 amino acids long and 
conforms to the general chemokine structure. Ligand binding o f IL -8  to CXCRl and 
CXCR2 activates Gaii, which initiates several signal transduction pathways 
including the activation of phoshoinositide-specific phosphlipase C, protein kinase C 
(PKC), small GTPases, Sre-related protein kinases and protein kinase B/Akt. The 
multitude o f signalling pathways activated lead to the plethora o f IL-8 -stimulated 
effects including changes in cell morphology, the generation of ROS, the expression 
o f bioactive lipids and the increase in adhesion molecule expression (Harada et ah, 
1996; Mukaida et ah, 1998; David and Mortari, 2000).
The regulated expression o f cytokines and chemokines co-ordinate the cellular 
response, which mediates the effective destruction and removal o f the initial 
pathogenic stimuli. In the latter stages o f inflammation, the secretion and expression 
o f growth factors is essential to the efficient repair o f damaged tissue and the 
restoration of homeostasis.
1.6 Growth factors
Growth factors such as platelet-derived growth factor (PDGF) are an essential 
requirement for tissue re-modelling that accompanies repair to damaged tissue.
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following inflammation. They also play a role in switching off the pro-inflammatory 
immune response in order to prevent chronic activation.
1.6.1 Platelet-derived growth factor (PDGF)
PDGF is a potent stimulator of growth and migration of connective tissue cells 
including fibroblasts and smooth muscle cells and also o f other cell types including 
neurons and endothelial cells. Homodimeric PDGF-AA and PDGF-BB and 
heterodimerie PDGF-AB are synthesised and released by many cell types including 
vascular endothelial eells, smooth muscle cells and platelets. All isoforms act at two 
distinct protein tyrosine kinase receptors, PDGF-a (170 kDa) and PDGF-[3 (180 
kDa) which are expressed on a variety of epithelial, endothelial and neural cell types. 
Consistent with other receptor tyrosine kinase receptors, the PDGF receptors undergo 
autophosphorylation upon ligand binding. This recruits several Src-homology-2 
(SH2) domain-containing proteins to the receptor including phosphoinositide-3- 
kinase (PI3K), phospholipase C (PLC), Grb2/S0S, SHP-2 and STAT proteins that 
activate downstream signalling pathways, which promote wound healing following 
inflammation (Heldin et a l,  1998; Heldin and Westermark, 1999).
Many o f the actions of cytokines, chemokines and growth factors are controlled at 
the level o f transcription by several transeription factors such as NF-kB, AP-1, and 
STAT proteins. NF-kB is a key transcription factor responsible for many pro- 
inflammatory signals which will be explored in more detail.
1.7 Activation of NF-kB
NF-kB plays a central role in controlling gene expression of proteins involved in cell 
survival and inflammatory responses. The inducibility o f NF-kB target genes in 
response to a diverse range o f stimuli is essential to this role. Different pathogenic 
stimuli activate NF-icB-dependent transcription of target genes, which include Bcl-2, 
cellular inhibitor o f apoptosis (cIAP) proteins, E-selectin and ICAM-2 via different 
mechanisms. For example, NF-kB activation in response to TN Fa, has been widely 
studied and many o f the proteins involved in the cascade have been characterised. In 
contrast, stimuli such as oxidative stress and X-rays are believed to cause NF-KB
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activation by a different mechanism via an as yet undetermined pathway (Imbert et 
al, 1996; Canty era /, 1999).
NF-kB is localised in the cytoplasm of unstimulated cells, in an inactive state bound 
to a member of the IkB family o f inhibitory proteins (Ghosh et al, 1998; Figure 1.5, 
1.6). The degradation o f this inhibitor upon signal-induced activation has been 
regarded as the conventional model by which NF-icB is activated (Baeuerle et al, 
1988). This exposes the NLS o f NF-icB thereby allowing N F-kB to translocate to the 
nucleus to activate transcription. Many aspects of the signalling pathway that leads 
to the degradation of IkB family members have been elucidated. Briefly, stimuli- 
specific signalling pathways converge on the IkB kinase (IKK) which is a multi­
protein complex comprising of IKKa/1, IKKp/2 and IKKy/NF-icB-essential 
modulator (NEMO). This specifically phosphorylates IkB at particular residues that 
prime IkB for polyubiquitination. This targets IkB for proteolytic degradation by the 
26S proteosome such that NF-icB-dependent transcription can occur. This outline 
misrepresents the complexity o f NF-KB signalling which involves multiple protein- 
protein interactions between the different members, whieh I will now explore in 
more detail.
1.7.1 IkB Kinase (IiaC)
In 1997, five papers were published that used molecular cloning techniques to 
identify a novel cytokine-responsive iKB-kinase complex that was not dependent on 
ubiquitination to aehieve IkB phosphorylation. Three o f these papers described a 
900 kDa complex that specifically phosphorylated iKBa at S32 and S36, and IkBP at 
S19 and S23, upon TN Fa stimulation (DiDonato et al, 1997; Mercurio et al, 1997; 
Zandi et al, 1997). This complex contained two polypeptides (85 IcDa and 87 kDa in 
size) associated with kinase activities that were eluted on affinity columns (DiDonato 
et al, 1997). DiDonato et a l (1997) subjected the 85 IcDa polypeptide to 
microsequencing and showed it to contain sequences identical to a human 
serine/threonine kinase named CHUK (Conserved Helix-loop-helix Ubiquitous 
Kinase). Its function was unknown, but with the identification o f it now as an IkB- 
kinase, CHUK was renamed IKK (IicB kinase; Connelly et al, 1995). In addition.
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Figure 1.5 Activation of NF-kB by different extracellular stimuli.
Many different extracellular stimuli can activate the N F-kB signalling 
cascade. (See sections 1.4.1, 1.4.2, and 1.4.4.) In general, receptor 
activation leads to the recruitment o f several stimuli-dependent adaptor 
proteins e.g. TRADD, MyD8 8 . This causes the recruitment o f kinases that 
can activate the IKK complex. This complex specifically phosphorylates 
IkB resulting in its polyubiquitination-mediated degradation via the 26S 
proteosome. Several kinases can then phosphorylate N F-kB prior to its 
nuclear translocation. The phosphorylation o f p65 directs the association 
with HATs that in concert with N F-kB, direct transcription o f target genes. 
Adapted from Israel, 2000.
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Mercurio et al, (1997) and Zandi et aï, (1997) showed that the 87 IcDa polypeptide 
was also similar to CHUK, sharing 52% homology with the 85 kDa polypeptide. In 
addition, it was more efficient at phosphorylating IicSp. Therefore, the two 
polypeptides were re-named IK X a (85 l<Da) and IKTCp (87 kDa). Using a yeast two- 
hybrid screen for N F-kB -inducing kinase (NIK)-interacting proteins, Regnier et al, 
(1997) also identified IKKa. NIK was previously was reported to activate N F-kB in 
response to TN Fa and IL -ip , whilst inactive NIK mutants inhibited NF-icB 
activation (Malinin et aL, 1997), suggesting that NIK is a probable converging point 
o f both signalling cascades. Woronicz et al, (1997) were also able to isolate IKKp 
from a Jurkat T cell cDNA library, using an EST that shared 57% identity to residues 
624-658 o f IK K a in order to isolate full-length cDNAs. From these papers it 
became evident that phosphorylated IkB was located in the cytoplasm in a larger 
multi-protein complex with other unidentified proteins.
Further immunoprécipitation studies by Rothwarf et al, (1998), identified two extra 
polypeptides of 50 and 52kDa. Microsequencing identified both as different forms 
o f the same protein, which were termed IKKyl and IKKy2. Yamaoka et al, (1998) 
also separately discovered IKKy using a complementation cloning approach, in 
which cDNAs thought to be involved in NF-icB signalling, were transfected into cells 
deficient in NF-kB activity and assayed for restoration o f function. They termed this 
protein NEMO (NF-icB essential modulator; Yamaoka et aL, 1998).
IKKy/NEMO is a glutamine-rich protein, 419 amino acids in length containing no 
kinase catalytic domain. It contains coiled-coiled structural motifs, which facilitate 
binding to IK K a/p heterodimers. Removal of the C-terminus o f NEMO prevents 
signal-induced activation by a variety of stimuli fxirther indicating the significance of 
this regulatory subunit of the IKK complex (Rothwarf et al, 1998). These 
observations helped to establish that the integrity o f the IKK complex was critical for 
phosphorylation of IkB leading to activation of NF-icB. IK K a, IKKp and NEMO 
form a core signalling complex that leads to the phosphorylation of IkB family 
members. In addition to the core IKK complex, a novel IKK-related kinase has also 
been identified called IKKs/IKKi. This kinase is an EPS and PMA-inducible kinase
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whose role in NF-kB activation is less well understood (Shimada et al, 1999; Peters 
et al, 2000; Nomura et al, 2000).
1.7.2 IKK activation
Presently, how various stimuli converge on the IKK complex is not yet clearly 
established. M EK Kl, MEKIC2, MEKK3 and NIK, members o f the MAP3K 
(mitogen-activated protein kinase kinase kinase) family, have all been shown to 
phosphorylate IKK in vitro (Mercurio and Manning, 1999; Nakano et al, 1998). 
However, only MEKK3 has been identified as a physiologically relevant IKK kinase 
in vivo. M EK Kl, which can preferentially bind to IKKp, is also part o f the INK 
pathway. In contrast, NIK, preferentially activates IK K a which depends upon a 
T N Fa pathway component, TNF receptor associated factor type 2 (TRAF 2) (Ling et 
al, 1998). However, the precise role of NIK in IKK activation is unclear as NIK"^" 
laiockout mice are still responsive to TN Fa and IL-1 but not to lymphotoxin-p (LTP) 
(Yin et al, 2001). Nevertheless, when comparing mouse embryo fibroblasts (MEFs) 
from NIK with those from WT, no differences were observed in NF-kB DNA 
binding activity, in response to either stimulus. This evidence suggests NIK may 
mediate NF-kB transcriptional activity in a receptor-specific manner via the IK K a 
subunit.
Other kinases known to activate the IKK complex include TBK/NAK/T2K (TANK 
binding kinase-1/NF-kB activating kinase/TRAF 2-associated kinase) in response to 
PDGF (platelet-derived growth faetor) and the kinase subunit TPL-2 (Tumour 
Progression Locus 2) in response to T-cell signalling (Lin et al, 2000; Tojima et al, 
2000). TPL 2 also performs a major role in pl05 processing to p50 (Belich et al, 
1999), although none of these have shown a direct association with IKK. Aside from 
protein kinases, other molecules can also activate the IKK complex. Latent 
membrane protein-1 (LM Pl), a transmembrane protein expressed in Epstein-Barr 
vims (EBV)-associated carcinomas, results in NF-icB activation by utilising proteins 
in the TN Fa signalling pathway (Sylla et al, 1998). It activates IKK by interacting 
with TRAF2 via its carboxy-terminal domain, laiown as the TESl (Transformation 
Effector Site 1) domain, and with RIP and TRADD (TNFR-associated death 
domain) via a second site known as TES2, Another protein, TAX involved with the
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Human T-cell leukaemia virus (HTLV) has been suggested to activate the IKK 
complex by directly binding to IKKy/NEMO (Geleziunas et al, 1998).
Since proteins other than kinases can also activate the IKK complex directly, it has 
been postulated that protein-protein interaction rather than kinase activity induces 
IKK phosphorylation. For example, TN Fa binding to TNFRl recruits TRADD and 
TRAF 2 and TRAF 6 , which then recruit the kinase complex to the receptor, where 
the protein kinase RIPl can activate IKKl via MEKK (Kelliher et al, 1998; Devin et 
al, 2000). However, IKK activation has been shown not to require RIPl kinase 
activity suggesting kinase activity is not essential for this (Devin et al, 2000). In 
addition, IL-1 stimulation, which utilises IRAKI to activate IKK, also does not 
require its kinase activity for activation purposes (Li et al, 1999). Another kinase 
that appears to activate IKK via protein-protein interactions is PKR, which responds 
to dsRNA, viral infection, and LPS from Gram-negative bacteria (Chu et al, 1999). 
To summarise it is possible that protein-protein interactions facilitate 
autophosphorylation within the IKK complex.
The integration of the many upstream signals leads to the phosphorylation of IK K a 
(S176, S180) and IKKp (S177, S18I; Mercurio et al, 1997). These are conserved 
serine residues present in the activation loops of either catalytic subunit. Gene 
targeting experiments have shown that although cytokines such as TN Fa and IL -lp  
result in phosphoiylation of IK K a and IKKp, IKKp is more necessary for NF-kB 
activation by most pro-inflammatory stimuli (Li et al, 1999; Tanaka et al, 1999). 
However, it is important to note a degree o f specificity, IK K a is required for IKK 
activation in response to RANK (Receptor activator o f NF-kB) protein and the B- 
lymphoeyte stimulator Blys/BAFF (B-lymphocyte stimulator/B-cell activating 
factor; Gao et al, 2001; Claudio et al, 2002). Therefore, although certain signals can 
activate the kinase complex via IKKa, the majority of NF-kB inducers target the 
IKKp subunit. In addition, the IKK complex, although phosphorylating both hcBa 
and IicBp, it will preferentially target IicBp subunits (Zandi et al, 1997). The complex 
regulation of IKK activity by upstream interactions result in the phosphorylation of 
the IkB family o f proteins which we shall discuss in more detail.
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1.7.3 IkB proteins
The IkB family currently comprises eight members; IicBa, p, 5, y, 8 , R and bcl-3 
(Figure 1.6; Ray et al, 1995; Ghosh, et al, 1998; Yamazaki et al., 2001). IkBÔ and 
IkB s are the C-terminal products o f p 100 and pl05 proteolytic processing, forming 
p50 and p52 respectively. All IkB proteins share a conserved domain comprising 
five to seven ankyrin repeats, which are responsible for interactions with NF~kB 
(Lux et al, 1990). Each IkB protein specifically binds to particular N F-kB subunits. 
For example, while IicBa and p, preferentially bind complexes containing RelA, and 
c-Rel, IicBy binds to p50 and p52 homodimers (Thompson et al, 1995; Whiteside et 
al, 1997). p i 00 and p i 05 preeursors complexes with p50, Rel A and c-Rel in the 
cytoplasm. However the IkB members, bel-3 and IicB^ are unique in that they are 
expressed primarily in the nucleus, bcl-3 degradation causes p52-dependent 
repression of transcription (Bours et al, 1993), while IKB^ retains NF-icB proteins in 
the nucleus, instead of the cytoplasm (Yamazaki et al, 2001).
Presently, o f the eight IicB proteins, only IicBa, IicBp and IicBe are known to be 
involved in the signal-induced activation of NF-icB with IicBa being the most 
extensively studied, as it is rapidly degraded in response to most NF-icB-mobilising 
stimuli. It is a 37 IcDa protein that can be divided into three parts; a 70 amino acid 
N-terminus containing a signal response domain, a central protease-resistant 250 
amino acid domain consisting o f six ARD and a final 42 amino acid C-terminus 
comprising o f PEST (proline, glutamic acid, serine, threonine) rich sequences that 
confer rapid IicBa turnover (Lin et al, 1996; Brown et al, 1997; Kroll et al, 1997). 
Crystallographic studies have indicated that the anlcyrin repeats, mask the NLS of 
NF-kB, thereby inhibiting NF-icB activity by impeding access to the nuclear import 
machinery. (Huxford et al, 1998; Jacobs et al, 1998). IicBa also contains a nuclear 
export sequence (NES), which is recognised by the nuclear export protein CRM l 
(Malek et al, 2001). Transcription o f IicB is NF-icB-dependent, consequently, newly 
synthesised IicB is able to enter the nucleus and sequester NF~icB from icB dependent 
promoters. This inhibits NF-icB-dependent transcription by facilitating export to the
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Figure 1.6 The family of NF-kB and IkB proteins.
The vertebrate N F-kB family consists o f five different members which all 
share a highly conserved Rel-homology domain (RHD). Rel A, c-Rel and 
Rel B also contain a transactivation domain necessary for activation o f 
transcription. p50 and p52 are cleaved from larger precursors p i 05 and 
plOO respectively (Section 1.7.5). The C-terminal products o f this cleavage 
are IkBÔ and IkB s respectively, which are two members o f the wider IkB 
family. There are eight IkB family members in total which all contain 
ankyrin repeat regions required for interactions with N F-kB (Section 1.7.4). 
Adapted from Karin and Ben-Neriah 2000
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cytoplasm, using the NES present on ÏKBa (Arenzana-Seisdedos et al, 1995). In 
contrast, IicBp and IkB s degrade less rapidly and this may account for slower 
activation o f NF-icB responsive genes (Thompson et al, 1995; McKinsey et al, 
1996). However, studies in IicBa knockout mice that express a transgene containing 
IicBp under the control o f an IkB a  promoter, suiprisingly indicate some degree of 
redundancy, as IicBp can fldly complement the lack of IicBa (Cheng et al, 1998),
The degradation of IicB proteins occurs via a process laiown as polyubiquitination. 
Ubiquitin is a highly conserved 76 amino acid protein that is added to target proteins 
in three stages. Firstly the C-terminal Gly residue of ubiquitin is activated in a step 
requiring ATP by the E l activating enzyme. Next, the activated ubiquitin is 
transferred to a ubiquitin-carrier protein E2 on a specific Cys residue. Finally, 
ubiquitin is linked to a specific Lys residue o f the target protein via an isopeptide 
linkage mediated by ubiquitin-ligase, E3. This pathway is repeated so that proteins 
become poly-ubiquitinated. This is then used to target the protein to the 26S 
proteosome where the protein is digested. As ubiquitin conjugation occurs at lysine 
residues, site-directed mutagenesis of IicBa identified K21 and K22 as the amino 
acids responsible for this modification (Scherer et al, 1995; Baldi et al, 1996; 
Rodriguez et al, 1996). The polyubiquitinated forms o f IicBa were shown to rely on 
prior phosphorylation as the presence of a S32A/S36A mutation prevents 
phosphorylation or ubiquitination whilst the K21R/K22R mutant was able to undergo 
signal-induced phosphorylation but not ubiquitination, consequently neither mutant 
could be degraded preventing NF-icB activation.
There has been some debate about this model, as the precise location for ubiquitin- 
mediated proteolysis, resulting in IicB degradation, is not yet established. (3- 
TrCP/E3RS, a component involved in the ubiquitination o f IicB appears to be 
exclusively nuclear (Davis et al, 2002). Therefore further investigation is required to 
define the different cellular compartments of this pathway.
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1.7.4 NF-kB
N F-kB was first discovered in 1986 by Sen and Baltimore as a constitutively active 
nuclear factor binding to a site in the kappa-light chain immunoglobulin enhancer in 
B cells (Sen and Baltimore, 1986). Since then it has been identified as a transcription 
factor existing in an inactive state in the cytoplasm o f most cells (Liou and 
Baltimore, 1993). NF-KB transcription is induced by various stimuli, including 
cytokines (e.g. TN Fa, IL-1 P), baeteria, viruses, UV irradiation and hypoxia 
(Baldwin et al, 1996; Pahl, 1999). Aetivated NF-kB regulates the expression of 
numerous target genes involved in survival and inflammatory responses. These 
include genes critieal for inhibiting apoptosis (e.g. bcl-2, cIAP 1 and 2), and genes 
involved in leukocyte trafficking such as adhesion molecules, VC AM and E-selectin 
(Ghosh et al, 2002). Consistent with its importance, dysregulation of N F-kB is 
intimately involved in the pathogenesis o f rheumatoid arthritis, atherosclerosis, 
AIDS, and cancers like Hodgkin’s lymphoma resulting in its intense study to date 
(Baldwin e / Û!/, 1996).
N F-kB transcription factors are a family of structurally related, evolutionary 
conserved proteins that form either homo or hetero-dimers (Ghosh et al, 2002), In 
vertebrates, they are composed from five distinct subunits that share a highly 
conserved 300 amino acid DNA-binding and dimérisation domain known as the Rel 
homology domain (RHD). These subunits can be subdivided into two functional 
groups; those that contain transcriptional activation domains and those that do not. 
The former include p65 (RelA), Rel B, and c-Rel, in whieh each possess at least one 
transcriptional activation domain in their C-terminus (Ryseck et al, 1992; Blair et al, 
1994; Schmitz et al, 1994). The other members o f the family are p i 00 and p i 05, 
which are precursors to the p50 and p52 subunit forms. The precursor forms both 
have large C-terminal regions containing 5-7 ankyrin repeat domains (ARD), which 
allow them to be retained in the cytoplasm. Proteolysis results in shorter proteins, 
which function by forming heterodimers with subunits from the other group, for 
example p50:p65. Indeed the p50 homodimer, lacking a transactivation domain, has 
been identified as a transcriptional repressor (Brown et al, 1994).
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There are several different structural combinations of subunits possible in the 
cytoplasm, o f which p50:p65 NF-kB is the most common. This is found in virtually 
all cell types bound to the inhibitory protein IkBœ (Baeuerle et al, 1988). Following 
stimulation, degradation o f iKBa allows NF-icB to translocate rapidly to the nucleus 
and bind to a KB-binding motif conforming to the sequence, 5’GGGACTTTCC 3’ 
(Kunsch et al, 1992; Parry et al, 1994). Studies have shown that p50 will bind to the 
conserved 5’ end, whilst p65 binds the less conserved 3 ’ end (Urban and Baeurele,
1991). Other types o f NF-kB dimers bind preferentially to different DNA sequence 
elements, contributing to the specificity o f target genes that can be regulated by this 
family of transcription factors.
Crystal structures o f NF-kB bound to DNA have been solved for p50, p52, RelA 
homodimers and the p50/p65 heterodimer (Ghosh et al, 1995; Muller et al, 1995; 
Chen et al, 1998). The crystal structures containing the RHDs o f three Rel/NF-icB 
family polypeptides eomplexed with various DNA targets obtained indicate that the 
RHD is organised into three distinct sub-domains (Ghosh et al, 1995; Muller et al, 
1995; Chen et al, 1998). The amino-terminal 180 amino acids fold into an Ig-like 
domain, connected by a short, 10 amino acid long, flexible linlcer region to a second 
Ig-like domain of approximately 100 amino acids in length. The amino-terminal Ig- 
like domain is involved in DNA recognition while the carboxy-teiTninal Ig-like fold 
is involved in dimérisation. Fourteen residues from each subunit participate in dimer 
formation, which is dominated by Van der Waals interactions. The C-terminal Ig-like 
fold also contains the 13 amino acid nuclear localisation sequence (NLS) required for 
translocation.
1.7.5 Regulation of NF-kB by post-translational modifications
In addition to regulation by IkB proteins, the localisation and transcriptional activity 
o f p65 is regulated by phosphorylation-dependent acétylation (Chen et a l ,  2002). 
Acétylation is a common post-translational modification, which was first associated 
with the regulation o f histone packaging into chromatin fibres. Acetylated histones 
are associated with transcriptionally active segments of chromatin, whereas 
deacetylated histones are present in transcriptionally inactive segments 
(Marmorstein, 2001; Legube and Tronche, 2003). Further studies indicated a range
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of transcriptional coactivator proteins that contained histone acetyltransferase (HAT) 
activity including CBP-associated factor (PCAF), p300/CREB binding protein 
(p300/CBP), TATA-box binding protein associated factor (TAFn250) and steroid 
receptor coactivator (SRC-1; Marmorstein, 2001). Subsequently, proteins were also 
identified which contain histone deacetylase activity, termed ‘HDACs’, which 
actively repress transcription (de Ruijter et aL, 2003).
Phosphorylation o f p65 occurs at different phosphorylation sites S276, S529 and 
S536, which are targeted by several upstream kinases including mitogen- and stress- 
activated protein kinase (M SKl; S276), protein kinase A catalytic subunit (PKAc; 
S276), casein kinase II (CKII; S529), IKK(S536), protein kinase C ( (PKC<;; RHD) 
and Ca^^/calmodulin kinase IV (CaMKIV; C-terminus; Vermeulen et aL, 2002). 
Phosphorylation status is also determined by the activity o f phosphatases; protein 
phosphatase 2A (PP2A) is associated with p65 in unstimulated melanocytes and can 
dephosphorylate p65 following stimulation (Yang et aL, 2001). Phosphorylated p65 
can then enter the nucleus where the specific phosphorylation pattern directs the 
interaction of NF-icB with either p300/CBP or HDACs (Ashburner et aL, 2001; Chen 
et aL, 2002; Kiernan et aL, 2003). Using truncated NF-kB mutants and site-directed 
mutagenesis, several possible Lys residues have been identified as sites for 
acétylation, K122, K123, (Kiernan et aL, 2003) and K218, K221, K310 (Chen et aL,
2002). The precise role for acétylation is still unclear as Chen et aL, (2002) report 
that acétylation at K221 enhances p65-DNA interactions. In contrast, Kiernan et aL, 
(2003) report that acétylation reduces binding of p65 to icB-containing DNA 
promoters and facilitates p65-IicB interactions that direct nuclear export o f p65 via a 
CRM-1 dependent process. Further investigation will be required to identify the 
temporal nature of acétylation and its effects on transcription.
In conclusion, NF-kB is an essential transcription factor required for the effective 
transcription of pro-inflammatory genes. Up-regulation of these genes increases 
surface expression o f proteins, which direct the recruitment of neutrophils, 
monocytes and macrophages to sites o f inflammation. It responds to a diverse array 
o f initial pathogenic stimuli via the integration of signals at the IKK eomplex, which 
leads to the degradation of IkB and the subsequent translocation of NF-kB to the
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nucleus. Post-translational modifications such as phosphoryation of p65 and 
acétylation further regulate NF-kB activity.
1.8 Role of G-protein coupled receptors in iiitlammation
G-protein coupled receptors (GPCRs) play a key role in immune and cellular 
responses. They can bind to a diverse range of important inflammatory ligands that 
include, chemokines, serotonin (5HT), thrombin, histamine and adenosine. As such, 
they represent important sites for potential anti-inflammatory therapeutics. The 
general properties of GPCRs and the specific inflammatory properties o f the 
adenosine family of receptors will be discussed here.
GPCRs are integral membrane proteins that make up the largest protein superfamily, 
consisting of ~ 750 members in human. They are single polypeptide chains that 
contain seven hydrophobic TM-spanning a-helical regions, a hydrophillic 
extracellular N-terminus and an intracellular C-terminus which vary in length. They 
can be divided into four different classes of receptor dependent upon amino acid 
sequence similarity. Class la receptors are termed “rhodopsin-like” owing to the 
similarity between family members and rhodopsin and include receptors for IL-8, 
prostaglandins, prostacyclins, histamine and adenosine. Class Ib receptors are termed 
“calcitonin and secretin-like”, again owing to the similarity between family 
members, which include the glucagon receptor, parathyroid hormone receptor and 
growth hormone releasing-hormone receptor. Class Ic include the thyrotropin 
stimulating hormone and Class II GPCRs include metabotropic glutamate and 
pheromone receptors, which share similarities with other members including Ca^ "^ - 
sensing receptors and y-amino butyric acid (GABA) receptors.
1.8.1 General GPCR signalling
The seven-transmembrane spanning domains o f type la receptors are thought to form 
a central pore accessible to the extracellular surface where it can bind to its cognate 
ligand. Signal transduction across the plasma membrane is activated when the 
receptor binds to its cognate extracellular ligand. This causes a conformational 
change within the structure that is responsible for coupling to and activation of an 
associated heterotrimeric G-protein. This heterotrimeric G-protein can then in turn 
activate downstream effector molecules to initiate intracellular signalling. The
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structure of these receptors was originally identified in studies involving the bovine 
rhodopsin and p2-adrenergic receptors (pzAdR; Dixon et aL, 1986; Henderson et aL, 
1990) with further studies identifying key features that appear to be highly conserved 
throughout all GPCRs. Recently, Palczewski et aL, (2000) solved the crystal' 
structure of rhodopsin, which allows a more accurate description o f the structure.
1,8.2 Structural features of Class la  GPCRs
The TM domains of GPCRs display a relatively constant length with variation in the 
members of this superfamily seen primarily in the N-and C-termini and extracellular 
loop domains. The N-terminal domain has been shown to range from between 340- 
450 residues in mature glycoprotein hormone receptors to less than 10 residues in the 
Aza adenosine receptor. Receptors also vary in the C-tenninal domain, for example 
the metabotropic glutamate receptor (niGluRla) contains 359 amino acid residues 
compared to 2 amino acids for the gonadotrophin releasing hormone receptor 
(GRHR) (Masu et aL, 1991; Brooks et aL, 1993). The third intracellular loop often 
displays a degree o f variability as well with amino acid residues ranging from 239 in 
the m3 muscarinic acetylcholine receptor (niAcliR) (Peralta et aL, 1987) to ~15 
amino acids in the human complement C5a receptor (Gerard and Gerard, 1991; 
Figure 1.7).
In most receptors, the N-terminal domain contains potential sites of N-linked 
gly cosy lation, represented by the sequence Asn-X-Ser/Thr where X is any amino 
acid except proline (Hubbard and Ivatt, 1981). It has not yet been established 
whether all potential N-linked glycosylation sites are functional, but there is evidence 
o f their requirement for receptor expression and ligand binding activity o f GPCRs 
(Segaloff and Ascoli, 1993; Liu et aL, 1993). Class Ib GPCRs, such as receptors for 
endothelin A, B (ETa, ETb) and tlnombin also contain an N-terminal hydrophobic 
leader sequence or signal peptide (Haendler et aL, 1992; Zhong et aL, 1992). This 
sequence directs newly synthesised receptor to the plasma membrane from the 
endoplasmic reticulum and is cleaved off to generate the mature receptor (Von 
Heijne, 1990). Almost all GPCRs contain Cys residues in the first and second 
extracellular loops that form a conserved disulphide bond. This is critical for 
maintaining the tertiary stiiicture o f the receptor as mutations of these residues in 
rhodopsin (Karnik et al, 1998), PzAdR (Dixon et al,  1987) and the muscarinic
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Figure 1.7 X-ray crystallographic structure of rhodopsin, a prototypical C lasslA  
GPCR
GPCRs contain seven transmembrane a-helices (I-VII), an intracellular C- 
tenninus and an extracellular N-terminus. The extracellular surface o f the 
protein contains sites for N-linked glycosylation (Section 1.8.2), Rhodopsin 
also has a C-terminal a-helix (VIII) required for activation (Taken from 
Palczewski et aL, 2000)
Intracellular C-terminus
Extracellular N-terminus
Sites o f Glycosylation
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acetylcholine receptor (mAchR) (Hulme, 1990) result in reduced expression levels, 
aberrant ligand binding properties and altered receptor activation in response to 
agonist. Consistent with a conserved role, Dohlman and colleagues (1990) showed 
that mutation o f these Cys residues in other receptor families resulted in low levels of 
radioligand binding (Dohlman et aL, 1990). The C-terminal domain and third 
intracellular loop of GPCRs typically contain numerous Ser and Thr residues that are 
potential sites of regulation via phosphorylation. This is typically mediated by 
kinases such as G-protein-coup led receptor kinases (GRK) and/or second messenger 
kinases such as protein kinase A (PKA) and protein kinase C (PKC) (Dohlman et aL, 
1987; Kobilka, 1992). These residues are particularly significant for desensitisation 
o f receptor signalling.
Most GPCRs also contain a conserved Cys residue at the N-terminal region of the 
cytoplasmic tail. This has been shown in the PzAdR (O ’Dowd et aL, 1989), 
rhodopsin (Ovchinnikov et aL, 1998) and several other GPCRs (Quanbar and 
Bouvier, 2003) to be a site o f palmitoylation. Palmitate is a saturated 16-carbon fatty 
acid chain that can attach to Cys residues tlnough a labile, reversible thioester 
linkage, regulation of which is controlled by the activation state o f the receptor 
(Wedegaertner et aL, 1995). Sites of palmitoylation are fi'equently found close to 
other lipid modifications, such as myristate or prenyl groups, or to stretches of 
hydrophobic amino acids such as those found in GPCR transmembrane domains 
(Mumby, 1997). This anchorage introduces an additional intracellular loop to the 
molecular structure of the receptor that may affect the interaction o f the receptor with 
the G-protein (Milligan et aL, 1995). Chemical removal o f the palmitate from 
rhodopsin has been reported to enhanee coupling o f the receptor to the G-protein 
transducin (M omson et aL, 1991). In contrast, a PzAdR with mutation o f Cys 341 to 
Ala or Gly (Glycine) resulted in a receptor displaying a dramatic impairment in 
functional coupling to Gs (stimulatory) (O ’Dowd et aL, 1989; Moffett et aL, 1993). 
Cys^^^^Gly was also observed to have an increased phosphorylation level in the 
absence of agonist and displayed no increase in either phosphorylation levels or 
uncoupling from Gg upon agonist stimulation. The properties of the mutant pzAdR 
resembled those of WT receptors that had undergone agonist-induced desensitisation, 
suggesting a role for palmitoylation in regulating the accessibility of the C-terminal
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region to the action o f protein kinases. This data implies that a universal role for 
palmitoylated cysteine residues is unlikely. However, it is possible that these Cys 
residues have varying functions in receptor regulation from interaction with G- 
proteins to receptor turnover, expression and subcellular localisation (Quanbar and 
Bouvier, 2003).
Class I GPCR TM regions contain the greatest degree of amino acid similarity 
among GPCRs with the greatest conservation observed between subtypes of receptor 
families (Probst et aL, 1992). Particularly well conserved throughout the GPCR 
superfamily are Pro residues occurring in TM regions 4, 5, 6 and 7. These residues 
are thought to be important for formation of the ligand-binding pocket in receptors 
such as the mACliR and also for expression of the pzAdR at the cell surface (Strader, 
1989). The sequence Asp-Arg-Tyr (DRY) occurring at the intracellular side of 
transmembrane region 3 is also very highly conserved. The Arg residue is invariant, 
with the Asp and Tyr replaced in very few receptors. For almost all GPCRs, this 
region along with the membrane proximal region of the second intracellular loop, is 
thought to be involved in receptor-G-protein coupling.
1.8.3 Receptor and G-protein interactions
Mutagenesis of TM helices and biochemical experiments using a variety of GPCRs 
suggest that receptor activation causes changes in the orientation o f TM helices 3 and 
6, which was confirmed by the crystal structure o f rhodopsin. The activation of 
rhodopsin causes a 30° rotation in helix 6 causing the separation o f TM helices 3 and 
6. This forms a cleft for the binding o f the Ga-subunit of the G-protein (FaiTcns et 
aL, 1996; Bourne, 1997). Deletion and site-directed mutagenesis studies have 
established that receptor-G-protein interaction relies on the receptors third 
cytoplasmic loop, and in particular, the regions o f the loop lying immediately 
adjacent to TM regions 5 and 6 (Savarese and Fraser, 1992)
Although much is known about the structural features of GPCRs involved in ligand 
recognition and G-protein binding, the mechanisms underlying ligand-induced 
activation and subsequent G-protein coupling remain unclear. The DRY m otif is a 
highly conserved triplet o f amino acids located at the transmembrane region of TM 
helix 3 and the second intracellular loop (Probst et aL, 1992). With the Arg residue
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being âüly  conserved among all Class I GPCRs, mutations of this residue in the M l 
muscarinic and aiB-adrenergic receptor (aieAdR) produced receptors with impaired 
signal transduction properties and it is therefore thought to be a key residue required 
for interaction of receptor with G-protein (Zhu et aL, 1994; Jones et aL, 1995). The 
importance o f the DRY sequence has also been described for rhodopsin, angiotensin 
II (Angll) and the interleukin-8 (IL-8) receptors (Konig et aL, 1989; Ohyama et aL, 
1992; Damaj et aL, 1996).
Analysis of several gain-of-function mutant receptors that result in constitutive 
receptor activity have shown that multiple regions of the receptor including the 
extracellular, intracellular and TM domains may be involved in keeping the receptor 
in a constrained state in the absence o f agonist (Leflcowitz, 1993; Lefkowitz et aL, 
1993; Leff, 1995). In the presence of agonist, conformational changes in the receptor 
lead to a disruption of complex intramolecular interactions that constrain the receptor 
in the inactive state. This causes rearrangement of the TM domains and exposure of 
the cytoplasmic regions to the G-protein to trigger signal transduction (Ulloa-Aguirre 
et aL, 1999).
1.8.4 Regulation of GPCR function
The precise control o f receptor expression and function is critical for the role that 
GPCRs play in inflammation. It is essential that they can respond to rapid changes in 
agonist concentration in a precise manner. Consequently, they are regulated by 
phosphorylation o f specific Serine, Threonine or Tyrosine residues by several 
different kinases. This allows multiple protein-protein interactions that lead to 
receptor desensitisation, sequestration from the cell surface, recycling o f the receptor 
back to the surface and in some cases down-regulation of the receptor. One o f the 
best characterised systems to study these processes is using the pzAdR.
1.8.4.1 Desensitisation
Desensitisation has been defined as the process whereby a GPCR-initiated response 
reaches a plateau and then decreases despite the continued presence o f agonist. It 
can be frirther sub-divided into homologous and heterologous desensitisation. 
Homologous desensitisation causes the desensitisation o f only agonist-stimulated 
receptors. In contrast, heterologous desensitisation causes the desensitisation of both
47
agonist-induced and non-ligand bound receptors. Heterologous desensitisation is 
mediated by phosphorylation o f specific residues by second messenger-activated 
kinases such as PKA and PKC, resulting in a decrease in the ability of the receptor to 
stimulate the associated G-protein (Benovic et aL, 1985; Pitcher et aL, 1992). In 
studies using the PzAdR, Benovic et al, (1991) were able to purify a kinase from 
bovine brain responsible for homologous desensitisation, termed ^-adrenergic 
receptor kinase (pARK), later renamed as G-protein coupled receptor kinase 2 
(GRK2; Benovic et aL, 1991). Seven mammalian GRKs have subsequently been 
cloned to date, termed GRKl-7. GRKs 1 and 7 are expressed exclusively in the eye, 
while GRK 4 is solely expressed in the testis. GRKs 2, 3, 5 and 6 are ubiquitously 
expressed suggesting an important role for these kinases in mediating homologous 
desensitisation for a wide variety of GPCRs.
1.8.4.2 Sequestration
Sequestration is the process whereby agonist stimulated GPCRs, having been 
phosphorylated by GRKs, are removed from the cell surface. This typically requires 
prior receptor phosphorylation and subsequent binding o f an “arrestin’’ protein 
(Pippig et aL, 1993; Diviani et al.,\996; Ferguson et aL, 2002). There are four 
Imown mammalian arrestins, termed arrestin 1-4, which share 45% identity overall. 
AiTcstins 1 and 4 are found only in the eye (Shinohara et aL, 1992; Murakami et aL,
1993) while arrestins 2 and 3 (Lohse et aL, 1990; Sterne-Marr et aL, 1993) are 
ubiquitously expressed and therefore play a general role in sequestration of many 
GPCRs. Binding o f arrestin to phosphorylated GPCRs also results in the uncoupling 
o f activated receptors from the G-proteins, which ‘switch o f f  or arrest GPCR 
intracellular signalling (Btinemann and Hosey, 1999). Arrestins 2 and 3 are also able 
to simultaneously interact with clathrin via a clathrin-binding domain in the C- 
terminus. Clathrin is a ubiquitously expressed protein comprised of three 1901cDa 
heavy chains, each with an associated light chain radiating from a central hub to form 
a triskelion structure (Pearse, 1976). The coat surrounding a phospholipid bilayer is 
made up of triskelions that form a network of pentagons and hexagonal structures 
enclosing the whole stmcture. Sequestration is due to the phosphoiylation o f GPCRs 
by GRKs, the recruitment of arrestin proteins and the recruitment and assembly of 
the clathrin complex around the internalised vesicle. Several other proteins are
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involved in the process of internalisation including dynamin and the Rab GTPases, to 
which the reader is directed to for a more complete review o f receptor internalisation 
(Seachrist and Ferguson, 2003).
In eells expressing PzAdR following agonist stimulation, arrestins have also been 
shown to redistribute to the PM with activated Src (c-Src), a tyrosine kinase that 
phosphorylates She and G abl, proteins involved in Ras dependent activation of ERK 
(Luttrell et aL, 1999). In the absence of arrestin, c-Src was no longer able to associate 
with the PzAdR suggesting a role for arrestins in signalling by acting as a scaffold for 
the docking o f other proteins.
1.8.4.3 Down-regulation
Prolonged agonist exposure over a period of hours results in receptor down- 
regulation, defined as an overall decrease in total receptor number (Gagnon et aL,
1998). Using the PzAdR as a model, it has been suggested that sequestered receptors 
traffic from early endosomes to lysosomes where they undergo degradation. Many 
GPCRs including the thrombin (Hein et aL, 1994), thyrotropin (Petrou et aL, 1997) 
and cholecystokinin (Tarasova et aL, 1997) receptors have been shown to sort to 
lysosomes in an agonist-dependent manner.
After receptors and their ligands have been sequestered from the cell surface by 
clathrin coated vesieles, the vesicles are uncoated and the internalised molecules are 
delivered to ‘early’ sorting endosomes (Rothman and Schmid, 1986). Due to the 
acidic pH in early endosomes, the receptors and ligands are dissociated and the 
receptors are recycled back to the membrane for another round o f agonist activation 
for receptors such as the transferrin receptor and the low-density lipoprotein receptor 
(LDL) (Dautry-Varsat et aL, 1983). Other receptors are degraded by the lysosome 
such as substance P receptor (Koenig and Edwards on, 1997; von Zastrow, 2003). 
The effective regulation of receptor surface expression maintains the sensitivity of 
GPCRs to extracellular concentrations o f agonist which is important in the activation 
o f signal transduction pathways via G-proteins.
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1.9 G-proteins
The term “G-protein” refers to a heterotrimeric plasma membrane-associated GTP- 
binding protein which functions as an intermediary in transmembrane signalling 
pathways to transduce signals across the plasma membrane from activated receptors 
to effector enzymes or ion channels (Albert and Robillard, 2002). Evidence for the 
existence of G-proteins first came from Rodbell and Birnbaumer who described the 
stimulation o f adenylyl cyclase to be dependent upon the presence of GTP (Rodbell 
and Birnbaumer, 1971). It was not until 1981 (Sternweis et aL, 1981) that the first 
G-protein was purified and initially described as a ‘GTP-binding regulatory 
component of adenylyl cyelase’. This 45 IcDa protein is now better laiown as the Gg 
G-protein a-subunit (Gilman, 1987). Consequently, another G-protein was soon 
described as an inhibitory regulatory component o f adenylyl cyclase and termed G; 
(Bokoch et aL, 1983). G-proteins are now laiown to consist o f thiee distinct 
subunits, namely a , p, and y. To date, 27 a , 6 P, and 14 y genes have been cloned 
(Albert and Robillard, 2002). This variety allows a wide degree o f specificity based 
on individual subunit composition.
Classically subunits of the heterotrimerie G-protein partieipate in a cycle of 
association and dissociation that is dependent upon the activation state of the G- 
protein. Upon receptor activation, the Ga-sububnit will dissociate from the 
heterotrimeric complex in response to the binding o f GTP. The released a-subunit 
and Py-subunits can each activate downstream effector proteins. The inherent 
GTPase fLinction o f the a-subunit will then hydrolyse GTP to GDP, which allows the 
G-protein to reassociate with the py-subunit in preparation for another cycle of 
activation. Conventional signalling by G-proteins was until recently thought to 
involve only one type of G a subunit/receptor. This is now known not to be the case 
with several receptors activating more than one type o f G-protein. This is teinred 
“differential G-protein coupling” and is found in a range o f different receptors, 
including the thyrotrophin receptor (Laugwitz et aL, 1996), AzbAR (Gao et aL, 1999) 
and many others (Hur and Kim, 2002; Hermans, 2003). However, the precise 
mechanisms that determine receptor-G-protein coupling specificity remain unclear.
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G-proteins are classified according to the function of the a-subunit (Hamm, 1998). 
Gs and Gi are so-named due to their ability to stimulate and inhibit adenylyl cyclase 
respectively. Gq/n family proteins activates PLCp (Offermans, 1994) and the G 12/13 
family regulate the small GTP-binding protein Rho (Barac et aL, 2003). Activation 
o f the G-protein generates both a  and Py subunits that can each interact with 
downstream effector targets to generate an intracellular response. The downstream 
effectors reportedly regulated by Py-subunits include adenylyl cyclase isoforms, 
(PLCp), inward rectifier G-protein-gated potassium channels, voltage-sensitive 
calcium channels, and PI3K. (Ford et aL, 1998; Hur and Kim, 2002)
1.9.1 Gs proteins
The Gs family o f G-proteins is defined by its ability to stimulate adenylyl cyclase 
activity leading to the generation of cAMP. It has four isoforms, two of 451<Da and 
two o f 47 l<Da in size generated by alternative splicing o f the same gene product 
(Sunahara et aL, 1996). Gs is ubiquitously expressed and is sensitive to cholera toxin 
which catalyses ADP-ribosylation of Arg 201 found within the GTP-binding site 
(Kassis et aL, 1982). This causes a block in the GTPase activity o f the subunit 
rendering it constitutively active, leading to multiple cellular events that characterise 
the pathophysiology of cholera (Enomoto et aL, 1980.)
1.9.2 Gi/Go proteins
The Gi/Go family proteins comprise of Go a, Giza, Gisa, Goi and Goz and are 
classified based on differences in size (Gilman et aL, 1987; Hur and Kim, 2002). 
Defined by the inhibition of adenylyl cyclase activity they can also target other 
downstream signalling components including certain sodium, potassium and chloride 
channels and PLCP (Go; Moriarty et aL, 1990). They are all sensitive to the bacterial 
toxin from Bordatella pertussis. This toxin causes ADP-ribosylation of a conserved 
Cys residue in the C-terminus of the a-subunit. This prevents GDP/GTP exchange, 
leaving the subunit in a permanently inactive GDP-bound state. The retinal-specific 
G-proteins G ^a  and Gtza are also members of this family. They couple stimulation 
of rhodopsin to the activation of retinal cGMP phosphodiesterases (PDEs; Berg et 
aL, 2002).
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1.9.3 Gq family
This family has several members including Gqa, G u a , G n a , and Giea, which are 
insensitive to any o f the toxins previously mentioned and are important in coupling 
GPCR activation to the activation of PLC|3 (Rliee, 2001). PLC(3 catalyses the 
hydrolysis of phosphatidyl inositol-4, 5-bisphosphate (PIP2) to inositol-1,4,5- 
triphosphate (IP3) and 5« -l,2 -diacylglycerol (DAG) which mediate the release of 
Ca^^ and activate PKC respectively. Interestingly with respect to inflammation, 
DAG can be metabolised into arachidonic acid by diacylglycerol lipase. This fatty 
acid is the precursor in the biosynthesis of eicosanoids, pro-inflammatory lipid 
molecules including prostaglandins, prostacyclins and thromboxanes (Berg et aL, 
2002).
1.9.4 G a i2 family
This family comprises of two family members Giz and G 13, each o f which is 441<Da 
in size. The primaiy structure of this family diverges by more than 50% from other 
G-protein sequences. They couple GPCR activation to multiple downstream targets 
such as the Rlio family of small GTP binding-proteins, INK, phospholipase D, and 
non-receptor tyrosine kinases (Offermanns, 2003) which regulate a wide range of 
effects such as actin cytoskeleton remodelling, c-jun activation and transcription. 
Recently they have also been reported to internet with a class o f adhesion molecules 
called “cadherins” . This causes the release of the transcriptional activator p-catenin 
(Meigs et aL, 2001; Meigs et aL, 2002) to regulate transcription. They are 
ubiquitously expressed and are insensitive to cholera or pertussis toxin.
1.9.5 Gpy subunits
In recent years it has been widely acknowledged that Py-subunits also target specific 
effector molecules such as PLCp and adenylyl cyclase (Kim et aL, 1989; Pang and 
Sternweis, 1990; Tang and Gilman, 1991; Vanderbild and Kelly; 2000). It has also 
been reported that there exists py-binding sites on GRK2. This allows regulation of 
GRK2 phosphoiylation and inhibits Gpy signalling (Lodowski et a l ,  2003; 
Eichmann et aL, 2003). With many different subunit combinations possible between 
family members, there exists a great potential for specificity, leading speculation that 
a specific combination o f -P and -y subunits, will activate a specific effector in 
response to specific GPCR activation. For example, piy4 subunits have been shown
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to selectively couple the activation o f muscarinic receptors to L-type calcium 
channels (Kleuss et aL, 1992; Garcia et aL, 1998). In contrast, studies by Quitterer 
and Lohse (1999) studied the synergy between Gi and Gq coupled receptors and 
reported no differences in inositol phosphate accumulation when co-transfected with 
different combinations o f py-subunits (Quitterer and Lohse, 1999). Consequently, 
the specificity of Py-subunits is not yet fully understood.
Several X-ray crystal structures o f GPy subunits have been solved and show an 
overall seven-bladed p-propeller structure, with the y-subunit interacting with the 
coiled-coil domain of the p-subunit (Gautam et aL, 1998). The y-subunit also 
contains a CAAX m otif on its C-terminal region that directs prénylation o f the 
molecule (Resh, 1996; Higgins and Casey, 1996). Prénylation involves the direct 
attachment o f a 15-carbon farnesyl or a 2 0 -carbon geranylgeranyl isoprenoid group 
to the conserved Cys residue within the motif (Casey, 1994). Prénylation is known 
to facilitate Gpy anchorage to the plasma membrane, as mutation o f the conserved 
Cys to Ser resulted in cytosolic expression of G Py-subunits (Muntz et aL, 1992; Gelb 
etaL, 1998).
1.10 Inflammation and Adenosine
Several lines of evidence point to a role for adenosine in the regulation inflammation: 
1) adenosine accumulation during ischemia and inflammation protect tissues from 
injury (Linden, 2001), 2) adenosine inhibits phagocytosis, the generation of reactive 
oxygen species, and adhesion to some surfaces, e.g. endothelial cells (Cronstein,
1994), 3) the anti-inflammatory effects o f sulfasalazine and methotrexate involve an 
adenosine-dependent mechanism (Morabito et aL, 1998), 4) receptors for adenosine 
are found on cells throughout the immune system (Thiel et aL, 2003). Strong 
evidence therefore exists that adenosine has a general anti-inflammatory, however, 
how does it mediate these effects on inflammation?
1.10.1 Adenosine receptors
Adenosine receptors (ARs) belong to the Class lA receptor family and are known as 
purinergic receptors as they the bind the purine agonist adenosine (See Section
1.11.1 Figure 1.8). There are two main types of purinergic receptors: Pi or adenosine
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receptors, and Pz receptors. The Pz receptors recognise and bind to nucleotides such 
as ADP, ATP, UDP and UTP. Pi/ARs can be fiirther subdivided into four distinct 
subtypes, namely AiAR, A zaAR, A zbA R and A3AR (Tucker and Linden, 1993; 
Figure 1.9), which all couple to G-proteins. Pz reeeptors are divided into Pzx and Pzy 
subgroups. The Pzx receptors are ligand-gated ion channels (Benhani and Tsien, 
1987), while the Pzy receptors are GPCRs (Abbracchio and Burnstock, 1994; 
Fredholm et aL, 1994).
There are several structural components within ARs that are found within the general 
Class la  GPCR family (Section 1.8.2). Each receptor has an extracellular N- 
terminus and intracellular C-terminus linked by 7 TM hydrophobic a-helices. 
Within the TM regions, helices 2, 3 and 5 show a large degree o f sequence identity 
and residues within these regions are reported as being crueial for ligand binding and 
specificity. Studies by Klotz et aL, (1998) on the AiAR reported that His residues 
were important in the binding specificity o f agonist and antagonist. His residues 
have also been implicated in ligand binding for the A zaA R  (Jacobson et aL, 1992). 
AiAR, A zaA R and A zbA R receptors contain two such His residues within the TM 
regions and mutations o f these residues to Leu, resulted in receptors having a 
decreased receptor affinity for agonist and antagonist ligands supporting a role for 
these residues in ligand binding (Olah et aL, 1992).
ARs also have consensus sites for N-linked glycosylation (N-X-S/T; Olah et aL, 
1990; Barrington et aL, 1990; Palmer et aL, 1992) on their second extracellular 
loops, although the A3ARS also possesses an additional site on its N-terminus. The 
precise role o f glycosylation is relatively unclear, as it does not play a role in agonist 
binding (Piersen et aL, 1994), although it may be required for efficient receptor 
targeting to the plasma membrane. Conserved Cys residues in the second and third 
extracellular loops, which are predicted to form a disulphide bridge, are also a feature 
of ARs in common with other Class la GPCRs. This is reported as being essential to 
the pharmacology of the receptor, as treatment with inereasing concentrations of 
dithiothreitol decreases agonist affinity (Mazzoni et aL, 1997).
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Figure 1.8 The structure of adenosine and the AzAAR-selective drugs CGS21680, 
NECA and ZM241385.
The chemical structure of the endogenous ligand adenosine, the AgAR- 
selective agonist NECA, the AzAAR-selective agonist CGS21680 and the 
AzaAR antagonist ZM241385 are shown. Both CGS21680 and NECA 
contain an adenine ring and ribose group similar to the endogenous 
adenosine, while ZM241385 is distinctly different in strueture. (Taken from 
Olah and Stiles, 2000)
N ''-p ositionNH,
HOCK
5'-p osition
HO OH
adenosine
Agonists
NK.
• N
H0,G(CH,)£ -^ 0>-(CHah>NH
CH3CH2NI-ICP o
CGS 21680 HO OH
NH;
HO OHNECA
Antagonist
HO
NH-
N ~N H
ZM 241385
56
specific cytoplasmic stmctural features involved in signalling from the ARs include 
the conserved DRY m otif found at the C-terminal end o f TM3. This is important in 
G-protein interactions and maintaining GPCR stability (Chung, 2002). In addition to 
G-protein binding sites, there is a common Cys residue present on the AiAR 
(Cys^^^), which has been shown to be the site of pahnitoylation (Gao et al., 1999). 
A2bAR and A3AR also have predicted sites for pahnitoylation in their C-termini. In 
contrast, A2aARs do not possess a similar Cys residue suggesting that pahnitoylation 
is not essential for downstream signalling by this receptor (Wedegaertner et a l ,
1995).
As observed for other GPCRs the A2aAR, A2bAR and A3AR contain several 
potential sites o f phosphorylation within the C-terminal tail, while the A |AR contains 
some phosphorylation sites in the third intracellular loop. Palmer et a i ,  (1997) have 
reported that phosphorylation of the canine A2aAR on Thr^^^ is associated with the 
onset of rapid desensitisation in response to agonist (See Section 1.9.1). It is also 
reported that multiple isoforms o f PKC can activate a downstream kinase responsible 
for the phosphorylation of the A2aAR in response to the phorbol ester PMA, 
although the significance o f this is unclear (Palmer et a i ,  1999).
1.10.2 Adenosine receptor subtypes
1.10.2.1 AiARs
The AiAR receptor from several species including rat (Mahan et al., 1991; Reppert 
et al., 1991), cow (Olah et al., 1992; Tucker et al., 1992) and man (Libert et al., 
1992; Townsend-Nicholson et a l ,  1992; Ren and Stiles, 1994) have been cloned, and 
found to encode proteins of 326 amino acids, with a corresponding size o f ~37kDa. 
Overall sequence identity is 87% across the different species, rising to 92% within 
the TM regions. AiAR mRNA has been found in brain, testis (Mahan et a l ,  1991; 
Reppert et a l ,  1991), heart and kidney (Olah et a l ,  1992). Activation of AiARs 
leads to the inhibition o f adenylyl cyclase activity via Gj-liiiked G-proteins. It also 
leads to the mobilisation of intracellular Ca^ "^  due to the activation of phospholipase 
C (Hansen et a l ,  2003). It has been reported that the AiAR will also activate PKCp 
in a mechanism that involves M EKl and PI3-K (Hill et al,  2003). It has also been 
recently reported to dimerise with the dopaminergic D; receptor (Gines et a l ,  2000).
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Ill addition, the enzyme adenosine deaminase (ADA) can also interact with the AiAR 
in CHO cells leading to increased receptor binding of the AR agonist NECA (Ciriiela 
et a l ,  1996).
1 .1 0 .2 .2  AzaARs
A2aARs have been cloned from several species, including dog (Libert et a l ,  1990) 
rat (Fink et a l ,  1992) and man (Furlong et a l ,  1992) and show 84% sequence 
identity between rat and human forms. They encode proteins that are 410-412 amino 
acids long, and -45  kDa in size, with over 120 amino acids comprising the C- 
terminal tail of the receptor (Barrington et a l ,  1990; Olah et a l ,  1997). The A2aAR 
is expressed in several cell types including the immune system, platelets, vascular 
smooth muscle cells and endothelial cells. It is highly expressed in specific regions 
o f the brain (nucleus accumbens, olfactoiy tubercle, striatum) that are also enriched 
in D2 dopamine receptors. The A2aAR classically signals through the Gg family of 
G-proteins leading to the activation of adenylyl cyclase and an increase in cAMP 
levels (Daly et a l ,  1983). However, it has also been shown to promote p2 1 '^L 
dependent activation o f ERR in endothelial cells independent o f Gg activation (Sexl 
e ta l ,  1997).
1.10.2.3 AjbARs
A2bARs have been cloned from several species including human (Pierce et a l ,
1992), rat (Rivkees and Reppert, 1992) and mouse (Marquardt et a l ,  1994). cDNAs 
encode for a protein o f 322 residues with a molecular weight of -36kD a (Lynge et 
a l ,  2003). It is expressed at low levels on many cell types in most species thus far 
examined (Ralevic and Burnstock, 1998). It was first shown to couple to Gg proteins 
to activate adenylyl cyclase activity like the A2aAR (Linden et a l ,  1998), but has 
since been shown to also couple via Gq/n proteins to activate PLC(3 leading to an IP3- 
dependent increase in intracellular calcium (Feoktistov and Biaggioni, 1995; Linden 
et a l ,  1999). Recently it was also reported that A2bAR activation leads to ERK 
activation in a p 2 f ‘^ Ldependent mechanism. This mechanism is regulated by PEG as 
U73122, a PLC-selective inhibitor, could decrease EREC phosphorylation by -50%  
(Gao et a l ,  1999). A2bARs have also been found associated with ADA in CHO cells 
and Jurkat T Lymphocytes. The presence of ADA increases the affinity o f A2bAR 
for NECA and increases cAMP production (Herrera et a l ,  2001).
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1.10.2.4 AsARs
The most recently discovered o f the ARs, the A3AR has also been cloned from 
multiple species including rat, dog, sheep, rabbit and human (Salvatore et al., 2000; 
Fredholm et al., 2001). The human A3AR is 318 residues long encoding a protein of 
~36kDa. The A3AR displays the greatest degree of difference between species, with 
the rat and human sharing only 72% sequence identity reflecting marked differences 
in pharmacology for example, all non-nucleoside antagonists e.g. MRS 1220 display 
high affinity for the human A3AR but low affinity for the rat A3AR. Recent studies 
indicate a small N^-subsitiuent is important in the species differences (Gao et al.,
2002). In rodents it is expressed primarily on mast cells with some expression in the 
testis, and in the brain (Fredholm et al., 2001; Hammerbeg et al., 2003). In contrast, 
in humans and sheep it is expressed on eosinophils and not on mast cells. It is 
loiown to couple to the activation o f Gi proteins leading to the inhibition of adenylyl 
cyclase activity. It is also known to activate pathways leading to ERK 
phosphorylation. This pathway is dependent upon G(3y release from Gi proteins, 
p2 f ‘''^dependent activation of PI3K and M EKl but is independent o f calcium, PKC, 
and Src activation (Schulte and Fredholm, 2002). Signalling has also been 
demonstrated in astroglia cells from the A3AR to the activation of Rlio proteins 
involved in actin cytoskeletal re-arrangement (Abbracchio et al., 2001).
1.11 Evidence for a role of ARs in inflammation
Inflammatory agents, such as those previously mentioned and inflamed conditions, 
such as asthma, cause a net increase in the concentration of adenosine by several 
potential mechanisms: increased catabolism of 5’AMP to adenosine by ecto- and 
endo- 5’nucleotidases, inhibition of adenosine kinase and adenosine deaminase 
activity, and activation of S-adenosylhomocysteine hydrolase, responsible for S- 
adenosylhomocysteine hydrolysis into adenosine (Hasko et al., 2004; Figure 1.9). 
These mechanisms generate adenosine, which can act at the four adenosine receptor 
subtypes, each of which play distinct roles in inflammation. In general, several 
studies suggest that the AiAR, AibAR and A3AR have both pro- and anti­
inflammatory properties dependent upon the model system used, as described below.
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Figure 1.9 The synthesis and catabolism of adenosine.
Adenosine is synthesized by the action o f several ecto- and endo- 
5’nucleotidases, which degrade 5’ AMP to adenosine. In addition, the 
production of adenosine is catalysed by S-adenosylhomocysteine hydrolase 
using S-adenosylhomocysteine as a substrate. Intracellular concentrations 
of adenosine can also increase due to the action o f the nucleoside 
transporter. Catabolism o f adenosine involves the phosphorylation of 
adenosine into 5 ’AMP by adenosine kinase and the deamination o f 
adenosine to inosine.
tD
zn
§
cd
m  5
sI
<
t- Hzn
zn
CO
61
1.11.1 The inflammatory effects of AiAR activation
AiAR activation is known to have a prominent cardio-protective effect in animal 
models of ischaemia by the activation of KATP-channels (Vinten-Johansen et al.,
1999). In addition to its role in cardioprotection, it also has both pro- and anti­
inflammatory effects. In rodent models o f inflammation and nerve-injury pain, 
AiAR activation reduces hypersensitivity to acute heat or acute paw pressure (Li et 
al., 2003). In addition, rat adjuvant-induced models o f arthritis show improvement 
when treated intrathecally with AiAR agonist (Boyle et al., 2002). A protective 
effect of the AiAR is also suggested by studies of renal ischaemia-reperhision injui'y 
in AiAR laiockout mice. Mice lacking the AiAR, exhibit increased renal injury as 
determined by renal tubular neutrophil infiltration, ICAM-1, TN Fa, and IL-1 mRNA 
expression, compared with their WT littermate controls (Lee et al., 2004). In 
contrast, animal models o f asthma suggest that the AiAR is involved in mediating 
bronchospasm (Meade et al., 2001) via a neural mechanism independent of mast cell 
degranulation. The different roles of AiAR within each animal model suggest 
alternative signalling pathways that mediate the different effects.
1.11.2 The inflammatory effects of AzaAR activation
A2bARs also display both pro- and anti-inflammatory properties within different 
model systems. In rodent models o f Alzheimers disease, chronic infusion of LPS 
into the fourth ventricle, induced neuro-inflammation that coiTesponded to a reduced 
expression of AzsARs. Treatment with a NO-releasing non-steroidal anti­
inflammatory drug prevented the down-regulation of A2bARs suggesting the 
potential involvement o f A2bARs in the pathogenesis o f the disease (Rosi et al.,
2003). In vitro studies of murine bone marrow-derived macrophages show that 
specific A2bAR agonists induce cAMP production, which inhibits macrophage 
proliferation through a mechanism involving the induction of p27^'^^ expression 
(Xaus et al., 1999). Pro-inflammatory effects of the A2bAR are also reported in 
different models o f inflammation. The A2bAR is important in mast cell 
degranulation, which triggers bronchospasm in rodent models of asthma (Meade et 
al., 2001). In addition, in vitro studies of intestinal inflammation indicate that 
adenosine acting at A2bARs increases the secretion o f IL-6 , a pro-inflammatory 
cytokine involved in neutrophil degranulation and lymphocyte differentiation 
(Sitaraman et al., 2001).
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1.11.3 The inflammatory effects of A 3AR activation
Like the AiAR and A2bAR, the A3AR exhibits both pro- and anti-inflammatoi-y 
effects. In two murine models of colitis, an A3AR agonist, N^-(3-iodobenzyl)- 
adenosine-5 ' -N-methyluronamide (IB-MECA), decreased inflammatory cell 
infiltration into the colon and decreased cytokine and chemokine levels (Mabley et 
al., 2003). In vivo studies on AsAR"' '^ mice indicate that the A3AR activation can 
inhibit LPS-induced TN Fa production (Salvatore et al., 2000). In addition, Szabo et 
al., (1998) reported that A3AR activation can reduce macrophage inflammatory 
protein (M lP )-la  production and collagen-induced arthritis by reducing the 
production of IL-12, IL-6 and NO production (to a lesser extent; Szabo et al., 1998). 
In addition, A3AR agonists act as cardio- and neuroprotective agents and attenuate 
ischaemic damage (Fislnnan and Bar-Yehuda, 2003). In contrast, A3AR activation in 
basophils and mast cells, stimulates degranulation and consequently bronchospasm 
leading to asthma (Nagano et al., 2000; Tilley et al., 2003). Additionally, studies of 
carrageenan-induced inflammation in A3AR knockout mice indicate a pro- 
inflammatory role for the A3AR, as laiockout mice had significantly reduced 
inflammation when compared to WT litter mates (Wu et a l ,  2002).
1.11.4 The anti-inflammatory role of AzaAR  activation
In contrast to other adenosine receptors, multiple in vivo and in vitro studies suggest 
a potent anti-inflammatory effect of the A2aAR. Early reports indicated that A2AR 
activation could inhibit superoxide release from guinea pig eosinophils stimulated 
with opsonised zymosan and from human eosinophils (Yukawa et al., 1989). Further 
studies by Salmon and Cronstein (1990), reported that NECA, an A2AR selective 
agonist could inhibit Fc-y R-mediated phagocytosis and superoxide generation in 
polymorphonuclear leukocytes (PMN). This effect was blocked by the AR 
antagonist, 8-p-sulfbphenyltheophylline. In further studies, Cronstein and colleagues 
also reported that at concentrations of adenosine and NECA sufficient to inhibit the 
generation of ROS, they could detect a decrease in the adhesion o f fMLP-induced 
PMN to endothelial cells (Cronstein et al., 1992). Later studies in neutrophils 
indicated that this reduction was due to the inhibition of anPz integrin expression, 
which is required for adhesion. (See Section 1.2.3; Wollner et al,, 1993).
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The potent anti-inflammatory role of the folate antagonist methotrexate (MTX) was 
also shown to be dependent upon adenosine. When used at low concentrations, 
injection of MTX could reduce leukocyte accumulation in caiTageenan-inflamed air 
pouches, due to the accumulated presence of adenosine following up-regulation of 
the adenosine transporter AICAR, in splenocytes. This effect was completely 
reversed by an A2AR antagonist DMPX suggesting that adenosine acting at an A2AR 
subtype mediated the protective effect. In additional studies, inhibition of adenosine 
kinase could also reduce leukocyte accumulation in the same model. This effect 
could also be completely reversed by co-injection o f ADA further implicating a role 
for adenosine acting at A2ARS (Cronstein et al., 1994).
With the cloning of the A2bAR, studies suggested a more potent anti-inflammatory 
role for the A2aAR. In models o f ischaemia-reperfusion injury in the rat kidney, an 
A2AAR-selective agonist could reduce serum creatinine levels, blood urea nitrogen 
levels and reduce tubular epithelial necrosis. This effect was blocked by the A2aAR- 
selective antagonist, ZM241385 (Okusa et al., 1999). In vivo rat models of 
meningitis have also indicted that A2aAR activation could decrease neutrophil 
accumulation in the sub-arachnoid space, reduce cytokine-enhanced neutrophil 
adherence and superoxide release. These effects were also blocked by the A2aAR 
antagonist ZM241385 (Sullivan et al., 1999). Furthermore in rodent studies of 
atherosclerosis, A 2aAR activation could reduce endothelial activation and neo- 
intimal growth in sections of carotid artery.
Studies have also been carried out on the role o f the A2aAR in allergen-induced 
pulmonary aiivvay inflammation. In ovalbumin-sensitised rats, CGS21680 treatment 
given intrathecally, dose-dependently inhibited broncheolar lavage fluid leukocyte 
numbers, protein content and myeloperoxidase and eosinophil peroxidase activities 
measured 24hr post-challenge. This effect was blocked when the A2AAR-selective 
antagonist ZM241385 was administered Ih  prior to agonist (Fozard et al., 2002). In 
addition to the anti-inflammatory role o f the A2aAR, it has also been shown that 
activation of the A2aAR can promote wound healing and mediate angiogenesis in 
response to tissue injury (Montesinos et al., 2002). Further, systemic administration 
of ATL-146e during reperfusion following spinal cord ischaemia, decreased neuronal 
apoptosis leading to improved preservation o f hind limb function. (Cassada et al..
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2001). Animal models o f acute intracerebral brain hemoniiage also indicate a 
protective effect of CGS21680 when administered directly into the striatum 
immediately prior to the induction of haemorrhaging (Mayne et ah, 2001).
In vivo studies also indicate that in mouse models o f ischaemia/reperflision injury, 
co-reperfusion of the A2AAR-selective agonist ATL146e, decreases liver injui'y by 
90%. Co-administration of the A2AAR-selective antagonist ZM241385, attenuates 
this effect indicating the receptor specificity of the response (Day et a l ,  2004). In 
addition, A2aARs were also recently shown to protect from concanavilin A-induced 
liver injury in vivo (Ohta and Sitkovsky, 2001). Further studies in vitro, suggest the 
anti-inflammatory response is due to a reduction in the expression of cytokine and 
chemokines from cells expressing A2A ARs. THP-1 cells treated with LPS increased 
the expression of A2aARs and adenosine. Further treatment o f the cells with an 
A2aAR selective agonist CGS21680, decreased LPS-stimulated TN Fa production in 
a time- and dose-dependent manner. This inhibitory pathway involves A2aAR 
stimulation o f adenylyl cyclase generating cAMP that results in the activation of 
PKA and phosphoiylation of cAMP response element binding protein (CREB; 
Bshesh et a i ,  2002).
The consistent anti - inflammatory role for A2aAR receptor signalling in a variety of 
different animal models of inflammation, indicates a possible common mechanism of 
action. Initial studies showed that A2aAR activation can inhibit the expression of 
pro-inflammatory cytokines and chemokines, key components in the inflammatory 
response, suggest that this inhibition may occur at the level of transcription. 
Transcription factors important in the expression of many pro-inflammatory genes 
include NF-kB and AP-1. The aim of my project was to determine the molecular 
mechanism by which the A2aAR can modulate pro-inflammatory gene expression, 
by studying the upstream transcription factors and signalling components. The 
dissection of the pathways involved could lead to more specific drug design that may 
benefit a wide range of disease states.
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Chapter 2 
Materials and Methods
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2.1 Chemicals and Suppliers
All reagents were of the highest grade commercially available and obtained by the 
following suppliers:
Affinity Bioreagents, Golden, CO, U.S.A.
Anti-AiAAR specific antibody
Alexis Corporation, San Diego, CA, U.S.A.
Dithiothreitol (DTT)
Amers ham Biosciences UK Ltd., Little Chalfont, Buckinghamshire
Sodium iodide
Bio-Rad Laboratories Ltd, Maylands Avenue, Hemel Hempstead
Bradford’s Reagent
BD Biosciences, Pharmingen, San Ljose, CA, U.S.A.
Anti-iNOS antibody
BDH Chemicals Ltd., Poole
Acrylamide
Cambrex Bio Science Wokingham Ltd. BioWhittaker House, Wokingham, 
Berkshire
Endothelial Basal Media-2™, Singlequots™ (foetal bovine semm (FBS), 
hydrocortisone, fibroblast growth factor-B (hFGF-B), vascular endothelial growth 
factor (VEGF), insulin-like growth factor-1 (IGF-1), ascorbic acid, epidermal growth 
factor (hEGF), gentamicin sulphate and amphotericin-B (GA-1000) and heparin), 
human umbilical vein endothelial cells (HUVECs)
Calbiochem-Novabiochem (UK) Ltd., Nottingham
Forskolin, phorbol-12-myristate-13-acetate (PMA), SB 203580, PD98059, 
pyn'olidinedithiocarbamate (PDTC), N-acetyl cysteine, H-89
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Cell Signalling Technology Inc., Beverly, MA U.S.A.
Anti-Ser^^Ser^'"-phosphoiylated iKBa, anti-Ser^^-phosphorylated c-jun, anti 
Thr^^^Tyr^^^-phosphoiylated p38
CN Biosciences, Merck Biosciences Ltd., Beeston, Nottingham
Gene Juice transfection reagent
European Collection of Cell Cultures, CAMR, Porton Down, Salisbury, 
Wiltshire
C6 glioma cells
Fisher Scientific, Loughborough, Leicestershire
N-(2-Hydroxyethyl)piperazine“N'-(2-ethanesulfonic acid) HEPES, sodium dodecyl 
sulphate (SDS), ethylenediaminotetraacetic acid (EDTA), dimethyl sulfoxide 
(DMSO), ethidium bromide solution, glacial acetic acid, methanol, ethanol, 
concentrated hydrochloric acid (HCl), sodium fluoride
GIBCO BRL Life Technologies, Paisley
PhenohchlorofoiTn:isopropanol, Lipofectamine, new born calf serum, Optimem, 
phosphate-free Dulbecco’s modified Eagle’s medium (DMEM)
Interactiva-Thermo Hybaid, Thermo Biosciences GmbH, Ulm, Germany
Oligonucleotides
Inverclyde Biologicals, Strathclyde Business Park, Bellshill, Lanarkshire
Protran nitrocellulose Schleicher and Schuell membrane
Melford, Chelsworth, Ipswich, Suffolk
Kanamycin
Merck, Darmstadt, Germany
Bactotryptone, agar
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Molecular Probes,Poortgebouw, Leiden, The Netherlands
Alexa™594“Conjugated goat anti-mouse IgG, Alexa™594-conjugated goat anti­
rabbit IgG
New England Biolabs Inc., Beverley, MA U.S.A.
Pre-stained protein molecular weight marker, restriction enzymes
NEN Life Science Products Inc., Boston, U.S.A.
ECL reagents, [^^P]-orthophosphate
PAA Laboratories, Linz, Austria
G-418 disulphate sodium salt
Perkin-EImer Life Sciences, Monza, Italy 
[Y-“ P] ATP
Pierce, Rockford, IL, U.S.A.
EZ-Link™ biotin-LC-hydrazide, horseradish peroxidase (HRP)-conjugated 
streptavidin, Western Blot Stripping Solution
Promega, Southhampton
T4 DNA Ligase, SV DNA mini-prep kit, G-418 disulphate sodium salt, restriction 
enzymes, dNTPs
Qiagen, Crawley, West Sussex
DNA gel purification kit, DNA plasmid maxi-prep kit
Research Biochemicals International, Natick, MA, U.S.A.
NECA, CGS 21680
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Roche Molecular Biochemicals/ Boehringer-Mannheim, Mannheim Germany
Tris[hydroxymethyl]aminomethane; (Tris), DNA molecular size marker, restriction 
enzymes
Santa Crnz Biotechnology Inc., Santa Cruz, CA, U.S.A.
Mouse anti-hemagglutinin(HA) epitope (YPYDVPDYA) antibody, mouse anti-p65 
(A) antibody, rabbit anti-IicBa (C-21) antibody
Serotec Ltd., ICidlington, Oxford
Mouse anti-human E-selectin/CD62E (CL2/6) antibody
Sigma-Aldrich Company Ltd., Poole, Dorset
Triton X-100, soybean trypsin inhibitor, benzamidine, bovine serum albumin, protein 
A-Sepharose, sodium periodate, bisacrylamide, horseradish peroxidase (HRP)- 
conjugated anti-mouse IgG, horseradish peroxidase (HRP)-conjugated anti-rabbit 
IgG, horseradish peroxidase (HRP)-conjugated rabbit anti-goat IgG, horseradish 
peroxidase (HRP)-conjugated streptavidin, thimerosal, bromophenol blue, sodium 
azide, 3-[(3 -cholamidopropyl)dimethylammonio]-1 -propanesulfonate (CHAPS), 
agarose, deoxycholic acid sodium salt, polyethylenimine, ampicillin, adenosine 
deaminase, paraformaldehyde, N,N,N’,N’-tetramethylethylenediamine (TEMED), 
phenylmethylsulfonyl fluoride (PMSF), Ham’s F-12 media, Dulbecco’s modified 
Eagle’s medium (DMEM), sterile phosphate buffered saline (PBS), foetal bovine 
serum, trypsin, penicillin/streptomycin, L-glutamine, recombinant human tumour 
necrosis factora (TNFa), recombinant murine TNFa, lipopolysaccharide (LPS), 30:1 
acrylamide: bisacrylamide solution, tetracycline, protein G-Sepharose, rat interferon- 
y (IFN-y), sulphanilamide, A -1 -naphthylenediamine dihydrochloride, bicinchoninic 
acid, 3,3 ’ 5,5 ’-tetramethyIbenzidine (TMB)
Stratagene
Pfu Turbo DNA polymerase
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Whatman International Ltd., Maidstone, Kent
GF/B glass fibre filters, filter paper.
9E10 monoclonal antibody specific to the myc epitope EQKLISEEDL, was prepared 
in-house at Duke University, Durham, NC, USA by Dr. Tim Palmer.
ZM241385 was a kind gift from Dr. Simon Parker, Astra-Zeneca, Macclesfield, 
Cheshire and was iodinated according to Palmer & Stiles, (1999)
Rec BJ5183 E.coli bacterial cells were a generous gift from Prof. B. Vogelstein, 
John Hopkins University, MD, USA.
C6  glioma cells stably expressing the canine AiaAR were prepared in-house at Duke 
University, Durham, NC, USA by Dr. Tim Palmer (Palmer and Stiles, 1999)
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2.2 Cell Culture & Transfection Methods
2.2.1 Cell maintenance
All cell types were grown at 37°C in a humidified atmosphere containing 5% (v/v) 
CO2.
HUVECs were maintained in endothelial basal medium supplemented with 2% (v/v) 
foetal bovine semm, 0.04% (v/v) hydrocortisone, 0,4% (v/v) human fibroblast 
growth factor-B (hFGF-B), 0.1% (v/v) vascular endothelial growth factor (VEGF), 
0.1% (v/v) insulin-like growth factor-1 (IGF-1), 0.1% (v/v) ascorbic acid, 0.1% (v/v) 
human epidermal growth factor (hEGF), 0.1% (v/v) gentamicin sulphate and 
amphotericin-B (GA-1000) and 0.1% (v/v) heparin. Cells were routinely sub­
cultured until passage 6 as HUVECs will adapt to cell culture conditions over time, 
by regulating the expression o f different cellular proteins such as adhesion molecules 
(Muller et al., 2002). When confluent, cells were washed in 3 ml o f FIBSS (30 niM 
HEPES Buffered Salt Solution) and then treated briefly with 3 ml endothelial grade 
trypsin in order to detach the cells. The trypsin was then neutralised with 3 ml 
trypsin-neutralising solution and the contents transferred to a 13 ml centrifuge tube. 
Cells were centrifuged for 5 min at lOOOg and the supernatant was discarded. The 
cell pellet was gently resuspended in medium at a dilution factor suitable to establish 
a cell density that could be reliably counted within a standard haemocytometer, 
which was typically 1:10 dilution. Wells were then seeded at an appropriate level 
according to the analysis performed as indicated in the Figure Legends. Typically a 
6 -well plate would be seeded with 5x10^  cells/well ready for infection the following 
day, or 5 x 1 0 ^  cells if a confluent monolayer of cells was required for the next day. 
A minimum of 1 x 10"^  cells was used to maintain the eell line in a fresh 75-cnf 
tissue culture flask to which 9 ml of fresh medium was added.
Human Embryonic Kidney 293 cells (HEK 293) were maintained in DMEM 
supplemented with 10% (v/v) FBS, 1 mM L-glutamine, 100 units/ml penicillin and 
100 jLig/ml streptomycin. Confluent monolayers were washed onee in 5 ml of sterile 
PBS and then treated with 1 ml trypsin. Cells were then returned to the incubator for 
a few minutes before the flask was disrupted to dislodge the cells. Cells were then 
typically diluted 1:8, 7 ml was used in experimental analysis and 1 ml was used to 
maintain the cells to which 9 ml of fresh DMEM was added. C6 cells were similarly
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passaged and maintained in DMEM supplemented with 10% (v/v) FBS, 1 mM L- 
glutamine, 100 units/ml penicillin and 100 pg/ml streptomycin. Chinese Hamster 
Ovary cells were maintained in Ham ’s F-12 media supplemented with 10% (v/v) 
FBS, 1 mM L-glutamine, 100 units/ml penicillin and 100 pg/ml streptomycin and 
were subcultured in an analogous fashion to HEK 293 cells. Stable cell lines were 
also were supplemented with 0.0016mg/ml G418 disulphate salt in order to ensure a 
constant selection pressure. U937 cells were maintained in RPMI medium also 
supplemented with 10% (v/v) FBS, 1 mM L-glutamine, 100 units/ml penicillin and 
100 pg/ml streptomycin. As these cells grow in suspension, they were maintained by 
dilution o f the cell population into fresh medium.
2.2.2 Transfection with Lipofectamine
The following transfection method is based on one well of a six-well plate. In a 
sterile microfuge tube, 120 pi of Optimem and 2 pg o f plasmid DNA were gently 
mixed/per well to be transfected. In a separate sterile microfuge tube, 120 pi of 
Optimem and 4 pi o f Lipofectamine transfection reagent/well were also gently mixed 
and then added to the microfiige containing the plasmid DNA/Opitmem mix. This 
was then incubated at room temperature in the dark for 45 min. While the mix was 
incubating, 70-80% confluent cells were washed once with 2 ml/well of Optimem 
and the medium replaced with 760 pi o f Optimem. The DNA-Lipofectamine mix 
was then added dropwise to the eells and incubated for 3 hr. The transfection was 
then removed and the medium replaced. For experiments, cells were analysed 24 hr 
after transfection.
2.2.3 Transfection with GeneJuice
For transfection into C6  glioma cells, GeneJuice yielded greater transfection 
efficiency compared with Lipofectamine, therefore GeneJuice was the preferred 
choiee. In a sterile microfuge Ipg o f plasmid DNA was incubated with 100 pi of 
Optimem and vortexed briefly. In a different microfrige tube 6 pi of GeneJuice 
transfection reagent was also incubated with lOOpl of Optimem. After 5 min, the 
GeneJuice was added to the plasmid DNA, mixed gently, and incubated for 30 min at 
room temperature in the dark. The DNA-GeneJuice mix was then added to each well 
eontaining 3 ml of fresh medium and left to incubate for 3-5 hr then replaced with 
fresh DMEM. Cells were then analysed 24 hr post-transfection.
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2.3 Molecular Biology
2.3.1 Preparation of antibiotie agar plates
LB agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium 
chloride, 1.5% (w/v) agar) was prepared, autoclaved and allowed to cool before 
addition of antibiotic at the following final eoncentrations, (ampicillin 50 pg/ml 
kanamycin 30 pg/ml. The liquid LB agar was then poured into 90 mm-diameter 
Petri dishes, allowed to solidify and then allowed to sweat overnight at room 
temperature to get rid o f excess moisture. Plates were then stored at 4°C until 
required for a maximum period of 2  weeks.
2.3.2 Preparation of competent X L l Blue E.CoU
An overnight culture o f X Ll Blue E.Coli was grown in 3 ml o f LB broth containing 
50 pg/ml tetracycline. The following day, this was used to inoculate 250 ml o f LB 
broth, which was then grown with aeration in a 37°C shaking incubator at 200 rpm, 
until the growth rate reached log phase as determined by the culture reaching an 
optical density at 600 nm of 0.35-0.375. Bacteria were transferred to two chilled 250 
ml centrifuge tubes and left for one hour on ice. Bacteria were then sedimented by 
centrifiigation at 3,500 g for 20 min at 4“C and the supernatant discarded. The 
bacterial pellet was then washed and resuspended in 62.5 ml o f ice-cold O.IM 
magnesium chloride. Following another 20 min centrifiigation at 3,500g, the 
bacteria were resuspended in 62.5ml of ice-cold 15% (v/v) glycerol with O.IM 
calcium chloride. 250 pi of bacteria were aliquoted into sterile microfuge tubes in a 
dry ice/methanol bath to induce rapid freezing, and stored at -80°C until required.
2.3.3 Transformation of competent X L l Blue E.Coli
Approximately 30-50 ng o f plasmid DNA was added to a plastic 13 ml Falcon 
round-bottom tube on ice. Once thawed 50 pl/tube o f competent E.coli was 
immediately added and the mix incubated on ice for 10 min. The tubes were 
incubated for 5 min at 37°C before 0.5 ml of LB per tube was added. Tubes were 
then shaken at 37°C for 45 min. 0.2 ml of the transformation mix was then plated out 
onto LB agar plates containing the appropriate selection antibiotic and incubated 
overnight at 37°C.
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2.3.4 Preparation of plasmid DNA
Transformed colonies picked from agar plates using sterile pipette tips, were used to 
inoculate 10 ml of LB broth supplemented with the appropriate selection antibiotic, 
and placed in the shaking incubator at 37°C overnight. Plasmid DNA was then 
isolated using the Promega^^ Wizard Plus SV miniprep purification system as per 
the manufacturer’s instructions. For larger quantities of plasmid DNA, the initial 10 
ml culture was then used to inoculate a 500 ml culture containing the appropriate 
antibiotic and grown overnight. Plasmid DNA was isolated using the Qiagen Maxi 
Kit system as directed by the manufacturer’s instructions. The concentration of 
double stranded DNA obtained was calculated based on the assumption that 1 
absorbance unit (A260) is equivalent to 50 pg/ml o f double stranded DNA. An 
absorbance ratio (A260/A280) equal to 1 indicated good quality DNA.
2.3.5 Digestion of plasmid DNA
1-2 pg of purified plasmid DNA was digested in a sterile microfiige tube containing 
the appropriate enzyme buffer and 2-4 units of enzyme as per the manufacturer’s 
instructions. In certain cases it was necessary, due to incompatible buffer
restrictions, to purify the linearised plasmid DNA from the first digestion, before 
digestion with the second enzyme and buffer. This was achieved by ethanol 
precipitation. Briefly 1/10 volume o f 3M sodium acetate and 3 volumes of ice-cold 
absolute ethanol were added to the sample. Following 30 min incubation on ice, 
samples were centrifuged at 4°C for 30 min at 13,000 g and the supernatant removed. 
The DNA pellet was washed once in 50 pi of 70% (v/v) ethanol, centrifuged at 4°C 
for 5 min at 13,000g and allowed to air-dry. It was then resuspended in 15 pi of the 
second enzyme buffer before the addition of 2-4 units of the second enzyme as per 
the manufacturer instructions. Restriction fragments were typically resolved on a 1% 
(w/v) agarose gel containing 2.5 pg/ml ethidium bromide run at 75 mV for 20-30 
min in TAB buffer (40 mM Tris-acetate, 1 mM EDTA, and 0.1% (v/v) glacial acetic 
acid). Purification of DNA from agarose gels was by Qiagen QIAquick gel 
purification kit as per manufacturer’s instructions.
2.3.6 Ligation of DNA fragments
Ligation of DNA fragments into vectors was carried out overnight at 4°C using 
Promega™ T4 DNA ligase. A typical ligation contained 1.5 pi I OX Ligation buffer
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(30 mM Tris-HCl pH 7.8, 10 niM magnesium chloride, 10 mM dithiothreitol (DTT), 
1 mM ATP, a 4:1 ratio of cut insert DNA to the relevant cut vector DNA, and 10 
units of T4 DNA Ligase in a final reaction volume o f 15pi. Ligation reactions were 
then used to transform competent X Ll Blue E.coli as described in Section 2.3.3.
2.3.7 Construction of a myc-His tagged human A%A adenosine receptor 
mammalian expression construct.
The Twyc-His tagged human A2aAR was constructed using a polymerase chain 
reaction (PCR) approach. The oligonucleotide primers used in the PCR were 
designed to amplify the human A2aAR coding sequence, remove the stop codon, and 
add anXbal site (underlined) at the C-terniinus using pCMV5/human-A2AAR cDNA 
as a template. This was carried out using the following primers:
5 ’-TAGCAGAGCTCGTTTAGT-3 ’ (sense)
and 5’-TGATTTCTAGAGGACACTCCTGCTCCATCCTG-3’ (antisense).
This was used to amplify a 1.8 kbp PCR product in a reaction containing 100 ng 
template cDNA, 100 pM dNTPs, 50 pmol sense/antisense primers, 0.002 units of Pfu 
Turbo polymerase, 10% (v/v) Pfu Turbo amplification buffer and 5% (v/v) DMSO in 
a final volume of 100 pi. The reaction was then subject to 25 cycles of 95°C for 1 
min, 45°C for 1 min, 72°C for 1.5 min followed by one cycle o f 95°C for 1 min, 55°C 
for 1 min and 72°C for 10 min. The PCR product was extracted with 
phenol:chloroform:isopropanol (25:24:1,v/v) and further purified by ethanol 
precipitation. The resulting product was then digested using the restriction enzymes 
H indlll and Xbal as described in section 2.3.5. Products were then resolved on a 1% 
(w/v) agarose gel in parallel with HindllUXbal digests o f pcDNA3/mycHisA vector 
(Invitrogen). The products were then gel purified using the Qiagen Gel Extraction 
kit as per the manufacturer’s instructions. Purified, digested DNA products were 
then ligated overnight as deseribed in Section 2.3.6 and used to transform competent 
X Ll Blue E.coli as descried in Section 2.3.3. Ampicillin-resistant colonies were 
screened for successful ligation, by PHndllliXbal digestion of minipreped cDNA 
prepared from 10 ml LB medium cultures supplemented with 50 pg/ml ampicillin 
and grown overnight at 37°C in a shaking incubator. The construction o f the A2aAR 
truncated mutants was carried out in precisely the same fashion. The same PCR 
eonditions were used exeept using the following antisense primers.
76
A2aAR A55 5 ’-TGATTTCTAGAGCCATTGGGCCTCCGCTC -3 ’
A2aAR  AlOl 5’- TGATTTCTAGATTGCTGCCTCAGGACGTGGCT-3’
Both primers were designed to truncate the wild-type receptor and add an Xbal site at 
the C-terminus. The A2aAR A55 truncation removed 55 amino acids from the C- 
terminus containing six potential phosphorylation sites, five serine and one threonine 
residue. The A2aAR AlOl truncation removed 101 amino acids, removing a further 
five serine residues and one threonine residue. Correct sequences were eonfirmed 
using dideoxynucleotide sequencing.
2.4 Propagation and purification of human Aza adenosine receptor adenovirus
In order to express myc-tagged human A2aAR in HUVECs, an adenoviral gene 
transfer approach was used. This is because it achieved much greater expression 
when compared with commercially available transfection reagents, electroporation or 
calcium phosphate-mediated transfection methods. The propagation and purification 
o f the AV-A2aAR/GFP and AV-GFP were carried out in accordance with the 
protocols o f Nicklin and Baker, (2001).
The pAdEasy^^ system from Qbiogene was used as per the manufacturer’s 
instructions in order to generate adenoviral cDNA stoeks which would express AV- 
A2aAR (See Figure 2.1). Briefly the first step required excision o f the myc-tagged 
human A2aAR from pcDNA3/mycHisA using HindllUPmel and the subsequent 
subcloning into a AmÆI/A'coÀV-digested shuttle vector pAdTrackCMV, destroying 
the EcoRV  and Pmel sites. The resulting pAdTrackCMV/mycA2AAR eonstruct was 
then cut at the Pmel site within the vector in order to expose the inverted terminal 
repeats, and co-transformed with the viral DNA backbone construct pAdEasyl into 
E. coli rec+ strain BJ5183 by electroporation (2 kV, 25 pF, 200 G. Recombination- 
positive colonies were screened by digestion with Pmel and PCR using /nycA2AAR- 
specific primers. These colonies were then expanded and the cDNA isolated. The 
plasmid cDNA was then linearised with P a d  and 10 pg was transfected using 30 pi 
Lipofectamine into low-passage HEK 293 cells in 10 cm tissue eulture dishes. The 
presence o f the gene encoding GFP in a separate open reading frame allowed us 
monitor viral expression by fluorescence microscopy. 8 days post-transfection, cells 
were scraped and collected in a sterile centrifrige tube and pelleted by a 5 min
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centrifugation step at 400 g at room temperature. The pellet was washed in 1 ml 
PBS, re-centrifuged and the supernatant discarded. Cells were then disrupted by 
three freeze/thaw cycles in a dry ice/methanol bath and the pellet resuspended in 10 
ml o f serum-free medium. This was then used to infect two T-150 flasks of 50-60% 
confluent HEK 293 cells, grown in medium containing 2% (v/v) FBS. Virus 
particles from these cells were then prepared 3 days later, and used to infect a larger 
seale culture of 20 x T-150 flasks o f HEK 293 cells. From this large scale 
preparation virus was isolated as per the method of Nicklin and Baker (2001). 
Briefly, dislodged cells were pooled and pelleted by a brief centrifugation at 250 g 
for 10 min at room temp. The supernatant was then discarded and the pellet 
resuspended in 1 ml o f sterile PBS. The pellet was then washed four times with 1 ml 
o f sterile PBS and the supernatant discarded. This was then subjected to three 
freeze/thaw cycles in order to lyse the cells and release the vims particles. The 
preparation was then added to a discontinuous caesium chloride gradient set up in a 
13ml sterile ultracentrifuge tube, in order to separate intact virus particles from other 
cellular debris and empty viral capsids. Turbulence caused by friction under braking 
would disrupt the separated adenoviral layer so the samples were subject to 
centrifugation at 100,000g for 18 hr with zero deceleration. The opaque adenovirus 
band was then isolated by syringe extraction and added into a Slide-A-Lyser that 
allowed efficient overnight dialysis at 4°C in IE of dialysis buffer (135 niM sodium 
chloride, 10 mM Tris-HCl (pH 7.5), 1 mM magnesium chloride) which was changed 
three times. This was then diluted in a 1:1 (v/v) ratio with sterile virus storage buffer 
(10 mM Tris-HCl, pH 8, 100 mM sodium chloride, 0.1% (w/v) BSA, 10% (v/v) 
glycerol) and stored at -80°C in 30pi aliquots.
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Figure 2.1 Generation of a recombinant adenovirus.
Plasmid cDNA from kanamycin-resistant AiAAR/GFP-positive colonies 
was isolated and linearised with P a d . 10 pg o f cDNA was then transfected 
into low-passage HEK 293 cells in 10 cm tissue culture dishes. 8-days 
later, virus particles were then harvested from infected cells and used to 
infect 20 x T150 flasks of low-passage HEK293 cells. Virus prepared from 
these cells, was then titred, aliquoted and used in further experiments. 
(Adapted from www.q bio gene. coml
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Once isolated, the vims was subject to titration by the end-point dilution method 
(Nicklin and Baker, 2001) using GFP as a marker for positive colonies. 1x10^  HEK 
293 cells/well were subcultured into 80 wells of a 96-well plate in order to reach 
approximately 50-60% confluency after 24 hr growth. 0.1 ml o f virus was then used 
to infect the wells over a range of serial dilutions (10"^-I0'^'). This was incubated for 
18 hi' before the virus was removed and the medium replaced. The medium was 
replaced evei-y 3 days up to 10 days post-infection until the well showed evidence of 
viral infection as assessed by GFP expression. After 10 days the number of positive 
colonies was counted for each concentration of virus and the virus titre was 
calculated. An example o f this ealculation is found in Appendix 1.
2.5 Laboratory techniques
2.5.1 Discontinuous SDS-PAGE and Immunoblotting
Samples prepared for SDS-PAGE were equalised for protein using the bicinchoninic 
acid assay described in Section 2.5.2. Pre-stained protein markers (Invitrogen 
Rainbow Markers, range 6.5-1751<Da) in sample buffer (50 mM Tris (pH 6.8), 10% 
(v/v) glycerol, 12% (w/v) SDS, 0.0001% (w/v) of bromophenol blue, 6 pM DTT) 
were also prepared in the electrophoresis in order to determine protein molecular 
mass. 30 pi o f sample, equalised for protein and volume, was then subjected to 
discontinuous SDS-PAGE using a 6 cm 10% (w/v) polyacrylamide resolving gel 
(10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M Tris (pH 8.8), 0.1% (w/v) 
SDS, 3% (v/v)glycerol, 0.01% (w/v) aiumonium persulphate and 0.001% (v/v) 
TEMED) and a 2 cm 3% (w/v) stacking gel (3% (v/v) acrylamide, 0.1% (v/v) 
bisacrylamide, O.IM Tris (pH 6.8), 0.1% (w/v) SDS, 0.01% (w/v) ammonium 
persulphate and 0.001% (v/v) TEMED). Electrophoresis was carried out using 
Biorad Mini-Protean II or III gel electrophoresis systems in running buffer (27.4 mM 
Tris, 0.19M glycine, 0.1% (w/v) SDS) at 150 V until the bromophenol blue dye front 
reached the end o f the gel. Proteins were then transferred electrophoretically onto a 
nitrocellulose membrane at 400mA for 45 min in transfer buffer (24.7 mM Tris, 
0.19M glycine in 20% (v/v) methanol). The nitrocellulose membrane was then 
removed, trimmed and briefly washed in PBS before incubating for 1 hr at room 
temperature in Blotto (5% (w/v) skimmed milk, 0.2% (v/v) Triton X-100 in PBS) to 
block non-specific binding of antibody. The membrane was then briefly washed in 
PBS before being transferred to a plastic bag containing 2 ml o f the relevant primary
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antibody, diluted in Blotto as indicated in the Figure Legends. This was incubated in 
the cold room overnight on a rotating platform. The membranes were rinsed briefly 
in PBS before being washed three times in Blotto for 10 min. Membranes were then 
washed again briefly in PBS before being transferred to a bag containing 2 ml of the 
appropriate secondary antibody conjugated to HRP in Fligh-Detergent Blotto (10% 
(v/v) Blotto in PBS supplemented with 1.02% (v/v) Triton X-100 and 0.1% (w/v) 
SDS). This was then placed on a rotating platform at room temperature and 
incubated for 1 hr. The membrane was then washed three times for 10 min in Blotto 
and then washed a further twice for 10 minutes in PBS. Membranes were then 
exposed to an enhanced chemiluminescent procedure. HRP-specific oxidative 
degeneration of luminal causes emission o f light at 428 nm, detected by Kodak X- 
OMAT Blue X-ray film in to visualise immunoreactive proteins.
2.5.2 Protein concentration determination using the bicinchoninic acid (BCA) 
protein assay.
Duplicate 0.01 ml samples of known BSA standards in the range 0-2 mg/ml and 
unknown protein samples were added to a 96-well plate. 0.2 ml BCA solution (1% 
(w/v) 4,4 dicarboxy-2,2 biquinoline disodium salt, 2% (w/v) sodium carbonate, 
0.16% (w/v) sodium potassium tartrate, 0.4% (w/v) sodium hydroxide, 0.95% (w/v) 
sodium bicarbonate pH 11.25, 0.08% (w/v) copper (II) sulphate) was then added to 
each well. Protein concentration-specific reduction o f Cu^^ to C u^  allows the 
bicinchoninic acid sodium salt to bind the C u ^  ion forming an intense purple colour 
allowing measurement o f the absorbance at 492 nm. Colour was therefore allowed 
to develop at room temperature for 30 min and the absorbance of the standards was 
used to determine a straight line from which unknown protein concentrations could 
be calculated (Smith et al, 1985).
2.5.3 Protein concentration determination using Bradford’s reagent
This assay was based on the method o f Bradford (Bradford, 1976). Duplicate 0.01 
ml o f known BSA standards in the range 0-2 mg/ml and unknown protein samples 
were added to a 96-well plate. 0.01 ml of Bradford’s reagent was then added to each 
well. Binding of protein to the dye component o f the Bradford reagent, Brilliant Blue 
G, causes a shift in the absorption spectra of the dye from 465nm to 595nm. Colour 
was therefore allowed to develop for 10 min and the ODgoo of the standards and
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samples measured. A straight line was produced based on the absorbance of known 
standards from which, unlcnown protein concentrations were calculated.
2.5.4 Cell surface biotin-Iabelling of AzaARs
Chinese Hamster Ovai*y (CHO) cells transiently transfected with cDNA encoding the 
mycHis-tagged human A2aAR were used to analyse receptor cell-surface expression. 
Following treatment, as indicated in the Figure Legends, cells were placed on ice and 
washed gently three times with 3 ml ice-cold PBS-CM (PBS supplemented with 1 
mM magnesium chloride and 0.1 mM calcium chloride). All further steps were 
carried out at 4°C unless otherwise stated. In subdued lighting conditions, washed 
cells were treated with 10 mM sodium periodate in PBS-CM for 30 min, to oxidise 
carbohydrate groups to aldehydes. Cells were then washed once with 3 ml PBS-CM 
and then twice with 3 ml O.IM sodium acetate-CM (O.IM sodium acetate pH 5.5 
supplemented with 1 mM magnesium chloride and 0.1 mM calcium chloride). In 
subdued lighting, cells were labelled for 30 min with 0.75 ml/well o f cell non- 
permeable 1 mM biotin-LC-hydrazide in sodium acetate-CM. The reactive aldehyde 
groups bind to the hydrazide group forming a stable hydrazone linkage that is stable 
and allows for the identification o f the cell-surface expressed proteins. Labelling of 
the eells was terminated by the removal of biotin and washing three times with 3 ml 
PBS without magnesium chloride and calcium chloride. Cells were then solubilised 
with 0.25 ml/well of RIPA+ buffer (50 mM HBPES pH 7.5, 150 mM sodium 
chloride, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate and 0.1% (w/v) 
SDS supplemented with 10 mM sodium fluoride, 5 mM EDTA pH 8, 0 .0IM  sodium 
phosphate, 0.1 mM PMSF and 10 pg/ml each o f soybean trypsin inhibitor and 
benzamidine) and transferred to a chilled mierofuge tube on ice. Wells were then 
rinsed with 0.25 ml of RIPA+ buffer which was added to the samples. Samples were 
then solubilised for 1 hr on a rotating wheel at 4°C. Solubilised samples were 
centrifuged for 15 min at 14,000g to pellet insoluble material from the cell lysate and 
450 pi o f supernatant was removed to a fresh pre-chilled mierofuge tube. Duplicate 
10 pi aliquots were used to determine the protein concentration using the BCA assay 
(Section 2.5.2). 400 pi of sample, normalised for protein concentration and volume, 
were then added to pre-chilled mierofuge tubes containing 20 pi of protein G- 
Sepharose beads and 5pi ascites fluid/tube generated against the wyc-epitope.
83
Samples were then immunoprecipitated overnight in the eold room on a rotating 
wheel. Samples were subsequently removed and the beads pelleted by 
microeentrifugation at 13,000 g for 30 sec. Supernatants were removed and beads 
washed three times with 1 ml of RIPA+ buffer. 50 pi o f sample buffer was then 
added and samples were placed at 37°C for 1 hr to elute immunoprecipitated 
proteins. Samples were vortexed briefly eveiy 15 min to aid in the elution. 
Following elution, samples were centrifuged to pellet the beads and the supernatant 
removed with a Hamilton syringe prior to loading on SDS-PAGE. These samples 
were then fractionated and transferred to a nitroeellulose membrane (Section 2.5.1). 
Membranes were then washed briefly in PBS and non-specific binding sites were 
blocked for 1 hr using Blotto. Biotinylated receptor proteins were detected by 
incubation with 1 pg/ml HRP-streptavidin for 1 hr in Blotto on a rotating platform at 
room temperature. Following washes as described in the immunoblotting procedure 
(Section 2.5.1), biotinylated immunoprecipitated receptors were identified by an 
enhanced chemiluminescent procedure.
2.5.5 Saturation radioligand binding studies with *^^I-ZM241385
A confluent T-75 flask containing CHO or COS-P cells, transiently expressing the 
constructs as indicated in the Figure Legends, was placed on ice. After three washes 
with 10 ml iee-cold PBS, cells were scraped in 4 ml of PBS and transferred to a pre- 
chilled 13 ml centriflige tube on ice. Cells were then pelleted by centrifugation at
3,000 g for 10 min at 4°C. The supernatant was then discarded and the cell pellet 
resuspended in 1 ml of cell lysis buffer (10 mM Tris, 5 mM EDTA, pH 7.5). Cells 
were then transferred to a chilled 8 ml tight-fitting glass-on-glass Dounce 
homogeniser on ice and lysed with 20 up-and-down strokes. The homogenate was 
then removed to a chilled mierofuge tube and membranes pelleted by centrifugation 
at 14,000g for 15 min at 4°C. The membrane pellet was then resuspended in 0.3 ml 
o f radioligand binding buffer (50 niM Tris, 10 mM magnesium chloride (pH 6.8)) 
from which 30 pi was removed for protein concentration analysis using the BCA 
assay (Section 2.5.2). 3.7 ml of radioligand binding buffer was then added to the 
membrane preparation and transferred to the chilled Dounce homogeniser. Ipl of 
stock ADA was added to the homogenate giving a final concentration o f 0.47units/ml 
and the membranes were lysed again with 20 up-and-down strokes.
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Duplicate assay tubes were set up containing iodinated radioligand ranging from 
0.25-8 nM to which 150 pi of membrane preparation was added. One set of 
duplicate tubes contained 50 pi o f water, in order to detemiine total binding of 
ZM241385, while in the other set of tubes, 50 pi NEC A at a final concentration of 10 
pM was included to determine non-speeifie binding. Assay tubes were then placed 
in a shaking water bath at 37°C for 45 min to allow the assay to reach equilibrium. 
The binding assays were washed through GF/B filters, pre-soaked in 300 ml of 
distilled water supplemented with 0.03% (v/v) polyethylenimine, using a Brandel 
cell harvester. Assay binding tubes were rinsed three times in 5 ml of assay wash 
buffer (binding buffer supplemented with 0.01%(w/v) CHAPS) to ensure efficient 
collection o f membranes. Filter discs representing each assay tube were then 
counted for 30 sec in a gamma counter. Duplicate 10 pi aliquots of the 
ZM241385 radioligand dilutions used in the assay were also counted to determine 
the exact concentration of'^^I-ZM241385 present in each tube.
Following subtraction of non-specific counts, the total amount o f specific receptor- 
bound radioligand was calculated using a graph o f specific counts versus radioligand 
concentration. This graph was fitted to a non-linear one-site hyperbolic curve using 
GraphPad Prism. From this, the total number o f receptors (Bmax) and the equilibrium 
dissociation constant (Kj) were calculated. An example of this calculation is found in 
Appendix 2.
2.5.6 Competition radioligand binding with ^^^I-ZM241385 in isolated 
membranes.
Membranes were prepared as for the saturation binding assay and 0.15 ml of 
resuspended membrane was added to each tube. In competition binding assays, 
duplicate tubes were set up containing 0.05 ml of '^^I-ZM241385 and 0.05 ml of 
unlabelled competing ligand between 10"'^ and lO'^M. Competition binding assays 
were then placed in a shaking water bath at 37°C for 60 min to reach equilibrium. 
Assays were then washed through pre-soaked GF/B filters, treated as above, and the 
radioactivity on each filter counted in a gamma counter. The IC50 (the concentration 
at which 50% of specific binding was inhibited) was determined by plotting specific
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binding (cpm) against log [competing ligand (M)] and fitted to a one-site competition 
curve using GraphPad Prism. The equilibrium dissociation constant (K,) of the 
competing ligand was then calculated using the Cheng-Prusoff equation (Lazareno 
and Birdsall, 1993) and expressed as a pM concentration. This equation is found in 
Appendix 3.
2.5.7 Determination of cell surface E-selectin expression by enzyme-linked 
immunoabsorbant assay (ELISA).
1x10^ HUVECs/well were seeded in a 96-well plate. The following day, cells were 
treated with the appropriate concentration o f cytokine/lipopolysaccharide (EPS) for 
the time indicated in the Figure Legends. The assay was stopped by transferring the 
plate to ice and eells were washed gently three times with 200 pi PBS. Cells were 
then treated with 0.1 ml of 4% (w/v) parafornialdhehyde in 5% sucrose (w/v) in PBS 
(pFI 7.2), covered and incubated overnight in the cold room. The next day, cells 
were washed gently three times with 200 pi PBS and then incubated for 1 hr at room 
temperature in PBS containing 0.1% (w/v) BSA in order to block non-specific 
antibody binding sites. Cells were then washed gently three times with 200 pi PBS 
before ineubation with mouse anti-human E-selectin antibody at 1:1000 dilution in 
PBS/0.1% (w/v) BSA for 2 hr at room temperature. A mouse anti-haemagglutinin 
(HA) epitope antibody at 1:1000 dilution was also used, in wells treated in parallel, 
to determine non-specific binding. Cells were then gently washed three times with 
200 pi PBS before the addition of HRP-conjugated anti-mouse IgG for 1 hr at room 
temperature. Cells were then gently washed five times with 200 pi PBS, before the 
addition of 100 pi, stock, 3,3’5,5’-tetramethylbenzidine (TMB). The colour was 
allowed to develop for 5-10 min at room temperature and the Agoo determined using 
a plate reader.
2.5.8 Electrophoretic Mobility Shift Assay (EMSA)
Confluent cells in a 6-well plate were incubated with the appropriate treatment for 
the time indieated in the Figure Legends. Cells were then washed gently twiee in 3 
ml ice-cold PBS and transferred to a sterile mierofuge tube on iee in a final volume 
of 1 ml PBS. Cells were then pelleted by centrifugation at 4,000g for 5 min at 4°C,
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and resuspended in 0.4 ml o f buffer A (10 mM Tris, pH 7.5, 10 mM potassium 
chloride, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.1 mM PMSF and 1 pg/ml 
each of soybean trypsin inhibitor and benzamidine). Cells were then allowed to 
swell for 10 min before NP-40 was added to a final concentration of 0.06% (v/v). 
Cells were then vortexed briefly and lysates pelleted by centrifugation at 13000g at 
4°C for 30 sec. The supernatant was removed and the pellet resuspended in 0.025 ml 
o f buffer B (10 mM Tris pH7.5, 450 mM sodium ehloride, 1 mM EDTA, 1 mM 
EGTA, 1 mM DTT, 0.1 mM PMSF and 1 pg/ml each of soybean trypsin inhibitor 
and benzamidine). This was left to incubate on ice for 15 min on a shaking platform. 
Nuclei were then pelleted by a 5 min centrifugation at 13,000g at 4°C. The 
supernatant was then assayed for protein coneentration using a Bradford assay as 
DTT present in the buffer interferes with the BCA assay.
A ssDNA probe (5 pmol/pl) containing the NF-kB consensus sequence 
GGGGACTTTCCC was used to detect any induced NF-kB transcription factors. 
Radiolabelled using [y-^^P] ATP and T4 polynueleotide kinase, the labelling reaction 
was performed at 37°C for 30 min in a total volume of 20 pi. The reaction was then 
incubated at 95°C for 2 min following the addition o f the eomplementary strand (5 
pmol/pl) and 0.5M sodium chloride. The reaction was then allowed to cool over the 
next few hours. The probe was then purified by centrifrigation in a spin column 
(Pharmingen) to isolate the radiolabelled DNA probe. The radiolabelled DNA probe 
was then incubated for 30 min at room temperature in a binding reaction containing 
5-10 pg of sample, 1 pi radiolabelled DNA probe in binding buffer (100 mM HEPES 
pH 7.9, 5 mM magnesium chloride, 0.5 mM EDTA, 250 mM sodium chloride, 50% 
(v/v) glycerol, 100 mM DTT, 10 mg/ml BSA, 1 mg/ml sodium 
polydeoxyinosinicdeoxycytidylic salt in a total volume o f 22 pi. The binding 
reaction was then loaded on a non-reducing 6% (w/v) acrylamide (60:1 
acrylamide:bisacrylamide) gel in 0.5X TBE (45 mM Tris-borate, pH 8.3, ImM 
EDTA). The gel was then run at 5 niA overnight until the dye reached the end o f the 
gel. The gel was then dried down under vaeuum and bands were identified using 
autoradiography.
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2.5.9 Monocyte adhesion assay
1x10"  ^HUVECs/well were seeded into a 24-well plate and grown to 70% confluence. 
The cells were then infected for 24 hours at a m.o.i. o f 25:1 with recombinant 
adenoviruses encoding either the mycAiAAR and GFP or GFP alone. Following 
treatment as indicated in the Figure Legends, the medium was removed and the 
HUVEC monolayers overlayed with 1x10^ U937 cells/well, a pre-monocytic cell 
line, and allowed to adhere for 1 hr at 37°C. U937 cells were then removed and the 
monolayers washed three times with 1 ml/well of serum-free DMEM to remove any 
non-adherent U937 cells. HUVEC monolayers were then fixed in 0.5 ml/well 4% 
(w/v) paraformaldehyde in 5% (w/v) sucrose/PBS, pH 7.2, and analysed using a 
combination of fluorescent and brightfleld microscopy to detennine the number of 
U937 cells that were adherent to GFP-expressing HUVEC s. At least 300 GFP- 
expressing cells were counted in 3-5 separate fields to calculate the average number 
of adherent cells per 100 GFP-expressing HUVECs for any given treatment.
2.5.10 Confocal Laser Scanning Microscopy
1x10^ cells were split onto coverslips and then treated as described in the Figure 
Legends. Following cell treatments, cell monolayers were washed three times in 1.5 
ml PBS and then fixed in 1.5 ml o f 4% (w/v) paraformaldehyde in 5% sucrose/PBS 
as previously described for 20 min. Cells were then washed again in 1.5 ml PBS and 
permeabilised in 0.4% (v/v) Triton X-100 in PBS for 3 min. Antibody dilutions were 
prepared in 0.1% (v/v) new born calf serum (NBCS), 0.2% (w/v) gelatin, in PBS. 
The primary antibody anti-p65 was used at a 1:200 dilution and the Alexa 594- 
conjugated anti-mouse IgG was used at 1:400 dilution. 100pi of antibody 
solution/coverslip was then spotted onto Nescofilm and the coverslip placed down 
onto the antibody dilution and incubated for 1 hr at room temperature. Cells were 
then washed twiee in NBCS/PBS/gelatin and placed onto Nescofilm containing 100 
pi of the relevant secondary antibody. This was again left to incubate for 1 hr at 
room temperature. Coverslips were then washed again twice in NBCS/PBS/gelatin 
before a final wash in PBS prior to being mounted on microscope slides with 40% 
(v/v) Glycerol in PBS.
Cells were observed using a Zeiss Axiovert 500 laser scanning confocal microscope 
(Zeiss, Oberkochen, Germany) using a Zeiss Plan-Apo 63 x 1.4 NA oil immersion
lens, pinhole of 20 and zoom set between 1 and 4. GFP was excited using a 488nm 
argon/ki'ypton laser and detected with 515-540 nm band pass filter. Alexa-594 
conjugated antibodies were excited at 543nm and detected with a long pass band 
filter at 590nni. The images were adjusted with Zeiss LSM software.
2.5.11 Nitric oxide measurements
1x10^ C6 glioma cells were plated out into a 96-well plate and left overnight to 
adhere. Cells were then treated as indicated in the Figure Legends and the cell 
culture medium removed. NO production was monitored by measuring nitrite 
accumulation in culture medium. This was performed by mixing 50 pi of sample in 
a 1:1 ratio with Greiss reagent, (1% (w/v) sulphanilamide, 0.1% (w/v) N -\-  
naphthylenediamine dihydrochloride and 2.5% (v/v) phosphoric acid). Known 
standards o f sodium nitrite (0-10 mM) were analysed in parallel to quantify nitrite 
levels. Absorbance was measured at 492 nm after 10 min incubation at room 
temperature.
2.5.12 Analysis of NF-kB transcription using a luciferase reporter assay.
1x10^ cells/well were seeded into a 6 well dish. The following day, cells were
transfected with 0.5 pg of a P-galactosidase reporter plasmid, 0.5 pg NF-kB 
Luciferase reporter plasmid and 1 pg of receptor cDNA using 6 pi Gene Juice (See 
section 2,2.3). The cells were then subject to the treatments stated in the Figure 
Legends. Incubations were stopped by transferring the plate to ice and washing the 
cells gently three times in 3 ml o f ice-cold PBS. Cells were then solubilised in 50 pi 
luciferase lysis buffer according to the manufacturer’s protocol ((3-Galactosidase 
Enzyme Assay System with Reporter Lysis Buffer, Promega). 20 pi o f lysate was 
used to determine luciferase activity, 20 pi of the lysate, was used to determine 
P-galactosidase enzyme activity and 10 pi was used to assay the protein 
concentration. Luciferase activities were determined using a luminometer coupled to 
WinGlo software. [3-Galactosidase enzyme activity was determined as per the 
manufacturer’s instructions while protein concentration was measured using a 
Bradford’s assay. Luciferase activities were then nomialised to (3-galactosidase 
enzyme activity and protein concentration.
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2.5.13 Pull-down assay of c-Jun N-terminal kinase (JNK) activation
Confluent C6 cells in 6-well dishes were treated as indicated in the Figure Legends. 
Incubations were terminated by placing the cells on ice and washing in ice-cold PBS. 
All subsequent procedures were perfoiined at 4^ C^ unless indicated otherwise. Cells 
were solubilised by scraping into 0.3 ml/well JNK lysis buffer (25 mM Hepes-KOH, 
pH 7.7, 20 mM p-glycerophosphate, 0.3 M sodium chloride, 1.5 mM magnesium 
chloride, 10 mM sodium fluoride, 0.1 mM sodium vanadate, 0.1 mM PMSF and 10 
pg/ml each of soybean trypsin inhibitor and benzamidine) and incubated on ice for 
30 min. Following isolation o f soluble fractions by microcentrifugation, samples 
equalised for protein content and volume were incubated overnight with rotation with 
10 pg recombinant c-Jun(l-73) immobilised to glutathione-Sepharose beads. 
Complexes were isolated by brief microcentrifiigation, washed tlu'ee times with 1 ml 
wash buffer (20 niM Hepes-KOH, 50 mM sodium chloride, 2.5 mM magnesium 
chloride, 0.1 mM EDTA and 0.05 % (v/v) Triton X-100) and then resuspended in 30 
pi kinase assay buffer (25 mM Hepes, pH 7.5, 10 mM magnesium chloride, 20 mM 
P-glycerophosphate, 75 mM sodium vanadate) supplemented with 100 pM ATP and 
2 mM dithiothreitol. Kinase assays were performed at 30°C for 30 min and 
terminated by the addition of 10 pi electrophoresis sample buffer containing 12% 
SDS followed by incubation at 95°C for 5 min. Samples were fraetionated by SDS- 
PAGE using 12% (w/v) polyacrylamide resolving gels and transferred to 
nitrocellulose for immunoblotting with anti-phospho-Ser^^ c-Jun antibody for 
visualisation o f GST-c-Jun(l-73) phosphorylation by immobilised cellular JNK.
2.5.14 Statistical Analysis
Statistical analysis was carried out using Student t-test using GraphPad Prism 3.0 as 
indicated in the Figure Legends, Significance assessed as p<0.05.
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Chapter 3
Characterisation Of A Myc-Tagged WT A zaAR
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3.1 Introduction
The potent anti-inflammatory properties o f the A2aAR have been demonstrated in a 
variety of different animal models (Section 1.11.4). However, the precise molecular 
mechanism that results in this general property is not yet fully understood. To 
investigate this property further, a myc-epitope was added to the C-terminus o f the 
human A2aAR, which could be specifically identified by a high-afflnity, low- 
background monoclonal dxvi\-myc (EQKLISEEDL) 9E10 antibody, as reported for 
other myc-tagged receptors (Watterson et al., 2002). This was used in further 
experiments to distinguish recombinant A2aARs from endogenously expressed WT 
receptors. (For future purification purposes, the construet also contained a His-tag; 
HHHHHH). To be a usefril tool, it was essential that this tagged receptor behaved 
similarly to the WT receptor. Therefore, it was necessary to characterise the myc- 
His/A2AAR and compare it with the WT human A2aAR.
3.2 Results and Discussion
A cDNA plasmid was generated which would express a myc-His-tagged human 
A2aAR using the strategy and protocol outlined in Methods Section 2.3.7. A full 
nucleotide and protein sequenee of the reeeptor is shown in Figure 3.1. To determine 
whether the anti-A2AAR antibody could specifically identify the recombinant myc- 
His/A2AAR, CHO cells were transiently transfected with cDNA plasmids that would 
express canine AiAR, and A2aARs. Western blotting was then performed as 
described in Section 2.5.1 of the Materials and Methods, using a commercially 
available A2aAR antibody raised against residues which are highly
conserved between human and canine receptors. As shown in Figure 3.2, the anti- 
A2aAR specifically identified only the A2aAR, which migrates as a smear centred at 
45kDa. Higher molecular weight immunoreactive bands are consistent with the 
formation o f dimers, which has been recently reported (Ciruela et al., 1995; Canals et 
al., 2004). Over-exposure of the western blot reveals the absenee of any AiAR 
cross-reactivity suggesting the high specificity for the A2aAR.
Having confirmed the specificity o f the anti-A2AAR antibody, CHO cells transiently 
transfected with myc-His/A2AAR cDNA plasmids, were used to confirm the 
specificity o f the anti-myc antibody. Cells were then solubilised and duplicate 
samples were fractionated by SDS-PAGE. Following transfer o f the proteins to each
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nitrocellulose membrane, immunoblotting was performed using either the anti-myc 
{left panel) or the anti-AzAAR antibody {right panel. Figure 3.3). A myc-epitope 
tagged LacZ construct was also transfected into cells to act as a positive control for 
the antibody. Lanes 3, 4, and 5 indicate that the anti-myc antibody displays a high 
level of affinity for the receptor as a band is still present when cells are transfected 
with low amounts o f cDNA. Figure 3.3 also indicates that there are three specific 
inununoreactive bands o f ~491cDa, -45  IcDa and 431cDa which correspond to the 
A2aAR. The right panel in Figure 3.3 indicates that the anti-A2AAR antibody 
specifically recognises the same three immunoreactive bands. This suggests that the 
anti-myc antibody could be used in Riture experiment to specifically identify the 
myc-His/A2AAR. The increase in size of the receptor is consistent with the tagging 
of the receptor while the lower molecular weight bands might represent partial and 
fully glycosylated receptors.
To determine if  the recombinant myc-His-tagged human A2aAR was accurately 
expressed at the cell surface, biotin-labelling experiments were performed as 
described in Section 2.5,4 of the Materials and Methods. Briefly, myc-His/A2AAR 
transfected CHO cells were incubated with biotin hydrazide and were subject to 
immunoprécipitation with the anti-myc antibody. Immunoprecipitated proteins were 
fractionated on SDS-PAGE and transferred to a nitrocellulose membrane. Following 
incubation with HRP-streptavidin, biotinylated cell-surface expressed A2aARs were 
visualised using enhanced chemiluminescence techniques. Figure 3.4 indicates that 
the myc-His/A2AAR is expressed at the cell surface. In addition, the presence o f only 
one A2AAR-specific band in transfected cells confirms the earlier conclusion that 
lower molecular weight bands in Figure 3.3 represent incompletely processed 
receptors.
To investigate whether the addition of the myc epitope interfered with the 
pharmacological properties of the A2aAR, tagged and WT A2aARs were transfected 
into COS-P cells from which membranes were prepared for saturation radioligand 
binding assays, using the A2AAR-selective antagonist ^^^I-ZM241385 as described in 
Section 2.5.5. Figure 3.5 shows typical saturation binding curves for both receptors. 
Bmax values for both receptors were similar and Ka values were slightly different 
although within a range reported for the A2aAR (Palmer et al., 1995). A  summary of
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saturation binding data is found in Table 3.1. As addition o f the myc epitope 
conferred minimal differences in the binding of antagonist to the recombinant 
receptor, it was important to investigate if  the presence o f the myc-epitope altered 
any agonist-binding properties. Therefore, agonist competitive binding assays were 
performed using NECA (See Figure 3.6 and Table 3,2) as described in Section 2.5.6 
o f the Materials and Methods. Ki values for tagged versus untagged receptors (53.7 
± 0 . 9  iiM versus 63.1 ± 0.9 nM; n=3) indicate that there was a slight ehange in 
agonist binding properties. Thus, from both saturation radioligand binding and 
eompetitive binding studies, addition o f the myc epitiope did not dramatieally alter 
any of the phaiiuacological properties o f the receptor. In addition, the Kd and Kj 
values obtained are consistent with published values for the A2aAR (Fredholm et al., 
2001). In conelusion, addition o f the myc-epitope confers no significant difference 
on the cell surface expression and pharmacological profile o f the A2aAR.
As previously stated the A2aAR has a large C-terminal domain containing two 
clusters o f potential phosphorylation sites; Cluster 1, s32o_q36o Cluster 2,
(See Figure 3.1). One ultimate aim of these studies was to determine the effect 
o f receptor phosphorylation on the A2AAR-mediated anti-inflammatory effects. 
Therefore, two truncated mutant A2aARs were generated. A2aARA55 and 
A2aARA101 had 55 amino acids and 101 amino acids respectively removed from the 
C-terminal domain o f the receptor. This would allow us to determine which if any 
possible phosphorylation sites were important for any anti-inflammatory effect. The 
truncated receptors were generated from the tagged receptor using a similar approach 
outlined in Section 2.3.8 o f the Methods. Figure 3.7 shows a schematic diagram of 
the truneated receptors.
To ensure the efficient expression o f the truncated receptors, CHO cells were 
transfected with cDNA plasmids encoding full-length wyc-His/A2AAR, A2aARA55 
and A2aARA101. 24 hr post-transfection, cell lysates were made which were 
fractionated on SDS-PAGE and transferred to nitrocellulose membrane. Figure 3.8 
shows western blotting o f the truncated receptors using the anti-/Myc antibody. The 
truncated receptors produced bands of ~48kDa and ~45kDa consistent with the 
truncation of the C-temiinus. In addition, biotinylation experiments were performed
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to investigate the effect o f truncation on the cell surface expression o f the receptor. 
Figure 3.9 indicates that truncation of 55 amino acids makes little difference on the 
cell surface expression of the receptor. In contrast, removal of 101 residues makes a 
significant impact on the cell surface expression o f the receptor.
The pharmacological profile of the truncated constructs was also assessed using 
saturation binding studies and competition binding analysis as previously described 
(See Figure 3.5 and 3.6). Figure 3.10 and Table 3.3 indicate that neither truncation 
made any significant difference to the Kd o f the receptors however, the Bmax value for 
the A2aAR AlOl, was significantly decreased when compared with the full-length 
receptor, which is consistent with the immunoblotting and biotinylation data (Figure 
3.8, 3.9). In addition, competitive binding assays using NECA and CGS21680 were 
also performed with the full-length A2aAR and the truncated receptor proteins. 
Results indicated that there was no significant difference in K, values between each 
of the receptors treated with either NECA or CGS21680. Figure 3.11 shows a 
typical competition curve and Table 3.4 shows a summary o f the data. In conclusion, 
the loss of 55 amino acids makes little difference on the cell surface expression or 
pharmacological profile o f the receptor. In contrast, truncation o f 101 amino acids 
had a prominent effect on the cell surface expression and pharmacology of the 
receptor.
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Figure 3.1 Schematic diagram of the myc-His tagged AiaAR
The myc-His tagged hA2AAR was constructed using a polymerase chain 
reaction (PCR) approach. A myc-His tag was added to the C-terminus o f the 
A2aAR. The C-terminus of the protein is indicated by an asterisk and the 
myc-epitope tag is underlined opposite.
ATGCCCATCATGGGCTCCTCGGTGTACATCACGGTGGAGCTGGCCATTG CTGTGCTGGCCATCCTGGGCAAT 72 
M P I M G S S V Y I T V E L A I A V L A I L G N
GTGCTGGTGTGCTGGGCCGTGTGGCTCAACAGCAACCTGCAGAACGTCACCAACTAGTTGTGGTGTCACTG 144  
V L V C W A V W L N S N L Q N V T N Y F V V S L
GCGGCGGCCGACATCGCAGTGGGTGTGCTCGCCATCCCCTTTGCCATCACCATCAGCACCGGGTTCTGCGCT 216  
A A A D I A V G V L A I P F A I T I S T G F C A
GCCTGCCACGGCTGCCTCTTCATTGCCTGCTTCGTCCTGGTCCTCACGCAGAGCTCCATCTTCAGTCTCCTG 288  
A C H G C L F I A C F V L V L T Q S S I F S L L
GCCATCGCCATTGACCGCTACATTGCCATCCGCATCCCGCTCCGGTACAATGGCTTGGTGACCGGCACGAGG 360 
A I A I D R Y I A I R I P L R Y N G L V T G T R
GCTAAGGGCATCATTGCCATCTGCTGGGTGCTGTCGTTTGCCATCGGCCTGACTCCCATGCTAGGTTGGAAC 432  
A K G I I A I C W V L S F A I G L T P M L G W N
AACTGCGGTCAGCCAAAGGAGGGCAAGAACCACTCCCAGGGCTGCGGGGAGGGCCAAGTGGCCTGTCTCTTT 504 
N C G Q P K E G K N H S Q G C G E G Q V A C L F
GAGGATGTGGTCCCCATGAACTACATGGTGTACTTCAACTTCTTTGCCTGTGTGCTGGTGCCCCTGCTGCTC 576 
E D V V P M N Y M V Y F N F F A C V L V P L L L
ATGCTGGGTGTCTATTTGCGGATCTTCCTGGCGGCGCGACGACAGCTGAAGCAGATGGAGAGCCAGCCTCTG 648  
M L G V Y L R I F L A A R R Q L K Q M E S Q P L
CCGGGGGAGCGGGCACGGTCCACACT6CAGAAGGAGGTCCATGCTGCCAAGTCACTGGCCATCATTGTGGGG 720  
P G E R A R S T L Q K E V H A A K S L A I I V G
C TCTTTGCCCTCTGCTGG CTGCCCCTACACATCATCAACTGCTTCACTTTCTTCTGCCCCGACTGCAGCCAC 792 
L F A L C W L P L H I Ï N C F T F F C P D C S H
GCCCCTCTCTGGCTCATGTACCTGGCCATCGTCCTCTCCCACACCAATTCGGTTGTGAATCCCTTCATCTAC 864  
A P L W L M Y L A I V L S H T N S V V N P F I Y
GCCTACCGTATCCGCGAGTTCCGCCAGACCTTCCGCAAGATCATTCGCAGCCACGTCCTGAGGCAGCAAGAA 936  
A Y R I R E F R Q T F R K I I R S H V L R Q Q E
CCTTTCAAGGCAGCTGGCACCAGTGCCCGGGTCTTGGCAGCTCATGGCAGTGACGGAGAGCAGGTCAGCCTC 1008 
P F K A A G T S A R V L A A H G S D G E Q V S L
CGTCTCAACGGCCACCCGCCAGGAGTGTGGGCCAACGGCAGTGCTCCCCACCCTGAGCGGAGGCCCAATGGC 1080 
R L N G H P P G V W A N G S A P H P E R R P N G
TATGCCCTGGGGCTGGTGAGTGGAGGGAGTGCCCAAGAGTCCCAGGGGAACACGGGCCTCCCAGACGTGGAG 1152 
Y A L G L V S G G S A Q E S Q G N T G L P D V E
CTCCTTAG CCATGAGCTCAAGGGAGTGTG CCCAGAGCCC CCTGG CCTAGATGACCCCCTGGCCCAGGATGGA 1224 
L L S H E L K G V C P E P P G L D D P L A Q D G
GCAGGAGTGTCCTCTAGAGGGCCCTTCGAACAAAAACTCATCTCAGAAGAGGATCTGAATATGCATACCGGT 1296  
A G V S S R G P F E Q K L I S E E D L N M H T G
CATCATCACCATCACCATTGA 1317  H H H H H H  .
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Figure 3.2 Immunodetection of the canine A2aAR using an anti-AiAAR antibody
CHO cells were transiently transfected with cDNAs encoding the canine 
A[AR and canine AzaAR. Cells were then solubilised and fraetionated on 
SDS-PAGE. Proteins were then transferred to nitrocellulose and 
immunoblotted for the presence of the AiAR {left panel) and the A2aAR 
{right panel) as described in Section 2.5.1 in the Materials and Methods. 
This western blot represents one of multiple experiments.
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Figure 3.3 Immunodetection of the human A2aAR using an anti-myc antibody
CHO ceils were transiently transfected with the following different cDNAs; 
pCMV5 vector, myc-tagged Lac Z and increasing concentrations o f myc- 
AiaAR in pg, as indicated. Cells were then solubilised and equalised for 
protein. Duplicate samples were then fractionated on SDS-PAGE and 
transferred to nitrocellulose. One blot was immunoblotted with the anti- 
9E10 antibody, as indicated in the left panel while the other was 
immunoblotted with an anti-A2AAR antibody {right panel). These blots 
represent one of multiple experiments.
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Figure 3.4 Biotinylation of cell-surface A2aARs
CHO cells transiently expressing the myc-His-tagged A2aAR were labelled 
with biotin-LC-hydrazide according to the Methods in Section 2.5.3. Cell 
lysates were then prepared, equalised for protein content, and 
immunoprecipitated with anti-myc (9E10). Immunoprecipitates were then 
fractionated by SDS-PAGE and transfen*ed to nitrocellulose. Biotinylated 
A2aARs were detected by incubation with HRP-conjugated streptavidin as 
described in Section 2.5.3. Biotin-labelled proteins were then visualised 
using enhanced chemiluminescence. This represents one o f several 
experiments.
. ( TM r (X10‘^ )
# mycA2AAR
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Figure 3.5 *^^I-ZM241385 saturation binding analysis of WT and myc-His tagged
human A iaARs
Saturation binding studies were carried out on COS-P cells transiently 
transfected with the WT AiaAR and myc-His tagged A2aAR using the 
A2AAR-selective antagonist '^^I-ZM241385. Membrane preparation and 
radioligand binding procedures are detailed in the Methods Section 2.5.4. 
The graph shown here represents one typical saturation binding curve. 
Composite data from three experiments is shown in Table 3.1.+ S.E.M.
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Table 3.1 *^^I-ZM241385 saturation binding analysis of WT and mjc-His tagged
human AzaARs
Membranes prepared from COS-P cells transiently transfected with WT 
A2aAR and myc-Yim tagged A2aARs were used for saturation binding 
analysis using the A2AAR-selective antagonist ^^^I-ZM241385 as described 
in Section 2.5.4 of the Materials and Methods. Results are presented as 
means ± standard error of the mean for three experiments.
Receptor Kd (nM) Bmax (pmol/mg protein)
WT A2aAR 0.50 + 0.07 1.45 + 0.51
A^c-His-tagged A2aAR 1.00 + 0.11 3.38 + 0.47
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Figure 3.6 Agonist competition radioligand binding assay at WT and wyc-His 
tagged AiaARs using the AR agonist NECA
Membranes were prepared from COS-P cells transiently transfected with 
the WT A2aAR and the wyc-His tagged A2aAR. Competitive binding assays 
were set up containing InM ^^^I-ZM241385 and increasing concentrations 
o f NECA as indicated (Section 2.5.6). The IC50 (the concentration at which 
50% of specific binding was inhibited) was determined by plotting cpm 
against log {[NECA] (M)} and fitted to a one-site competition curve using 
non-linear regression in GraphPad Prism. The Ki was then calculated using 
the Cheng-Prusoff equation. The graph shown here represents one typical 
competition curve. Composite data from three experiments is shown in 
Table 3.2 ± S.E.M.
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Table 3.2 Agonist competition radioligand binding assay at WT and myc-His 
tagged AiaARs using the AR agonist NECA
Membranes prepared from COS-P cells transiently transfected with WT 
A2aAR and myc-His tagged A2aARs, were used for competition radioligand 
binding analysis using *^^I-ZM241385 and increasing concentrations of 
NECA as described in Section 2.5.6 of the Materials and Methods. The 
IC50 (the concentration at which 50% of specific binding was inhibited) was 
determined by plotting cpm against log {[NECA] M} and fitted to a one- 
site competition curve using non-linear regression in GraphPad Prism. The 
Ki was then calculated using the Cheng-Prusoff equation. Results are 
presented as means ± standard error o f the mean for three experiments.
Receptor pKi NECA
WT A2aAR 121  ± 0.04
^ c -H is-tag g ed  AiaAR 7.20 ± 0.03
I l l
Figure 3.7 Schematic diagram of A 2aAR A55 and A 2aAR AlOl
The wyc-His tagged A2aAR was used as a template to generate truncated 
constructs at the positions indicated (*), according to the procedure outlined 
in Section 2,3.7 o f the Materials and Methods. The mutants contained 
deletions of two clusters o f potential phosphorylation sites, on the C- 
terminal tail o f the receptor indicated by either — (Cluster 1) or (Cluster 
2).
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Figure 3.8 Immunodetection of truncated receptor constructs using an anti-wj;c 
antibody
CHO cells were transiently transfected with cDNAs encoding the full- 
length A2aAR, A2aAR A55 and A2aAR AlOL Cells were then solubilised 
and fractionated on SDS-PAGE. Proteins were then transferred to 
nitrocellulose and immunoblotted for the presence of the A2aAR using an 
anti-?72yc antibody. This blot represents one o f multiple experiments 
performed.
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Figure 3.9 Biotinylation of cell surface expressed truncated receptor constructs
CHO cells were transiently transfected with cDNAs eneoding the full- 
length A2aAR, A2aAR A55and A2aAR AlOl. The next day cells were 
labelled with biotin-LC-hydrazide according to the Methods in Section
2.5.3, Cell lysates were then prepared, equalised for protein content, and 
inimunoprecipitated with anti-myc (9E10). Immunoprecipitates were then 
fractionated by SDS-PAGE and transferred to nitrocellulose. Biotinylated 
A2aARs were detected by incubation with HRP-conjugated streptavidin as 
described in Section 2.5.3. Biotin-labelled proteins were then visualised 
using enhanced chemiluminescence. This represents one o f several
experiments.
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Fig 3.10 ^^^I-ZM241385 saturation binding analysis of WT and truncated myc-
His tagged AzaAR receptors
Saturation binding studies were carried out on COS-P cells transiently 
transfected with the myc-Eis tagged AzaAR, AzaAR A55 and AzaAR AlOl 
using the A zaA R -selective antagonist ^^^I-ZM241385. Membrane 
preparation and radioligand binding procedures are detailed in the Section
2.5.4. of the Materials and Methods. The graph shown opposite represents 
one typical experiment. Composite data from three experiments is 
presented in Table 3.3 ± S.E.M.
0.30-1
0 .2 5 -
0 .2 0 -u>
5  0 .1 5 -
0.10
0 .0 5 -
0.00
0 1 2 3 4 5 6 7 8
[^^®I-ZM241385] (nM)
119
Table 3.3 ^^^I-ZM241385 saturation binding analysis of WT and truncated myc-
His tagged AzaAR  receptors
Membranes prepared from COS-P cells transiently transfected with myc-His 
tagged AzaAR, A zaA R  A55and A zaAR AlOl were used for saturation 
binding analysis using the AzAAR-selective antagonist ^^^I-ZM241385 as 
described in Section 2.5.4 o f the Materials and Methods. Results are 
presented as means ± standard error of the mean for three experiments.
Receptor Kd (nM) Bmax (pmol/mg protein)
AzaAR 1.00 + 0.11 3.38 + 0.47
AzaARA55 0.98 + 0.11 5.40 + 0.85
AzaARAIOI 1.27 + 0.24 1.61 + 0.03
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Figure 3.11 Agonist competition radioligand binding assay at WT and myc-His 
tagged AzaARs using the AR agonists NECA and CGS21680
Membranes were prepared from COS-P cells transiently transfected with 
ffiyc-His tagged A zaAR, AzaA R A55 and A zaA R AlOl. Competitive 
binding assays were set up containing InM  ^^^I-ZM241385 and increasing 
concentrations of NECA as indicated (Section 2.5.6). The IC50 (the 
concentration at which 50% of specific binding was inhibited) was 
determined by plotting epm against log {[competing ligand] (M)} and fitted 
to a one-site competition curve using non-linear regression in GraphPad 
Prism. The K, was then calculated using the Cheng-Prusoff equation. The 
graph shown here represents one typical competition curve. Composite data 
from three experiments is shown in Table 3.4 ± S.E.M.
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Table 3.4 Agonist competition radioligand binding assay WT and truncated myc- 
His tagged AzaAR receptors using the AR agonist NECA
Membranes prepared from COS-P cells transiently transfected with myc-His 
tagged A zaAR, A zaA R A55and A zaA R  AlOl, were used for competition 
radioligand binding analysis using ^^^I-ZM241385 and increasing 
concentrations of NECA as described in Section 2.5.6 o f the Materials and 
Methods. The IC50 (the concentration at which 50% o f specific binding was 
inhibited) was determined by plotting cpm against log {[NECA] M} and 
fitted to a one-site competition curve using non-linear regression in 
GraphPad Prism. The Ki was then calculated using the Cheng-Prusoff 
equation. Results are presented as means ± standard error o f the mean for 
three experiments.
Receptor pKi NECA pKi CGS21680
AzaAR 7 .1810 .06 7 .1010 .07
AzaARA55 7 .1710.03 7 .1210 .07
Az A ARA101 6.7610.125 6.8210 .154
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Chapter 4
Effect O f AzaAR  Gene Transfer On The Regulation O f NF-KB-Dependent 
Inflammatory Responses In HUVECs
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4.1 Introduction
Inflammation is a key factor in the progression o f several disease states such as ischaemia- 
reperfusion injury (Sullivan et al, 2000) and atherosclerosis (Greaves and Channon, 2002). 
The regulated interactions between endothelial cells and leukocytes are fundamental to the 
inflammatory response as they trigger further downstream events including cytokine, 
chemokine and growth factor release, surface expression of adhesion molecules and 
expression of other pro-inflammatory proteins such as iNOS, COX-2 and others (See 
Chapter 1). Thus, the suppression of endothelial cell-leukocyte interactions in chronic 
inflammation could provide therapeutic benefit. In several studies of inflammation, 
activation of the AzaAR has an anti-inflammatory effect in vivo (McPherson et a i,  2001; 
Cassada et al., 2002; Section 1.11.4). However, the precise mechanism that underlies this 
important property is not yet fully understood. In order to investigate this property, it was 
necessary to establish a suitable model of inflammation in vitro. HUVECS are a 
commonly used endothelial cell type used in studies of inflammation (Carman et al., 2003; 
Ahn et al., 2003; Mo et al., 2003), as they grow more easily in cell culture compared to 
other human endothelial cell types. However, a disadvantage o f using primaiy endothelial 
cells is the difficulty with which new cDNAs can be introduced. This was important as 
any inhibitory effect of the A zaA R  activation in transfected cells would be undetected if 
transfection efficiencies were poor. Generally standard transfection methods yield poor 
transfection efficiencies (2-10%) in endothelial cells (Teifel et al., 1997). Therefore, in 
order to bypass this problem, a replication-deficient recombinant adenovirus encoding a 
myc-His-tagged human A zaAR, was used to obtain higher levels of A zaA R transfection. 
The aim of this chapter was to determine what effect adenoviral gene transfer o f the myc- 
His-tagged human AzaA R would have on the inflammatory response in HUVECs, and 
what AzAAR-stiniulated molecular mechanisms were involved.
4.2 Results
To investigate the role of endogenous A zaA R s in vitro, confluent HUVEC monolayers 
were treated with increasing concentrations of TN Fa for 6 hours in the presence or 
absence o f an AzAAR-selective agonist CGS21680, and a monocyte adhesion assay was 
performed. Figure 4.1 indicates that there is a saturable dose-dependent increase in the 
number o f adherent U937 cells to TNFa-stimulated HUVEC monolayers. Co­
administration of CGS21680, reduces the monocyte adhesion suggesting that endogenous
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AzaAR activation has an anti-inflammatory role in vitro. The observation that some U937 
cells still adhere to TNFa-stimulated HUVECs in the presence o f CGS21680, suggested 
that potentiation o f the A zaAR effect might further reduce the number of adherent U937 
cells. Comparative studies by Armstrong et al., (2001) in AzaAR’*'^ " and AzaAR''^' cells 
revealed the absence o f any receptor reserve in murine T-lymphocytes suggesting that 
increasing agonist concentration would have no effect in increasing the reduction in 
monocyte adhesion. Taking this into consideration, one way of potentiating the A zaAR  
effeet was to increase AzaAR expression. In order to achieve this efficiently, a replication- 
deficient recombinant adenovirus expressing the /Myc-His-tagged-human AzaAR (AV/myc- 
His A zaAR) was used to drive A zaA R gene expression in HUVECs. A schematic outline 
o f the isolation and propogation o f the AV//7zyc-His A zaA R is described in detail in Section 
2.4 of the Materials and Methods. One advantage of the AV/myc-His A zaAR construct 
was the co-expression from a separate open reading frame o f GFP, thus allowing us to 
easily detect and monitor recombinant protein expression in AV-infected cells by 
fluorescence microscopy.
To confirm the efficient AV-directed expression o f the A zaAR, confluent HUVEC 
monolayers were infected with inereasing coneentrations of virus (pfu/ml; Figure 4.2). 
The next day cells were analysed by fluorescence microscopy and immunoblotting with the 
anti-myc antibody 9E10. Figure 4.2 indicates that there is a titration dependent increase in 
the percentage of cells infected with A zaAR, which is maximal at 25 pfu/ml. In addition, 
there is also a titration-dependent increase in AzaA R expression o f the myc-His A zaA R  
which peaks at 25 pfli/ml as determined by Western blotting. The immunoreactive bands 
present at -49  IcDa and -4 6  kDa correspond with that o f AzAAR-transfected cells (See 
Figure 3.2) indicating that expression of AV/myc-His AzaA R  in HUVECs, does not alter 
the A zaA R protein. It was then necessary to show that the AzaA R  was fully processed and 
expressed at the cell surfaee. ' Cell-surface biotinylation assays were performed on 
AV/myc-His AzaAR infected HUVECs as described in the Materials and Methods Section 
2.5.4. Figure 4.3 shows that only one reactive band is present which is consistent with the 
molecular weight of the major A zaAR immunoreactive band in Figure 4.2. This suggests 
that lower molecular weight bands most likely conespond to non-glycosylated receptors. 
The detection o f myc-His A zaAR expression in HUVECs confirmed the use o f the 
AV/myc-His A zaAR as an efficient means of gene transfer.
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^^^I-ZM-241385 saturation binding analysis was also performed upon membranes isolated 
from AV/myc-His AzAAR-infected HUVECs in order to quantify the expression of 
exogenously expressed myc-His A zaAR. Figure 4.4 shows a typical saturation binding 
curve for one such experiment. The B^ax of receptor expression is similar to levels found 
in the human striatum -0 .3  pmol/mg (Ji et al., 1992) and the Kd is similar to published 
values obtained in human neutrophils (Sullivan et al., 1999). No specific binding was 
detected in control AV-infected cells.
Confirmation of efficient AV/myc-His AzaAR expression in HUVECs, facilitated the 
investigation into the effect of AzaAR expression on monocyte adhesion to inflamed 
HUVECs. Therefore, confluent HUVEC monolayers infected with either AV/A zaA R or 
control virus were treated with TN Fa for 6 hours and subjected to a monocyte adhesion 
assay as described in Section 2.5.9. Consistent with Figure 4.1, Figure 4.5 indicates that in 
control infected HUVEC monolayers there is an increase in the number of adherent U937 
cells, when monolayers are treated with TNFa. This effect is not significantly affected 
when treated with the AR agonist NECA. In contrast, infection of HUVECs with AV/myc- 
His A zaA R significantly reduces the number of adherent U937 cells when compared with 
control virus even in the absence o f agonist. This indicates that the expression of the 
A zaA R  alone can constitutively inhibit U937 monocyte adhesion to TNFa-treated 
HUVECs in the absence o f agonist (84 ± 8%, n=3, p <0.05 versus TNFa-treated HUVECs 
infected with control AV/GFP).
Since the adhesion o f monocytes to endothelial cells is dependent upon the expression of 
adhesion molecules (See Figure 1.1), the monocyte adhesion data suggests that the A zaAR  
may decrease adhesion molecule expression. One adhesion molecule important in the 
initial rolling and tethering of monocytes to endothelial cells, under laminar flow, is E- 
selectin (Ulbrich et al., 2003; Section 1.2.1). Therefore to determine if  cell surface E- 
selectin was expressed, cell surface ELIS As were performed as described in Section 2.5.7 
of the Materials and Methods. In agreement with other studies (Mutin et al., 1997; Cohen,
2002), a dose response curve to TN Fa when treated for 6 hr indicates that E-selectin was 
maximally induced by 10 ng/ml (Figure 4.6). In addition, a time-course experiment in 
response to 10 ng/ml TN Fa indicates that E-selectin was maximally induced at 6 hr which 
then decreases to approximately half maximal expression where it remains elevated for up
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to 24 hr (Figure 4.7). Thus, E-selectin expression was maximally induced in HUVECs 
using 10 ng/ml TN Fa for 6 hr. The efficient identification o f cell surface E-selectin 
expression allowed its characterisation in AV/myc-His AzaAR and eontrol virus-infected 
TNFa-stimulated HUVECs. Figure 4.8 indicates that there is a 76 ± 5% reduction (n=3, 
p<0.05 versus TNFa-treated AV/GFP infected HUVECs) in the expression o f E-selectin in 
response to TNFa. These data are consistent with the monocyte adhesion assays and 
indicates that A zaA R  expression can inhibit E-selectin expression leading to a decrease in 
the adhesion of monocytes to TNFa-stimulated HUVECs. Treatment of AzAAR-infected 
HUVEC monolayers with purified EPS from E.coli was also used to determine if  the 
AzAAR-mediated effects on E-selectin expression were specific to TNFa. Figure 4.9 
shows that in control virus-infected HUVECs, treatment with EPS for 6 hr increases the 
expression of E-selectin similar to TN Fa. There is no difference in the presence of the AR 
selective agonist NECA. In contrast, in AV/myc-His A zaA R  infected HUVECs, there is no 
detectable increase in E-selectin expression indicating that A zaA R  activation can also 
inhibit EPS-stimulated E-selectin expression in HUVECs. One possible reason for this is 
that AzaAR activation can inhibit a shared component of both TNFa-stimulated and EPS- 
stimulated pathways. One such component is NF-kB, suggesting its potential involvement 
in the AzAAR-mediated inhibition o f E-selectin expression.
The regulation of E-selectin expression is controlled primarily at the level o f transcription 
(Meacock et al., 1994). Analysis of the human E-seleetin promoter indicates that there are 
four positive regulatory domains (PD), which regulate the inducible transcription of E- 
selectin. PDs I, III and IV are NF-kB binding sites while PD II is an AP-1 site at which an 
ATF2/c~jun heterodimer is constitutively bound (Read et al., 1997). Therefore induction 
o f E-selectin is dependent upon the activation of both NF-kB as well as the p38- and JNK- 
mediated phosphorylation o f ATF2 and c-jun respectively. Therefore AzaAR activation 
may inhibit one or more of the transcription factors or upstream signalling cascades 
responsible for E-selectin activation. Therefore different signalling cascade inhibitors, 
which target NF-kB and ATF2 were used to inhibit E-selectin expression in TN Fa- 
stimulated HUVECs. Figure 4.10 shows clearly the induction o f E-selectin following 
T N Fa treatment. Treatment o f the cells with the p38 MAPK inhibitor SB203580, an 
upstream kinase of ATF2, failed to inhibit the expression of E-selectin. This suggests that 
inhibition o f ATF2-dependent transcription by AzaAR activation would not inhibit E-
130
selectin expression. In addition, A2aAR activation in endothelial cells can also activate 
M EKl (Sexl et aL, 1997) in a Gs-independent manner, leading to ERK phosphorylation. 
Cells were therefore treated with the M EKl inhibitor PD98059, however it failed to inliibit 
E-selectin expression suggesting that ERK activity is not important for the A2aAR 
inhibition o f E-selectin expression. In contrast, treatment with PDTC, an antioxidant that 
selectively blocks the dissociation o f IkB from the cytoplasmic NF-kB, thus preventing the 
activation and nuclear translocation o f NF-kB (Schreck et a l,  1992), shows a marked 
decrease in E-selectin expression. Cells were also incubated with the anti-oxidant N- 
acetyl-cysteine as a control for the anti-oxidant effects of PDTC. This result indicates that 
A2aAR activation in AV/myc-His A2AAR-infected HUVECs may inhibit NF-icB activity. 
In addition, to the activation of ERK, other A2AAR-activated signalling pathways might 
mediate the inhibition of E-selectin. A2aAR activation classically stimulates the 
production o f cAMP by Gg-coupled activation o f adenylyl cyclase. Treatment with the 
adenylyl cyclase activator forskolin, which mimics receptor activation however, failed to 
inhibit E-selectin expression suggesting that the inhibition of E-seleetin, is not eAMP- 
dependent. Overall the results suggest that the inhibition o f E-selectin expression in 
AV/myc-His A2AAR-infected HUVECs, occurs at the level of NF-kB via an unidentified 
A2AAR-stiniulated mechanism.
The marked effects o f PDTC on monocyte adhesion and E-selectin expression in TNFa- 
stimulated HUVECs, which mimic the A2AAR-mediated responses, indicate that iidiibition 
o f NF-kB (Section 1.7.5) may be responsible for the A2aAR anti-inflammatory response. 
Therefore, to determine any differences in the DNA binding activity o f NF-kB in 
AV/A2AAR-infeeted ceils, nuclear extracts were prepared for EMSA analysis using a kB- 
specific-radiolabelled probe, from TNFa-stimulated HUVECs infected with either control 
virus or AVhnyc-Yiis, A2aAR as detailed in Section 2.5.9. Figure 4.12 indicates that in 
control virus-infected cells, treatment with TN Fa led to an increase in the level of NF-kB 
bound to the DNA probe. Use of subunit specific antibodies in supershift analysis 
indicated that this complex consists of p50 and p65 subunits. In contrast, in AV/zMyc-His 
A2aAR infected cells, the level of NF-kB bound to the DNA probe was dramatically 
reduced following TN Fa treatment.
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The reduction in NF-kB binding to DNA may represent one o f two possibilities, one in 
which there is a reduction in NF-icB activity or another in which there is a reduction in 
translocation o f NF-kB from the cytoplasm to the nucleus. To discriminate between these 
possibilities, confocal laser scanning microscopy of HUVECs infected with either control 
virus or AV/myc-His A2aAR, in the presence or absence o f T N Fa was performed as 
indicated in Section 2.5.11. Figure 4.13 indicates that in unstimulated AV/GFP infected 
cells, p65 (red) is predominantly located outside the nucleus. Upon stimulation with 
TNFa, p65 translocates into the nucleus in cells infected with control virus. In contrast, in 
cells expressing the AV/myc-His A2aAR, p65 is still predominantly located outside the 
nucleus. Notably, some uninfected cells present within the same field also show p65 
nuclear translocation similar to control virus-infected cells.
The nuclear import of p65 is tightly regulated by the interaction NF-icB with the 
cytoplasmic partner IkB (Section 1.7.4). This is due to masking o f the NLS present on 
p65. However, stimulus-dependent degradation of IkB unmasks this sequence and NF-kB 
can then translocate to the nucleus to drive NF-KB-dependent transcription (Section 1.7 of 
Introduction). Therefore having demonstrated an inhibitory effect of AV/myc-His A2aAR 
on nuclear translocation, it was important to ascertain if  AV/myc-His A2aAR had any 
effect upon IkB degradation. Thus immunoblotting analysis using anti-myc and anti-IicBa 
antibodies were performed on TNFa-stimulated virus infected HUVECs. Figure 4.14 
indicates that in control virus-infected HUVECs, IicBa was degraded by 15 min and 
returned by 60 min due to the fact that NF-kB regulates the transcription of IicBa (Section 
1.7.4). Surprisingly, in AV/myc-His A2AAR-infected cells, IicBa was degraded with the 
same kinetics of degradation and re-appearance, although reappearance at 60 min was 
reduced. Western blots were stripped and re-probed to indicate the presence o f the myc- 
His A2aAR. Thus AV/myc-His A2aAR directed gene transfer does not impair the 
degradation of IicBa.
4.3 Discussion
The anti-inflammatoiy effects o f the nucleoside adenosine have been documented in 
several animal models o f inflammation (See Section 1.11.4 o f Introduction). However, the 
precise molecular details are incompletely understood. The results presented here 
demonstrate that activation of endogenous A2aARs can decrease monocyte adhesion to
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T N Fa stimulated HUVECs in vitro. The number of A2aARs is rate-limiting in murine T 
lymphocytes as previously reported by Armstrong et a l ,  (2001), therefore one way to 
potentiate the anti-inflammatory effect of the A2aAR was to increase receptor number. 
Infection of low-passage HUVECs with AV/A2aAR, could significantly inhibit adhesion 
o f U937 monocytes to TNFa-treated confluent HUVEC monolayers. This A2aAR- 
mediated effect eon'clated with a significant decrease in cell surface expression of E- 
selectin, an adhesion molecule important in leukocyte-endothelial cell interactions (See 
Section 1.2.1). The decrease in E-selectin expression was associated with a decrease in the 
DNA-binding ability o f the transcription factor NF-icB. This decreased DNA binding 
ability correlated with a reduction of signal-induced p65-dependent nuclear import, which 
is an essential step in NF-KB-dependent transcription. As p65 nuclear import is dependent 
upon the signal-induced degradation o f IicBa, Western blot analysis of IicBa surprisingly 
revealed that there is no inhibition of iKBa degradation in response to TNFa. This 
suggests that the A2AAR-mediated mechanism o f inhibition occurs downstream of IicBa 
degradation. The results presented suggest that A2aAR activation can inhibit NF-icB 
activity at the level of nuclear translocation, although the precise mechanism is still 
unknown.
The results of this investigation are in agreement with several other investigations of NF- 
kB inhibition which occurs at the level o f nuclear transport, including inhibition by 
synthetic compounds (Wong et a l,  2003; Ariga et a l,  2002; Loewe et a l,  2002) or by 
naturally occurring anti-oxidants (Schubert et a l,  2002), although the role o f anti-oxidants 
remains unclear as N-acetyl cysteine showed no anti-inflammatoiy effect in endothelial 
cells in this study. One report by Majumdar and Aggarwal (2003), concludes that 
adenosine can inhibit NF-kB activation in human myeloid KBM-5 cells in an A2AR- 
dependent manner. This effect was not limited to KBM-5 cells as adenosine could also 
inhibit NF-kB activation in other lymphocytic and epithelial cell types. The A2AR- 
dependent effects were determined by EMSA analysis and reporter gene assays suggesting 
that adenosine inhibits NF-kB binding to DNA and consequent reporter gene activity. This 
decrease was not due to inhibition o f TNFa-indueed IkB a  phosphorylation, degradation or 
IKK activity. They proposed a mechanism whereby A2AR activation modulates the 
amount of adenosine in the cell resulting in the direct interaction o f adenosine with NF-kB, 
which inhibits NF-kB-DNA binding. It is unknown in this study if  intracellular adenosine
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can directly inhibit NF-kB, however, in contrast to their study, results presented in this 
chapter indicate that A2aAR expression blocked NF-KB-mediated induction o f E-seleetin 
by both TN Fa and EPS suggesting that A2aAR expression can affect a common 
component in TN Fa and LPS/TLR4 signalling cascades. One such possibility is the 
stimulus-induced translocation o f p65 to the nucleus.
The cuiTcnt model of NF-kB activation (Figure 1.5), although useful, does not adequately 
explain all aspects o f NF-kB activation. For example, Huang et al (2000) demonstrated 
that in unstimulated HEK293 cells, treatment with the nuclear export inhibitor leptomycin 
B resulted in the nuclear accumulation o f inactive p65:p50:Ii<Ba complexes. This suggests 
that inactive complexes constitutively shuttle between the nucleus and the cytoplasm. 
Further structural studies have indicated that this is due to incomplete masking o f the NLS 
present on p50, and the NES present upon iKBa and p65 (Arenzana-Seisdedos et a l,  1997; 
Rodriguez et al., 1999; Haraj and Sun, 1999; Ghosh and Karin, 2002). However, the 
cytoplasmic location o f these complexes, suggest that nuelear export o f the complex 
predominates over the nuclear import. The absence o f a NES on IkB(3 or IicBy suggests 
that only hcBa can shuttle in this way (Malek et a l,  2001; Tam and Sen, 2001). In 
addition, nucleocytoplasmic shuttling has already been reported for other transcription 
factors e.g. STAT3 (Pranada et a l ,  2004) and E2F4 (Deschenes et a l ,  2004).
The possibility o f nucleocytoplasmic shuttling between the nueleus and cytoplasm raises 
the question o f where cytokine-induced iKBa phosphorylation and degradation occurs. 
Cytosolic phosphorylation and degradation is supported by several findings, which include 
the observation that the IKK complex, which leads to the cytokine-induced 
phosphoiylation of iKBa, is mainly found in the cytoplasm. This is despite recent 
evidence supporting an additional role for IK K a in the nucleus where nuclear IK K a 
activity phosphoiylates Ser 10 on histone-3, an event known to correlate to active gene 
expression, however this is not required for cytokine-induced degradation o f IicBa (Anest 
et a l,  2003; Yamamoto et a l ,  2003)). In addition, the degradation of IicBa is blocked in 
leptomycin B-treated cells, suggesting that phosphorylation and degradation occur in the 
cytoplasm (Rodriguez et a l ,  1999). In contrast, studies by Renard et a l,  (2000) indicated 
that treatment of cells with leptomycin B for 40 min, resulted in the TN Fa- and IL-1- 
stimulated degradation o f IicBa suggesting that phosphorylation and degradation were still
134
possibly supporting a role for nuclear degradation. This is supported by evidence that 
shows that p-TrCP, a component of the IicBa ubiquitination pathway required for IicBa 
degradation is exclusively located in the nucleus via an association with hnRNP-u. Thus, 
the precise mechanism leading to the phosphorylation and degradation of IicBa is still 
unclear.
Applying these observations to the A2AAR-mediated inhibition of p65-dependent 
translocation, two models can be proposed. If  the existing model o f NF-icB activation is 
correct, ie non-cytoplasmic shuttling, the results suggest that A2aAR activation inhibits 
nuclear import. If  in contrast, nucleocytoplasmic shuttling does occur, then A2aAR 
activation could facilitate p65 nuclear export in addition to the inhibition o f nuclear import. 
Furthermore, if  licBa phosphorylation and degradation occurs in the nucleus, then A2aAR 
activity would facilitate the rapid nuclear export of p65 to the eytoplasm prior to gene 
activation. Irrespective o f the location of IicBa phosphorylation and degradation, each 
theoretical model relies upon either the inhibition o f nuclear import or the rapid nuclear 
export of p65. This could be achieved in a number o f different ways which will be 
outlined below.
One possible mechanism to inhibit nuclear import of active p65 into the nueleus would be 
the binding of another protein to p65, such that following IicBa degradation, p65 is 
retained in the eytosol in an analogous fashion to IicBa. Examples might include other IicB 
proteins e.g. IxBp or IkBs (Tam and Sen, 2001) or perhaps with other cytosolic proteins 
e.g. Fas-associated factor (FAF-1). FAF-1 was identified in a yeast-two hybrid screen for 
Fas-interacting proteins and has been shown to inhibit NF-kB activation by directly 
binding to p65 to suppress nuclear translocation (Park et a l,  2004). This suggests that 
A2aAR activation may promote the binding of p65 to other cytosolic proteins thereby 
inliibiting p65 nuclear translocation.
In addition to the interaction with FAF-1, p65 has also been shown to interact with P in-1. 
Pin-1 is a peptidyl-prolyl isomerase, which binds to phosphorylated serine or tlrreonine 
residues which precede proline residues on target proteins to induce conformational 
changes that modulate the activity, phosphoiylation status, subcellular localization and 
protein stability of target proteins. Investigations reveal that following cytokine treatment, 
Pin-1 specifically binds to the phospho-Thr^^'^-Pro m otif on p65, which inhibits the
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interaction with hcBa but has no effect on the interaction with p50. This results in 
enhanced nuclear accumulation and increased protein stability o f p65 and therefore 
enhances NF-kB activity (Ryo et a l, 2003). Thus in this model, A2aAR activation would 
inhibit the binding of P in-1 to p65 resulting in a decrease in nuclear translocation.
Other potential mechanisms that may also inhibit the nuclear import o f p65 include post- 
translational modification o f p65 such that p65 is no longer recognised by the nuclear pore 
complex. Several studies have shown that p65 is phosphorylated by a number of upstream 
kinases including IKK, M SKl, CKII and cPKA (Vermeulen et a l ,  2002). This post- 
translational modification has been shown to alter NF-kB activity by directing the 
association of p65 with CBP or HD AC. The interaction with GBP leads to the acétylation 
o f p65, which enhances p65-dependent transcription. However, neither of these 
modifications show a clear role in nuclear import. In contrast, studies in Drosophila o f the 
Rel-family transcription factor Dorsal, indicate that phosphorylation of S317 is necessary 
for nuclear import. As this residue is conseiwed amongst all Rel-family transcription 
factors it is possible that phosphorylation at this site in other family members may also 
regulate NF-kB activity (Drier et a l ,  1999). Further studies by Maier et a l,  (2003) 
indicate that mutation of Ser 281, the corresponding residue in p65, resulted in a decrease 
in DNA-binding activity and a decrease in NF-KB-dependent reporter gene transcription, 
but they did not analyse nuclear translocation (Maier et a l, (2003). However, 
investigations of the coiTcsponding residue in Rel B showed that mutation o f Ser 368 is not 
critical for nuclear import but is instead important for dimérisation with other members of 
the family.
Finally, one other potential mechanism that would impede nuclear import o f p65, is the 
direct alteration of nuclear pore complex components such as importin a  or p resulting in 
the cytoplasmic retention ofp65. Studies in dividing and quiescent nuclei suggest that 
soluble transport factors such as RanGTP present in the cytoplasm are required for nuclear 
transport. Despite the relative constant levels of RanGTP during the cell cycle however, 
nuclear pore complex composition and conformation may change depending upon cellular 
demands. Thus the state of the cell may dictate nuclear pore complex formation 
(Gasiorowski and Dean, 2003). However, the most common regulation of 
nucelocytoplasmic movement results from post-translational modifications of the cargo
136
proteins themselves, which have been discussed above. Therefore alteration of the nuclear 
pore complex is unlikely to account for the pattern of p65 expression observed in this 
investigation.
In contrast to the inhibition o f p65 nuclear import, rapid activation o f nuclear export could 
also account for the sustained cytosolic localisation o f p65. This could be facilitated by the 
NES present on p65 (Haraj et a l,  1999). In this model, p65 nuelear import would take 
place however, in contrast to its sustained nuclear localisation for NF-KB-dependent gene 
transcription, it would be rapidly exported out o f the nucleus leading to the observed 
cytoplasmic localisation. This model suggests that p65 interaction with a nuclear protein, 
for example CBP or HD AC (Zhong et al., 2002) is essential for the continued presence of 
p65 within the nucleus. Thus the A2aAR activation could inhibit this interaction leading to 
rapid export.
In addition to direct p65 nuclear export via the NES, it has also been recently reported that 
in Caco-2 cells, treatment with the non-pathogenic bacteria B. thetaiotaomicron can 
selectively antagonise NF-kB activity by enhancing its nuclear export by a peroxisome 
proliferator-activated receptor-y (PPARy)-dependent, Cmi-1-independent mechanism 
(Kelly et al., 2004). PPARs are a family of three ligand-activated nuclear receptors that 
are widely expressed in the body, although their relative levels differ greatly between 
tissues. PPARs are present in cells of the vascular wall and the immune system and are 
activated by natural ligands such as fatty acids, eicosanoids and oxidized fatty acids. They 
have previously been shown to regulate genes involved in lipid and lipoprotein 
metabolism, glucose and energy homeostasis, and as cellular differentiation (Chinetti et a l ,
2003). However, several investigations suggest they can also regulate the inflammatory 
response (Devchand et a l ,  1996; Delerive et a l,  2001; Wang et a l ,  2002). The precise 
mechanism by which PPARs control the inflammatory response is poorly characterised 
although it can antagonise a number of transcription factors which are important in 
activating the immune response such as NF-kB, AP-1, STAT and NF-AT. Further 
investigations indicate that PPAR-a and -y can inhibit NF-kB activation by a direct 
interaction with p65 via its RHD. In addition PPAR-a can also induce hcBa transcription. 
Thus the mechanisms o f PPAR-mediated inhibition suggest that PPAR activation leads to 
the transcription of IicBa, which may bind nuclear p65 and transport it out the nucleus.
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This model is however dependent upon Crm -1, therefore it is unlikely that this mechanism 
is present in the investigations by Kelly et a l, (2004). Therefore potentially p65 is 
exported via an as yet unidentified mechanism that is dependent upon PPAR activity. 
Interestingly, C rm -1-independent nuclear export has already been identified for the thyroid 
hormone nuclear receptor (Bunn et al., 2001), suggesting that this mechanism might 
represent an additional nuelear export pathway. The interaction o f PPARs with p65 would 
therefore represent a piggy-back mechanism of nuclear export, as has been suggested for 
the nuclear import o f hcBa following resynthesis (Turpin et al., 1999). Thus in this 
situation, A2aAR activation would promote the binding o f p65 to PPAR which would 
facilitate nuclear export. Further investigation o f p65 nucleocytoplasmic movements by 
fluorescence microscopy in live cells might allow further characterisation o f the 
subcellular distribution o f p65.
One other important observation from this study indicates that treatment o f HUVECs with 
the adenylyl cyclase activator forskolin failed to inhibit the induction of E-seleetin. This 
suggests that activation of the classical A2aAR signalling pathway, resulting in increased 
cAMP synthesis, may not be required for the anti-inflammatory effect of AV/w^c-His 
A2aAR gene transfer. This result is in contrast to other studies suggesting that eAMP 
mediates a potent anti-inflammatory effect in different cell types (Foey et a l,  2003; Wuyts 
et a l ,  2003). Recent studies by Sullivan et a l,  (2004), demonstrated that treatment of 
neutrophils with TN Fa or EPS followed by fMLP treatment, results in a four-five fold 
induction o f the very late antigen (VLA-4; a 4pi integrin). A 2aA R activation with the 
selective agonist ATL146e reduced expression o f VLA-4, an effect mediated by cAMP. In 
contrast, observations in this chapter suggest the improbable involvement o f cAMP, as 
treatment with forskolin could not mimic the A2AAR-mediated inhibition o f E-selectin 
expression. One possible cAMP-independent signalling mechanism activated by the 
A2aAR in freshly isolated HUVECs, has been reported by Sexl et a l,  (1997). This 
involves the p21™  ^ /M EKl-dependent activation of ERK. This possibility is however 
unlikely as the M EKl inliibitor, PD98059 failed to inhibit E-selectin expression in TNFa- 
stimulated HUVECs. Further investigations of the A2aAR signalling cascade including 
use of the A2aAR truncated eonstmcts may provide more information. In conclusion, the 
anti-inflammatoiy effect o f the A2aAR in HUVECs may not be mediated by either cAMP 
or ERK activation.
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In conclusion, expression o f the A2aAR led to the inhibition o f monocyte adhesion in 
T N Fa treated HUVECs. This correlated with a decrease in E-selectin expression in 
response to TNFa. In addition, A2aAR expression could also inhibit the induction of E- 
selectin in response to EPS suggesting that receptor expression can inhibit a common 
component of the TN Fa and LPS/TLR4 signalling cascades. This effect is specific to the 
inhibition of the transcription factor NF-icB as analysis of p38 and JNK activity indicated 
that A2aAR expression made little or no differenee. Further analysis o f the NF-kB 
signalling cascade indicated that receptor expression led to an inhibition in p65-DNA 
binding and transcriptional activity, which correlated with the reduced entry of p65 to the 
nucleus following TN Fa stimulation, despite the signal-induced degradation of IicBa.
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Figure 4.1 Effect of endogenous A 2aAR expression on U937 monocyte adhesion to 
TN Fa stimulated HUVECs
1x10^ HUVECs were seeded into a 24-well plate and grown to confluence. 
The following day, cells were pre-treated for 30 min with 5 pM CGS21680 
prior to incubation with increasing concentrations o f TN Fa for 6 hr as 
indicated. Following treatment, the medium was removed and the HUVEC 
monolayers were overlayed with U937 cells, which were allowed to adhere 
for 1 hr at 37°C. Cells were then washed gently to remove non-adherent 
cells and fixed in paraformaldehyde. The number o f U937 cells attached 
per 100 HUVECs was counted by microscopy. This graph represents one 
of multiple experiments.
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Figure 4.2 Titration-dependent expression of AV/m yc-H is A 2aAR
1x10^ HUVECs were infected with increasing multiplicities of infection 
(m.o.i.) as indicated. 24hr post-infection, cells were monitored for the 
expression o f GFP and the percentage of infected cells was determined by 
calculating the percentage of GFP-positive cells in five random fields of 
view. Cells were then transferred to ice, solubilised, equalised for protein 
concentration and fractionated on SDS-PAGE. Proteins were then 
transferred to nitrocellulose and immunoblotted for the presence of the 
A2aAR using the anti-myc antibody as described in Section 2.5.1 in the 
Materials and Methods. Blots were then stripped and reprobed for the 
presence o f Gi«2 as a loading control for protein equalisation.
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Figure 4.3 Biotinylation of cell surface expressed AV/wjc-His A 2aAR
ixlO^ HUVECs were infected with increasing multiplicities o f infection 
(m.o.i.) as indicated. 24hr post-infection HUVECs were labelled with 
biotin-LC-hydrazide according to the Methods in Section 2.5.3. Cell lysates 
were then prepared, equalised for protein content, and immunoprecipitated 
with anti-AHyc (9E10). Immunoprecipitates were then fractionated by SDS- 
PAGE and transferred to nitrocellulose. Biotinylated A2aARs were 
detected by incubation with HRP-conjugated streptavidin as described in 
Section 2.5.3. Biotin-labelled proteins were then visualised using enhanced 
chemilumineseence. This represents one of several experiments.
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Figure 4.4 ^^^I-ZM241385 saturation binding analysis of myc-Uis A 2aAR in
HUVECs
Saturation binding studies were carried out on membranes prepared 
from HUVECs infected with 25 pfu/eell using the AzAAR-seleetive 
antagonist '^^I-ZM241385. Membrane preparation and radioligand 
binding procedures are detailed in the Methods Section 2.5.4. The 
graph shown here represents one typical saturation-binding curve.
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Figure 4.5 Effect of AV//«jc-His A iaAR  expression on TNFa-stimulated U937 
monocyte adhesion to HUVECs
1x10^ HUVECs were seeded into a 24-well plate and grown to 70% 
confluence. 24hr after seeding, cells were infected with 25 pfu/cell of 
recombinant AV/myc-His À2aAR or AV/GFP. 24hr post-infection, cells 
were treated with 10 ng/ml TN Fa for 6hr in the presence or absence o f the 
AR-agonist NECA. Following treatment, the medium was removed and the 
HUVEC monolayers were overlayed with U937 cells, which were allowed 
to adhere for 1 hr at 37°C. Cells were then washed gently to remove non­
adherent cells and fixed in paraformaldehyde. The number of U937 cells 
attached per 100 HUVECs was counted using a combination o f bright-field 
and fluorescence microscopy. This result represents one o f multiple 
experiments performed.
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Figure 4.6 Effect of increasing concentrations of TN Fa on the induction of E- 
selectin in HUVECs
1x10^ HUVECs were seeded in triplicate wells and in parallel into a 96-well 
plate. 24hr after seeding, cells were treated with increasing concentrations 
of TN Fa for 61ir as indicated. The induction o f E-selectin was determined 
by cell-surface ELISA as described in Section 2.5.7 o f the Materials and 
Methods. Following subtraction o f non-specific binding, the mean ODeoo ± 
S.E.M. was calculated and fitted to a non-linear regression sigmoidal dose 
response curve using GraphPad Prism. This represents an average of 
several experiments log EC5o= 0.563 ng/ml
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Figure 4.7 Time course of E-selectin induction following treatment with TNFa
1x10^ HUVECs were seeded in triplicate wells and in parallel into a 96-well 
plate. 24hr after seeding, cells were treated for 0, 3, 6, 9, 12 and 24 hr with 
lOng/ml TNFa. The induction o f E-selectin was determined by cell-surface 
ELISA as described in Section 2.5.7 o f the Materials and Methods, 
Following subtraction o f non-specific binding, the mean ODeoo ± S.E.M. 
was calculated. This represents an average of several experiments.
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Figure 4.8 Effect of AV///ijc-His AiaAR  gene transfer on E-selectin induction in 
HUVECs when exposed to TNFa
1x10^ HUVECs were seeded in triplicate wells and in parallel into a 96-well 
plate. The next day, cells were infected with 25 pfu/cell o f AV/myc-His 
A2aAR and control AV/GFP. 24hr post-infection, cells were treated for 6hr 
with lOng/ml TNFa. E-selectin expression was then determined by cell- 
surface ELISA as described in Section 2.5.7 of the Materials and Methods. 
Following subtraction of non-specific binding, data were plotted as mean 
ODgoo ± S.E.M.
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Figure 4.9 Effect of AV/m yc-H is A2aAR gene transfer on E-selectin induction in 
HUVECs when exposed to EPS
1x10^ HUVECs were seeded into a 6-well plate overnight. The next day, 
cells were infected with 25 pfu/cell o f AV/wyc-His A iaAR  and control 
AV/GFP. The following day, cells were treated for 6hr with 1 pg/ml EPS 
in the presence or absence of 5 pM NECA (N). Cells were then transferred 
to ice, solubilised, equalised for protein concentration and fractionated on 
SDS-PAGE. Proteins were then transferred to nitrocellulose and 
immunoblotted for the presence of the E-selectin using the anti-E-selectin 
antibody as described in Section 2.5.1 in the Materials and Methods.
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Figure 4.10 Analysis of the signalling mechanisms that regulate E-selectin 
expression
1x10^ HUVECs were plated out in 6-well plates and pre-treated for 30 min 
with the p38 MAPK inhibitor SB203580 (10 pM), the M EK l inhibitor 
PD98059 (10 pM), the N F-kB inhibitor PDTC (100 pM), N-acetyl-cysteine 
(100 pM), and the adenylyl cyclase activator forskolin (50 pM). Cells were 
then treated with 10 ng/ml TN Fa for 6 hr. Cells were then solubilised, 
equalised for protein prior to fractionation by SDS-PAGE and 
inimuoblotted using an anti-E-selectin antibody as described in Section 
2.5.1. This represents one o f several experiments.
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Figure 4.11 Effect of the NF-kB inhibitor PDTC on TNFa-stimulated adhesion of 
U937 monocytes to HUVECs
1x10^ HUVECs were seeded into a 24-well plate and grown to 70% 
confluence. 24 hr after seeding, cells were pre-treated for 30 min with 100 
pM PDTC or 100 pM N-acetyl cysteine as indicated. Cells were then 
treated with 10 ng/ml TN Fa for 6 hours. Following treatment, the medium 
was removed and the HUVEC monolayers were overlayed with U937 cells, 
which were allowed to adhere for 1 hr at 37°C. Cells were then washed 
gently to remove non-adherent cells and fixed in paraformaldehyde. The 
number o f U937 cells attached per 100 HUVECs was counted by 
microscopy. This bar chart represents the average of several experiments.
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Figure 4.12 Effect of AV/wij^c-His A iaAR  expression on NF-kB binding to target 
DNA in HUVECs
1x10^ HUVECs were seeded into a 6-well plate and grown to 70% 
confluence. 241ir after seeding, cells were infected with 25 pfu/cell o f 
recombinant AV/myc~His A2aAR or AV/GFP. 24hr post-infection, cells 
were treated with 10 ng/ml TN Fa for 6hr and the nuclei isolated according 
to the protocol in Section 2.5.9 o f the Materials and Methods. Nuclear 
extracts were then incubated in a binding assay containing ^^P-labelled NF- 
k B  target oligonucleotide and the relevant supershift antibody as indicated. 
Binding reactions were then loaded onto a non-reducing 6% (w/v) 
acrylamide gel. The gel was then dried down under vacuum and bands 
were visualised using autoradiography. This figure represents one o f 
several experiments.
+  : 10 ng/ml TNFa
60  min
• Supershift Ab
AV/GFP AV/myc-humA2AAR
p50-p65
163
Figure 4.13 Effect of AV//wj^c-His AiaAR  gene transfer on the nuclear translocation 
of p65 in TNFa stimulated HUVECs
1x10^ HUVECs were seeded into 6-well plates onto sterile coverslips. 24 
hr after seeding, cells were infected with 25 pfu/cell o f recombinant 
AV/«z}/c-His A2aAR or AV/GFP. 24hr post-infection cells were treated 
were then treated with (lower panels) and without (upper panels) 10 ng/ml 
TN Fa for 60min. Following treatment cells were washed and fixed in 
paraformaldehyde. Cells were then semi-permeabilised and incubated with 
anti-p65 antibody (1:200 dilution) for Ihr at room temperature. Cells were 
then rinsed and incubated with the Alexa 594-conjugated secondary 
antibody (1:400) for Ihr at room temperature. Following several rinses, 
coverslips were mounted onto microscope slides and analysed using a Zeiss 
Axiovert 500 laser scanning confocal microscope as indicated in Section 
2.5.11 of the Materials and Methods. Images were taken at 40x 
magnification.
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Figure 4 ,1 4  Effect of A iaA R  expression on the degradation o f IkB œ
1x10^ HUVECs were seeded into a 6-well plate and grown to confluence. 
24hr after seeding, cells were infected with 25 pfu/cell o f recombinant 
AV/myc-His A2aAR or AV/GFP. 24hr post-infection, cells were treated 
with lOng/ml TN Fa for the indicated time periods. Cells were then 
washed, solubilised, and fresh lysates were prepared. Proteins were then 
fractionated by SDS-PAGE and transferred to nitrocellulose. 
Immunoblotting was earned out using the m ti-m yc  antibody (1:500) and the 
anti-IicBa antibody (1:1000) according to the protocols in Section 2.5.1. 
This figure represents one of several experiments.
- 15 30 60 90 - 15 30 60 90 : Exposure toTNFa (min)
l/cBa
mycA2AAR
Control AV/mycA2AAR
167
Chapter 5
Effect Of cAzaAR Expression On The Regulation O f NF-KB-Dependent 
Inflammatory Responses In C6  Glioma Cells
168
5.1 Introduction
The potent anti-inflammatory effects of the A2aAR have been demonstrated in a variety o f 
different cell types (Section 1.11.4). One possible reason for this is that A2aAR activation 
can activate common mechanisms that lead to the suppression o f inflammation. The 
results in Chapter 4 suggest that A2aAR expression can inhibit the activation o f the 
transcription factor NF-kB. Therefore to determine whether this represents a common 
anti-inflammatory signalling mechanism employed by this GPCR, C6 glioma cells stably 
expressing the canine A2aAR (cA2aAR) were used to identify anti-inflammatory pathways 
present in glial cells. Glial cell inflammation plays a key role in disease states such as 
multiple sclerosis (Bradl and Hohlfeld, 2003), stroke (Price et ah, 2003) and Alzheimer’s 
disease (Akiyama et al., 2000), therefore any anti-inflammatory properties o f the A2aAR 
agonism could be therapeutically beneficial in a number of diseases. In addition, C6 
glioma cells represent a tractable model for the in-depth analysis o f the mechanisms that 
regulate the inflammatory response. One important consideration was that in contrast to 
HUVECs, C6  glioma cells do not express the N F-kB -regulated gene E-selectin, therefore 
the induction o f another N F-kB -regulated gene, iNOS was used as a marker for 
inflammation, as iNOS-derived nitric oxide has been shown to contribute to the ability of 
activated glial cells to entrance neuronal cell death (Brown and Bal-Price, 2003). The use 
o f the canine receptor in this study also allowed us to determine if  the anti-inflanunatory 
effects o f the human receptor represents a general feature o f A2aARs or if  it is specific 
only to the human form. Figure 5.1 shows a primary sequence alignment o f human and 
canine receptors and indicates that they share 87% sequence identity, with the greatest 
degree of divergence occurring in the C-terminus, which is thought to be important in 
regulating the efficiency o f signalling in downstream pathways (Klinger et al., 2002).
5.2 Results
Before determining whether cA2aAR expression could mediate similar anti-inflammatory 
effects in C6  glioma cells as in HUVECs, it was important to confirm that functional 
cA2aAR was efficiently expressed at the cell surface in C6 glioma cells. Therefore freshly 
prepared cell lysates from untransfected C6  and C6 /cA2aAR glioma cells were subject to 
SDS-PAGE followed by immunoblotting with an anti-A2AAR antibody as described in 
Section 2.5.1 of the Materials and Methods. Figure 5.2 shows clearly the presence of the 
cA2aAR at ~47 IcDa in transfected cells compared to control cells. To verify that the
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receptor was fully processed and expressed at the cell surface, cell-surface biotinylation 
assays were performed on untransfected C6 and C6 /cA2aAR glioma cells as described in 
Section 2.5.4 of the Materials and Methods. Figure 5.3 shows a smear of biotinylated 
protein centred at -4 7  kDa indicating that cA2aARs are expressed at the surface of the cell. 
In addition, there is a higher molecular weight species evident that is also expressed at the 
surface, which is consistent with the formation of multimers as reported by Canals et al., 
(2004). Finally to quantify the level of cA2aAR expression in glioma cells, ^^^I-ZM241385 
saturation binding analysis was performed upon membranes isolated from untransfected 
C6 glioma cells and C6 /cA 2aAR cells. Figure 5.4 shows a typical saturation binding curve 
for one such experiment. In C6 /cA2aAR glioma cells the Bmax for ^^^I-ZM241385 ranged 
between 2.57 and 6.02 pmol/mg o f membrane protein, with a Kd value of 1.10 ± 0.29 nM 
(n=5). No specific binding was observed in untransfected C6  glioma cells suggesting that 
there is very little or no endogenous A2aAR expression in C6 glioma cells. Taken together, 
these results confirm the cell surface expression of a functional flilly processed cA2aAR in 
stably transfected C6 glioma cells.
To investigate if  cA2aAR expression could regulate the release o f nitric oxide in C6 glioma 
cells, untransfected C6 and C6 /cA2aAR glioma cells were treated with maximally effective 
concentrations of LPS/TNFa/IFNy either alone or in combination for 24 hr. Supernatants 
were then removed and the level o f nitric oxide released was quantified by measuring the 
accumulation o f NO-derived nitrite in the supernatant using the Greiss reaction according 
to the protocol in Section 2.5.12. Figure 5.5 indicates that none o f TNFa, LPS or IFNy 
alone could stimulate a detectable increase in nitrite accumulation. However, when treated 
with IFNy plus either TN Fa or LPS, or when treated with LPS/TNFa/IFNy, there was a 
detectable increase in nitrite accumulation that was maximal at 2 0  pmol/well in 
untransfected C6 glioma cells. This effect however was completely abolished in 
C6 /cA2aAR cells even in the absence o f agonist, indicating that A2aAR expression can 
suppress nitric oxide production in response to LPS/TNFa/IFNy. The effect of A2aAR 
expression upon nitrite accumulation is not due to the presence o f extracellular adenosine 
acting at the receptor, as experiments were performed in the presence of 3 units/ml of 
ADA, which converts adenosine to inosine, which is inactive at the A2aAR (Jin et al., 
1997). In addition, treatment of the cells with the A2AAR-selective neutral antagonist 
ZM241385 could not reverse the inhibition of nitrite accumulation. Together, this suggests
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that the receptor is constitutively active, and can therefore constitutively inhibit nitrite 
accumulation. Further characterisation o f the AaAAR-niediated effect indicates that in 
control cells, treatment with LPS/TNFa/IFNy produced a time-dependent accumulation of 
nitrite in the medium (4.13+0.08 fold stimulation over control at 24 hr, n=4) as shown in 
Figure 5.6. In contrast, expression o f the A2aAR could suppress nitrite accumulation 
throughout the time course suggesting that cA2aAR expression produces a sustained 
suppression of nitrite accumulation. Composite data from these experiments is 
summarised in Figure 5.7.
The release o f nitric oxide is due to the activity of iNOS whose expression is largely 
regulated by gene transcription in response to extracellular stimuli (Section 1.2.4). 
Therefore, one possible mechanism that might explain the synergistic effect of 
LPS/TNFa/IFNy on the release o f nitric oxide is that LPS/TNFa/IFNy exposure can 
activate multiple transcription factors which synergistically enhance iNOS expression. 
Analysis of the rat iNOS promoter indicates the presence o f transcription factor binding 
sites for NF-kB, and ST AT proteins (Niwa et al., 1997; Taylor et al., 1998; Ganster et al., 
2001). As these transcription factors are downstream targets o f the pro-inflammatory 
signalling cascades initiated by TN Fa, LPS and IFNy, this mechanism seems most likely 
(Sections 1.4.1, 1.4.3, 1.4.4). Therefore, to determine the effect o f A2aAR expression upon 
the induction o f iNOS expression, freshly prepared cell lysates from untransfected C6 and 
C6 /cA2aAR glioma cells, treated with maximally effective concentrations of 
LPS/TNFa/IFNy were subject to SDS-PAGE followed by immunoblotting with an anti- 
iNOS antibody. Figure 5.8 shows that cytokine treatment o f untransfected C6 glioma cells 
could markedly increase iNOS expression consistent with the data on nitrite accumulation. 
However, in C6 /cA2aAR cells, this effect was completely abolished. Further treatment 
with the AR-agonist NECA did not further affect iNOS expression in untransfected C6 or 
C6 /cA2aAR glioma cells, further indicating that the effects are agonist-independent. These 
results indicate that A2aAR expression can completely attenuate the induction of iNOS in 
C6  glioma cells.
As detailed above the A2aAR is most likely to attenuate iNOS induction at the level of 
transcription. Two observations suggest that a likely target for the A2AAR-mediated effect 
is the transcription factor NF-kB. Firstly, the rat iNOS promoter contains two transcription
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factor binding sites for NF-kB, which are necessary for iNOS induction (Xie et al., 1994). 
Secondly, results from Chapter 4 indicate that A2aAR expression can inhibit NF-kB 
activity. This suggests that inhibition of NF-kB might mimic the A2AAR-mediated effects 
on iNOS induction. To test this hypothesis, nitrite accumulation assays were perfoiined on 
untransfected C6 glioma cells stimulated with LPS/TNFa/IFNy, in the presence or absence 
of the NF-icB inhibitor PDTC. N-acetyl-cysteine was also included in this study to control 
for the possible anti-oxidant side effects o f PDTC. Pre-treatment with 100 pM PDTC 
could attenuate nitrite accumulation by 55+7%, (p<0.05, n=3). This was not due to any 
anti-oxidant side effects o f PDTC as parallel pre-treatment with 100 pM N-acetyl cysteine 
failed to inhibit nitrite accumulation (Figure 5.9). This demonstrates that NF-kB plays an 
important role in the induction o f iNOS expression in C6 glioma cells and suggests that 
inhibition o f NF-kB can partly suppress iNOS induction.
The results from Figure 5.9 suggest that A2aAR expression may inhibit the activity o f NF- 
kB leading in part to the suppression of iNOS. Therefore, to determine what effect A2aAR 
expression had on NF-kB, EMSA analysis was performed in C6  and C6 /cA2aAR cells. 
Figure 5.10 indicates that there is an increase in the DNA-binding capacity of NF-kB in 
untransfected C6 glioma cells when treated with LPS or TN Fa but not with IFNy. This 
effect is markedly decreased in C6 /cA2aAR cells suggesting that cA2aAR expression 
inhibits the capacity of NF-kB to bind to target DNA. Both bands present in Figure 5.10 
represent p65/p50 heterodimers as both bands are retarded when co-incubated with anti- 
p65 or p50 antibodies in supershift experiments (W.Sands, personal communication). To 
test the functional consequences of decreased DNA binding, reporter gene analysis was 
performed and indicates that treatment of untransfected C 6  glioma cells with TN Fa 
induced a 53.4±3.6 -fold stimulation of luciferase expression (n=4), versus 4.3+2.7-fbld 
stimulation in C6 /cA2aAR cells (p<0.05, n=4, Figure 5.11). Together these results suggest 
that A2aAR expression can inhibit DNA-binding activity o f NF-icB and subsequently 
inhibit the ability o f NF-kB to activate target gene transcription.
Exposure to TN Fa and LPS leads to the activation of the p38 MAPK and JNK signalling 
cascades in addition to NF-kB (Section 1.4.1 and 1.4.4; Manning and Davis, 2003; Karin 
et al., 2004). Therefore, to determine if  A2aAR expression had other anti-inflammatory
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effects, experiments were performed to determine the activity o f p38 MAPK and JNK, 
Figure 5.12 indicates that in C6 cells, treatment with TN Fa induced a transient increase in 
p38 phosphorylation that peaks at 5 min and returned to basal levels after 30 min. In 
C6 /cA2aAR cells, p38 phosphorylation at 5 min was reduced by 25+6% (p<0.05,n=3), but 
similarly returned to basal levels after 30 min. Therefore A2aAR expression can decrease 
the maximal extent to which p38 was activated. In addition, Figure 5.13 indicates that 
there is no significant difference in the capacity of JNK to phosphorylate c-jun in response 
to T N Fa between C6 /cA2aAR and control cells (maximal activation reduced by 9+6% at 
15 min, NS, n=3). However, maximal activation was typically reached after 5 min 
exposure in C6 /cA2aAR cells, as compared with 15 min in control cells. These results 
suggest that A2aAR expression has minimal effects on p38 and JNK activation and that the 
main anti-inflammatory effects of A2aAR expression on T N Fa and LPS/TLR4 signalling 
is at the level of NF-kB activation.
As identified in Figure 5.10, A2aAR expression can inhibit the DNA-binding capacity of 
NF-kB to target DNA. However, as there are several different key upstream signalling 
events required for NF-kB activation by multiple stimuli, it is unclear how A2aAR 
expression can lead to the inhibition o f DNA-binding. One essential step necessary for 
cytokine-induced NF-kB activation is the phosphorylation-dependent polyubiquitination 
and degradation of IicBa (Section 1.4.1). Therefore, to determine what effect A2aAR 
expression had on IxB a degradation. Western blotting was performed using anti-lKBa 
antibodies in cell lysates made from C6 /A2aARs and control cells following treatment with 
TN Fa (Figure 5.14) and LPS (Figure 5.15). Treatment o f untransfected 06  cells with 
TN Fa or LPS led to a time-dependent degradation of IicBa that peaked at 15 min. In 
addition. Figure 5.15 indicates that there is a detectable rise in the levels of iKBa at 45 
min, consistent with the fact that IicBa transcription is regulated by NF-kB. In contrast, 
there was no detectable degradation o f IicBa in response to either TN Fa or LPS in A2aAR 
expressing cells suggesting that A2aAR expression can inhibit the degradation o f IicBa.
As highlighted above, one step essential for IicB degradation is its prior phosphorylation 
that specifically occurs at Ser^^ and Ser Therefore, to determine the effects o f A2aAR 
expression on the phosphorylation of IicBa in response to TN Fa or LPS, Western blotting
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was perfomied using anti-phospho Ser^^, Ser^ *^  antibodies. Results from Figure 15.4 and 
15.5 indicate that in control cells, phosphorylated IicBa was detectable after 5 min and 
remained evident up to 30 min after stimulation although at a reduced levels. In contrast, 
there was no significant increase in iKBa phosphorylation in C6 /cA2aAR cells. Together, 
these results indicate that A2aAR expression can inhibit the phosphorylation and 
degradation of IicBa in response to TN Fa and LPS. As both of these stimuli activate NF- 
icB via distinct signalling mechanisms (Sections 1.4.1; 1.4.4), A 2aAR expression must 
inhibit a component of the pathway that is common to both signalling cascades such as the 
IKK complex.
The ability of A2aAR expression to efficiently suppress iNOS induction is therefore partly 
explained due to the inhibition o f IicBa phosphorylation and degradation. However, as 
treatment with the NF-icB inhibitor PDTC, could attenuate only 55% of nitrite 
accumulation in C6 cells, other regulatory mechanisms must play a role in iNOS induction. 
One such mechanism is suggested by the presence of 5 GAS sites present on the rat iNOS 
promoter. GAS sites are targets for tyrosine phosphorylated dimeric STAT transcription 
factors, which are induced by a variety o f cytokines, including IFNy (Section 1.4.3). This 
suggested that the cA2aAR could potentially inhibit iNOS induction by inhibiting IFNy 
activation of the JAK-STAT signalling cascade. Therefore, to determine the effects of 
A2aAR expression on STATl activation, Western blotting using anti-STATl and anti- 
phospho~Tyr™' STATl antibodies was performed on freshly prepared cell lysates from 
untransfected C6 and C6 /cA2aAR glioma cells. Figure 5.16 indicates that in response to 
IFNy in untransfected C6  cells, there is a time-dependent increase in STATl 
phosphorylation that peaks at 60 min, which is markedly reduced in C6/cA2aAR cells. In 
addition the overall levels of STATl protein are reduced at later time points in C6 /cA2aAR 
expressing cells indicating that A2aAR activation may play a role in the degradation of 
STATl, resulting in a decrease in transcriptional activity. Thus the decrease in iNOS 
expression is likely due to at least two separate A2AAR-mediated effects; inhibition of 
IicBa phosphorylation resulting in a decreased NF-kB activation and degradation of 
STATl.
One possible mechanism for the cA2AAR-mediated anti-inflammatory response on both 
NF-kB and STATl is that activation o f the A2aAR causes the release o f anti-inflammatory
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factors, which could act in an autocrine or paracrine fashion to inhibit both NF-kB and 
STATl activation. To test this hypothesis, conditioned media from untransfected C6 
glioma cells and C6 /cA2aAR cells were used to treat untransfected C6  cells in the presence 
and absence of LPS/TNFa/IFNy. Figure 5.17 indicates that conditioned media from C6 or 
C6  cA2aAR cells could not prevent the induction of iNOS in response to LPS/TNFa/IFNy. 
This suggests that the A2AAR-mediated effect is intracellular and does not involve the 
regulated release of any autocrine or paracrine anti-inflammatory cytokines.
These results collectively predict a model whereby A2aAR expression can directly inliibit 
both the phosphorylation-dependent degradation o f iKBa in response to TN Fa and LPS. 
This in turn prevents the nuclear translocation o f NF-kB, resulting in a decrease in iNOS 
induction and a subsequent reduction in the accumulation of nitrite in cell supernatants. In 
addition, A2aAR expression can prime STATl for INFy-mediated degradation, which is 
also required for iNOS gene transcription.
5.3 Discussion
The anti-inflammatory effects o f the A2aAR have been widely demonstrated in a number 
of different cell types and in Chapter 4 one potential anti-inflammatory mechanism was 
identified. To determine if  this mechanism was generally applicable among different cell 
types, C6 glioma cells stably expressing the A2aAR, were investigated in a rodent model of 
glial cell inflammation. Glial cell inflammation contributes to the pathogenesis of several 
neurological disease states including multiple sclerosis (Bradl and Hohlfeld, 2003), stroke 
(Price et a l,  2003) and Alzheimer’s disease (Akiyama et a l,  2000). Therefore, therapies 
that mediate any decrease in inflammation could prove beneficial in a wide range of 
neurological disease states.
Our results demonstrate that efficient cA2aAR expression could inhibit the release of nitric 
oxide which correlated with the inhibition o f iNOS expression. As the expression o f iNOS 
is regulated by the transcription factor NF-kB, investigations were performed to determine 
if  A2aAR expression could modulate its transcriptional activity and activation. NF-kB 
reporter gene assays, EMSA analysis and nitrite accumulation assays in the presence of the 
NF-kB specific inhibitor PDTC, all indicate that cA2aAR expression can inhibit DNA- 
binding and reporter gene activity upstream of gene expression. Further investigation of
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the NF-icB signal transduction pathway, revealed that cAiaAR activity can inhibit the 
phosphorylation of IicBa which prevents the signal-induced degradation o f IicBa, an 
important step in the activation o f NF-icB by TNFa. In addition to the effects on NF-kB, 
cA2aAR activation can also decrease the phosphorylation of STAT resulting in an 
increased rate of STAT degradation. This suggests that cA2aAR activity can also inliibit 
STAT activity leading to the reduction in iNOS activity.
As phosphorylation o f IicBa is an essential step in the activation o f NF-icB one possible 
mechanism leading to the inhibition of IicBa phosphorylation is the cA2AAR-dependent 
inhibition of the IKK complex. This could be mediated in several ways including 
inhibition o f IKK activation by upstream kinases, post-translational modifications of IKK 
resulting in a decrease in activity or by reduction in IKK expression levels. Activation of 
the IKK complex leading to phosphoiylation o f IicBa occurs by phosphorylation of S I76 
and 180 in IK K a and 8177 and S181 in IKK{3. However, studies in IK K a knockout mice 
reveal that in T N Fa stimulation, IKKp is the dominant kinase (Hu et al., 1999). Several 
studies report a diverse array o f upstream protein kinases that can phosphorylate IKK, 
including different PKC isoenzymes (Lallena et a l,  1999), NIK (Woronicz et a l ,  1997), 
Protein Kinase B (PKB; Ozes et a l ,  1999), M EKKl (Lee et a l ,  1998), MEKK3 (Yang et 
a l,  2001), COT/TPL-2 (Lin et a l,  1999) and TGF-p activating kinase (TAKl; Sakurai et 
a l,  1999). However, the precise kinase required for activation varies according to which 
NF-KB-activating stimulus is used for example, TN Fa stimulation of IKK requires the 
MAP3K R IP l, however its catalytic activity is not required for this activation (Devin et 
a l,  2000) suggesting that A2aAR activity may inhibit RIP-IKK interaction preventing 
activation.
One further possible mechanism of A2AAR-mediated inhibition o f IKK activity is the 
activation of an IKK phosphatase. PP2C|3 is one such phosphatase which is reported to 
interact with IKK(3 , however this interaction only occurs at later time points following 
TN Fa stimulation and therefore more likely represents a mechanism to decrease IKK 
activity (Prajapati et a l ,  2004). Furthermore, PP2A has also recently been identified as 
interacting with IKKy. This interaction is reported to be responsible for the rapid 
deactivation o f IKK and that inhibition o f PP2A by the human T-lymphotropic retrovirus 
type-I trans-activator, Tax, leads to the constitutive activation of IKK and NF-kB activity.
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Thus A2aAR receptor activation may also stimulate PP2A activity resulting in decreased 
IKK activity (Fu et al., 2003). One way to address the issue o f A2A-mediated inhibition of 
upstream kinase activity or phosphatase activation would be to use Western blotting with 
phospho-specific antibodies for each IKK subunit. This would allow detection o f any 
defects in IKK phosphorylation.
In addition to the regulation of IKK activation by phosphorylation, IKK activity might also 
be controlled by further post-translational modification such as ubiquitination or 
sumoylation. Recent studies have identified that NEMO/IKKy ean be ubiquitinated in a 
manner which does not target it for degradation. This mechanism is directed by Bel 10, a 
common component o f the pathway leading from T cell and B cell activation to NF-kB 
activation (Zhou et al., 2004). In addition, TN Fa stimulation also results in the 
ubiquitination of NEMO in its zinc finger domain by cellular inhibitor of apoptosis (cIAP; 
Tang et al., 2003) in HeLa cells suggesting that this mechanism may play a role in 
different cell types. Ubiquitination o f NEMO therefore likely plays a key role in the 
aetivation of NF-kB signalling by certain stimuli including TNFa. To further support a 
role for ubiquitination in the activation of IKK, the tumour suppressor protein CYLD, 
which contains deubiquitinating activity, was recently reported to interact with TRAF 2 
and NEMO where it decreased IKK activity. Truncations of CYLD resulted in a marked 
decrease in enzyme activity and therefore restoration o f IKK activity (Kovalenko et al., 
2003). Thus A2AAR-activation could lead to the deubiquitination o f NEMO resulting in a 
decrease in IKK activity. More recently, IKKy/NEMO was reported to be subject to 
modification by sumoylation. Sumoylation is the attachment of SUMO (small ubiquitin 
like modifier) to target proteins which is thought to regulate protein stability by 
competition with ubiquitin thereby preventing proteolysis (Desterro et al., 1998), It may 
also modulate protein-protein interactions to alter subcellular localization. Huang et al., 
(2003) report that NEMO becomes sunioylated in response to geiiotoxic stress. This 
modification mediates nuclear translocation o f ‘free NEM O’ into the nucleus, where it 
becomes ubiquitinated in an ATM-dependent manner leading to the activation o f the IKK 
complex and NF-kB. Therefore SUMO-modification of the IKK complex may also occur 
in response to certain stimuli, however, this may not play a role in cytokine stimulated 
activation of NF-kB signalling.
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The identification o f ‘free IKKy/NEMO’ suggests that one further A2aAR mediated 
mechanism o f inhibition may be in the regulation of the individual IKK complex 
components. Since its initial characterization as a complex o f -900 kDa several 
investigators have tried to identify the total composition of the IKK complex. 
Stoichiometric analysis of reconstituted components in vitro and in yeast suggested a 1:1:2 
stoichiometry o f IKKa:IKK|3:IKKy (Miller and Zandi, 2001). However recent 
observations suggest a tetrameric head-to-head arrangement of IKKy in which each dimer 
can bind to IK K a/p (Tegethoff et al., 2003). Recently it has been reported that IKKy can 
constitutively shuttle between the cytoplasm and the nucleus where it interacts with the 
nuclear coactivator cAMP-responsive element-binding protein-binding protein (CBP; 
Vemia et al., 2004). Further investigation shows that IKKy/NEMO competed with p65 
and IKK alpha for binding to the N terminus of CBP, inhibiting CBP-dependent 
transcriptional activation by p65. Thus, regulation of the IKK component levels and there 
cellular localization may also alter IKK activity. In an analogous fashion, A2aAR 
activation leads to the phosphorylation o f cAMP response element binding protein (CREB) 
via PKA, which can also inhibit NF-xB-dependent transcription by recruiting CBP thus 
preventing p65:CBP interactions (Parry and Mackman, 1997). However, in this study 
A2aAR inhibits p65-DNA binding by the inhibition of IicBa phosphorylation suggesting 
that p65 is unlikely to enter the nucleus, this further implies that co-activator competitive 
inhibition o f NF-icB-dependent genes does not play a role in this model.
One final mechanism that might control the activity o f the IKK complex is the interaction 
of the IKK complex with other proteins. Several proteins have been identified as possible 
negative regulators o f IKK signalling in this manner. Hong et al., (2001) using a yeast two 
hybrid system for IKKy interacting proteins, identified a component o f the C0P9 
signalosome, CSN3 as an inhibitor of TNFa-dependent signalling but not IL-1 signalling. 
In addition, Zetoune et al., (2001) showed that A20, a NF-kB-inducible gene ean 
effectively inhibit NF-icB activity by inhibiting IKK(3 activity. Further yeast two hybrid 
analysis has also revealed the interaction of IKKy with ZNF216, an A20-like protein which 
can bind to IKKy, TRAF6 and RIP. This interaction negatively regulates activation o f NF- 
kB at the level o f the IKK as overexpression of p65 could restore NF-kB activity. Thus 
A2aAR activation may inhibit IKK activation by promoting the association of the IKK 
complex with negatively regulating proteins. Further investigation, for example by cross­
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linking and immunoprécipitation studies, may shed more light upon the interaction of the 
IKK complex with other negatively regulating proteins.
The reduction by 50% of iNOS induction when exposed to the NF-kB inhibitor PDTC is in 
contrast to the total attenuation of iNOS expression in A2aAR expressing cells, therefore it 
is evident that in addition to the cA2AAR-mediated inhibition of the IicBa phosphoiylation 
resulting in the decrease in iNOS activity, cA2aAR activation must also inhibit iNOS 
induction by inhibiting other iNOS-inducing signaling pathways e.g. JAK-STAT. Results 
indicate that this effect is not due to the activation o f JNK or p38 as A2aAR expression had 
a little or no effect on the activation o f either signaling cascade. In contrast, A2aAR 
expression led to the more rapid degradation o f STATl in the JAK-STAT signaling 
cascade. Cross-talk between cAMP-mediated signalling pathways and STAT activation 
has been previously reported (Sengupta et a l,  1996), and suggests that cA2aAR mediated 
inhibition of STAT is cAMP-dependent. In addition, studies by Ivaslildv et a l,  (1996) 
have shown that in T cell activation, cAMP can inhibit STATl activity by inhibiting DNA- 
binding and down-regulating the levels of STATl mRNA and protein. Thus it is likely 
that the slight inhibition of STAT phosphorylation and down-regulation of STATl protein 
levels is mediated by the A2AAR-dependent activation of cAMP.
Thus, it is apparent that cA2aAR activation can inhibit the induction of iNOS via two 
possible mechanisms. One mechanism involves the inhibition o f iKBa phosphorylation by 
several possible mechanisms that are outlined above. The second mechanism involves the 
inhibition of STAT activity most likely via the generation of the second messenger cAMP. 
Both of these mechanism act to coordinately inhibit the expression of iNOS and the 
consequent synthesis of nitric oxide.
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Figure 5.1 Comparison of human and canine AzaAR  primary sequence
The primary sequences of human and canine À2aAR receptors are aligned 
opposite indicating specific residue differences between both receptors 
(blue). Note that most differences occur in the C-terminal tail.
CANINE 1 M s  ' "m g s [ î i v y i t v e l a i a v l a i l g n v l v c w a  
HUMAN 1 i m g s s v y i t v e l a i a v l a i l g n v l v c w a
3 1  V W L N S N L Q N V T N Y F V V S L A A A D I A V G V L A I  
3 1  V W L N S N L Q N V T N Y F V V S L A A A D I A V G V L A I
6 1  P F A I T I S T G F C A A C H  fli] C L F  A C F V L V L T Q S
6 1  P F A I T I S T G F C A A C H G C L F I A C F V L V L T Q S
9 1  S I F S L L A I A I D R Y I A I R I P L R Y N G L V T G T R  
9 1  S I F S L L A I A I D R Y I A I R I P L R Y N G L V T G T R
1 2 1  A K G I I A Î ’j C W V L S F A I G L T P M L G W N N C G Q P K
1 5 1  E G ï N S Q G C G E G Q V A C L F E D V V P M N Y M V Y  [;’f| 
1 5 1  E G K N H S Q G C G E G Q V A C L F E D V V P M N Y M V Y F
1 8 1  N F F A F V L V P L L L M L G V Y L R I F L A A R R Q L K Q  
1 8 1  N F  F a | ' 1 v  L V P L L L M L G V Y L R I F L A A R R Q L K Q
2 1 1  M E S Q P L P G E R A R S T L Q K E V H A A K S L A I I V G  
2 1 1  M E S Q P L P G E R A R S T L Q K E V H A A K S L A I I V G
2 4 1  L F A L C W L P L H I I N C F T F F C P  C S H A P L W L M  
2 4 1  L F A L C W L P L H I I N C F T F F C P D C S H A P L W L M
2 7 1  Y L f i l  I V L S H T N S V V N P F I Y A Y R I R E F R Q T F R  
2 7 1  Y L A I V L S H T N S V V N P F I Y A Y R I R E F R Q T F R
3 0 1  K I I R S H V L R  E P F K A G G T S A R A L A A H G S D
3 0 1  K I I R S H V L R Q Q E P F K A  G T S  A R L A  A  H G S D
3 3 1  G E Q S L R L N G H P P G V W A N G S A P H P E R R P N G  
3 3 1  G E Q V S L R L N G H P P G V W A N G S A P H P E R R P N G
3 6 1  Y L G L V S G G I A E S G D ISvS G L P D V E L L S H E L1:3...3 6 1  Y A L G L V S G G  A Q E S Q G 0 T G L P D V E L L S H E L
3 9 1  K G A C P E S P G L  p+i  G P L A Q D G A G V S  
3 9 1  K G 1 3  C P E 1 3  P  G L D | | 1 P L A Q D G A G V S
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Figure 5.2 Immunodetection of the canine AiaAR  in C6 glioma cells
Plain C6 glioma cells and C6 glioma cells stably transfected with the HA- 
epitope-tagged canine A2aAR were plated out overnight in 6-well plates. 
The next day, cells were washed, solubilised, and then fresh lysates were 
prepared. Proteins were then equalised for protein concentration prior to 
fractionation by SDS-PAGE. Proteins were then transferred to 
nitrocellulose cells followed by immunoblotting with an anti-A2AAR 
antibody, as described in Section 2.5.1 in the Materials and Methods. This 
Western blot represents one of multiple experiments.
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Figure 5.3 Biotinylation assay of cell surface expressed canine A iaARs
Plain C6  glioma cells and C6  glioma cells stably expressing the HA-tagged- 
canine A2aAR were plated into 6 -well plates overnight. The next day, cells 
were labelled with biotin-LC-hydrazide according to the Methods in Section 
2.5.3. Cell lysates were then prepared, equalised for protein content, and 
immunoprecipitated with anti-HA (12CA5). Immunoprecipitates were then 
fractionated by SDS-PAGE and transferred to nitrocellulose. Biotinylated 
A2aARs were detected by incubation with HRP-conjugated streptavidin as 
described in Section 2.5.3. Biotin-labelled proteins were then visualised 
using enlianced chemiluminescence. This represents one o f several 
experiments.
d ô  ç p
6 2 -
4 7 -
32
A 2aA R
185
Figure 5.4 ‘^^I-ZM241385 saturation binding analysis for HA-tagged-canine
A 2aARs in C 6  glioma cells
Saturation binding studies were carried out on membranes isolated from 
plain C6  and C6 /cA2aAR glioma cells using the A2AAR-selective antagonist 
*^^I-ZM241385 according to the protocol in Section 2.5.4 o f the Materials 
and Methods. This experiment represents one of five different experiments.
0.80 •  TOTAL BINDING 
■  NON-SPECIFIC BINDING0.70
S  0.60
3  0.50
0.20
10
0.00
0 2 3 4 5 6 7 8
[■^25|.2M241385] (nM)
187
Figure 5,5 Effect of A2aAR expression on the pro-inflammatory stimuli-induced 
accumulation of nitrite in C6  glioma cells
C6 /cA2aAR and control glioma cells were plated out in 96-well plates 
overnight. The next day cells were treated with either 10 ng/ml T N Fa (T), 
1 pg/ml LPS (L) or 10 units/ml IFNy (I) alone or in combination as 
indicated in the presence o f 3 units/ml ADA for a further 24 hours. In 
addition, cells were also treated with the A2A-selective neutral antagonist 
ZM241385 either alone (Z) or in combination with TNFa/LPS/IFNy (ZM) 
Medium from the cells was then removed and analysed for nitrite 
accumulation as described in Section 2.5.12 of the Materials and Methods.
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Figure 5.6 Effect of À2 aAR expression on pro-inflammatory stimuli-induced 
accumulation of nitrite over time
Plain C6 glioma cells and HA-tagged cA2aAR expressing C6 glioma cells 
were incubated in the presence o f LPS (1 pg/m l)/TNFa (10 ng/ml)/ 
IFNy (10 units/ml) for the times indicated. Cell supernatants were then 
removed and nitrite accumulation was determined using the Greiss reaction 
described in Section 2.5.12 of the Materials and Methods.
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Figure 5.7 Effect of AiaAR expression on nitrite accumulation in C6  glioma cells
Plain C6 glioma cells and HA-tagged cA2aAR expressing C6 glioma cells 
were incubated in the presence of 1 pg/ml LPS, 10 ng/ml TN Fa and 10 
units/ml IFNy for 24 hr. Cell supernatants were then removed and nitrite 
accumulation was determined using the Greiss reaction described in Section 
2.5.12 of the Materials and Methods.
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Figure 5.8 Effect of A iaAR  expression on the pro-inflammatory stimuli-induced 
induction of iNOS
Plain C6 glioma cells and C6 cells stably expressing HA-tagged eAzAARs 
were treated for 24 hr with 1 pg/ml LPS, 10 ng/ml TN Fa and 10 units/ml 
IFNy. Prior to cytokine treatment, those cells indicated were pre-treated for 
30 mill with 5 pM NECA. Cell lysates were then subject to SDS-PAGE 
followed by immunoblotting with anti-AiAAR and anti-iNOS antibodies as 
described in Section 2.5.1 o f the Materials and Methods. This blot 
represents one o f several experiments
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Figure 5.9 Effect of PDTC treatment on nitrite accumulation in HUVECs
Plain C6 glioma cells were pre-treated with or without 100 pM PDTC or 
100 pM N-acetyl cysteine for 30 min prior to the addition o f vehicle or 1 
pg/ml LPS, 10 ng/ml TN Fa and 10 units/ml IFNy for a further 24 hr. 
Medium from treated cells was then removed and analysed for nitrite 
accumulation as described in Section 2.5.12 of the Materials and Methods.
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Figure 5,10 Effect of AiaAR  expression on the DNA-bindlng activity of NF-kB
Plain C6 glioma cells and C6 cells stably expressing HA-tagged cA2aARs 
were incubated with lOng/ml TN Fa, 1 pg/ml LPS or 10 units/ml IFNy for 
6 hr. Nuclear extracts were then prepared and subject to analysis be EMSA 
as described in Section 2.5.9 of the Materials and Methods. The identity of 
NF-kB subunits was determined by supershifl analysis. This figure 
represents one o f several experiments
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Figure 5.11 Effect of A2aAR expression on TNFa-stimuIated NF-kB reporter gene 
activity
1x10^ plain C6 glioma cells and C6 cells stably expressing HA-tagged 
cA iaARs were transiently transfected with cDNA plasmids encoding for P- 
galactosidase and an NF-kB-luciferase reporter plasmid. Following 
stimulation with T N Fa as indicated, cell lysates were prepared for 
luciferase analysis as described in Section 2.5.13 of the Materials and 
Methods. This experiment represents one o f several experiments.
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Figure 5.12 Effect of A 2aAR expression on p38 MAPK activity
1x10^ plain C6 glioma cells and C6 cells stably expressing HA-tagged 
cA2aARs were treated with lOng/ml TN Fa for the times indicated. Cells 
were also treated for 30 min with 5 pM anisomycin as a positive control (+) 
for p38 activation. Cell lysates were subject to SDS-PAGE followed by 
immunoblotting with anti-phospho-p38 antibodies as described in Section 
2.5.1 o f the Materials and Methods. This blot represents one of several 
experiments
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Figure 5.13 Effect of AzaAR  expression on JNK activity
1x10^ plain C6 glioma cells and C6 glioma cells stably expressing HA- 
tagged cAzaARs were treated with lOng/ml T N Fa for the times indicated. 
Cells were also treated for 30 min with 5pM  anisomycin as a positive 
control (+) for JNK activity. Cell lysates were then incubated with GST-c- 
jun (1-73) on glutathione-Sepharose beads and the precipitates used for in 
vitro kinase assays as described in Section 2.5.14 o f the Materials and 
Methods. Following termination of the assay, samples were subject to 
SDS-PAGE followed by immunoblotting with anti-Ser^^phospho c-jun 
antibodies as described in Section 2.5.1 o f the Materials and Methods. This 
blot represents one of several experiments.
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Figure 5.14 Effect of AzaAR  expression on TNFa-stimuIated IicBa phosphorylation 
and degradation
1x10^ plain C6 glioma cells and C6 cells stably expressing HA-tagged 
cA2aARs were incubated with lOng/ml TN Fa for the times indicated in 
min. Cell lysates were prepared and subject to SDS-PAGE followed by 
immunoblotting with anti-lKBa antibodies as described in Section 2.5.1 o f 
the Materials and Methods. Blots were then stripped and re-probed for the 
presence of phospho-IicBa. This blot represents one o f several 
experiments.
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Figure 5.15 Effect of AiaAR expression on LFS-stimulated IkB œ phosphorylation 
and degradation
1x10^ plain C6 glioma cells and C6 cells stably expressing HA-tagged 
cA2aARs were incubated with LPS for the times indicated in min. Cell 
lysates were prepared and subject to SDS-PAGE followed by 
immunoblotting with anti-lKBa antibodies as described in Section 2.5.1 of 
the Materials and Methods. Blots were then stripped and re-probed for the 
presence o f phospho-lKBa. This blot represents one of several 
experiments.
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Figure 5.16 Effect of A iaAR  expression on IFNy stimulated phosphorylation and 
degradation of STATl
Confluent plain C6  and C6/cA2aAR glioma cells were treated with lOng/ml 
T N Fa,l pg/ml LPS or 10 units/ml IFNy for the times indicated in min. 
Cells were then washed, solubilised, and fresh lysates were prepared. 
Proteins were then equalised for protein concentration prior to fractionation 
by SDS-PAGE. Proteins were then transferred to nitrocellulose cells 
followed by immunoblotting with STATl and anti-phospho STATl 
antibodies as described in Section 2.5.1 o f the Materials and Methods.
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Figure 5.17 Effect of conditioned media upon iNOS induction in C6 glioma cells
Fresh medium was added to confluent dishes o f plain C6 glioma cells and 
C6/cA2aAR s. The next day, the medium was removed, supplemented with 
or without lOng/ml TN Fa, 1 pg/ml LPS and 10 ng/ml IFNy and added to 
plain C6 glioma cells overnight. The following day cells were solubilised, 
equalised for protein concentration and fractionated by SDS-PAGE. 
Proteins were then transferred to nitrocellulose and immunoblotted with 
anti-iNOS antibodies as described in Section 2.5.1 o f the Materials and 
Methods.
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Chapter 6 
Final Discussion
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Inflammation plays a key role in the pathogenesis of several disease states and 
consequently the recent demonstration that adenosine acting via the A2aAR represents the 
natural ‘brakes’ o f the immune system (Ohta and Sitkovsky, 2001), suggests that any 
therapy which can improve AiAAR-dependent signalling could help resolve chronic 
inflammatory responses. However, the precise mechanism that underlies this important 
property of the AiaAR is poorly understood. Results presented in this thesis have 
demonstrated that A2aAR expression can inhibit the activation o f the key inflammatoiy 
transcription factor NF-kB via at least two distinct cell-specific mechanisms. In HUVECs, 
A2aAR expression can inhibit the transloeation of p65 to the nucleus in an IxB a- 
degradation-independent manner. In contrast, A2aAR expression in C6 glioma ceils 
inhibits phosphorylation o f IicBa preventing its degradation, thereby blocking NF-icB 
activation. In addition, A2aAR expression also has NF-KB-independent anti-inflammatory 
effects via the degradation of STATl in C6 glioma cells. Thus, the A2aAR represents a 
good anti-inflammatory therapeutic target that could inhibit excessive or inappropriate 
inflammation.
The key finding that A2aAR expression can inhibit NF-kB activity raises several important 
issues. One important feature o f this study is the distinct cell-specific mechanisms 
employed by the A2aAR to inhibit NF-kB activity. In HUVECs, A2aAR expression can 
inhibit the transloeation of p65 to the nucleus independent of IkBœ degradation. This 
suggests that under certain circumstances, an additional signal is required for the 
transloeation of p65 into the nucleus. One possibility is phosphorylation, which has been 
reported by a number of investigators (Vermeulen et a l ,  2002). It should be noted 
however, that phosphoiylation is thought to direct the interaction of p65 with co-aetivator 
proteins such as GBP, consequently the role of phosphorylation in regulating p65 nuclear 
transloeation is unclear at present. One further possibility is acétylation, which is also 
reported for p65. The precise role of acétylation is however unclear at present as 
acétylation of p65 at positions Lys^^‘ and Lys^^^ is reported to enhance transactivation by 
the NF-kB complex (Chen et a l, 2002). In contrast, acétylation of Lys^^' alone or in 
combination with Lys^*^ impairs the assembly of p65 and hcBa following gene activation 
(Chen et a l, 2002). The role o f p65 acétylation is therefore more likely to determine 
transcriptional activation and turn-off rather than impair nuclear import (Kiernan et a l, 
2003). Future studies using epitope-tagged p65 could be used to determine the addition of
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any post-translational modification and the functional consequences of such a 
modification.
In contrast to HUVECs, the inhibition of NF-icB-dependent transcription in C6 cells occurs 
at the level of IxB a phosphorylation. As A2aAR expression could inhibit IxB a 
phosphorylation when stimulated with LPS and TN Fa, this suggests that A2aAR 
expression can inhibit a common component o f the pathway leading to IxB a 
phosphorylation. One such possibility is the IKK complex, which integrates the signals 
coming from both LPS/TLR4 signalling and TN Fa signalling. The complex architecture 
of the IKK complex suggests that there are many possible ways to regulate the activity of 
the complex. One potential mechanism to inhibit the IKK complex is to inhibit one or 
more steps prior to its activation. IKK activation occurs by phosphorylation of residues 
Ser^^^ and Ser^^^ on IK K a and Ser^^^ and Ser'^^ of IKKp (Section 1.7.2) although IK K a is 
not essential to cytokine induced activation of NF-kB. In contrast to the range of possible 
upstream kinases identified in vitro, MEKK3 is the only upstream kinase that can directly 
phosphorylate IKK following TN Fa stimulation in vivo (Yang et a l ,  2001). It has also 
been demonstrated that the catalytic activity o f RIP is not required for the activation of 
IKK in response to TN Fa (Devin et a l, 2000). This has led to the suggestion that IKK 
activation can occur by autophosphorylation by either IK K a or IKK(3 (Ghosh and Karin,
2002). Therefore one possible way for the A2aAR to inhibit hcBa phosphorylation would 
be to inhibit IKK activation by upstream activators.
In addition to the stimulus-induced activation by upstream activators, A2aAR expression 
may also alter the components o f the IKK complex leading to the suppression of IKK 
kinase activity. Recent studies indicate that IK K a and IKKy may have extra roles within 
the nucleus in regulating NF-icB-dependent transcription. IK K a has been shown to 
translocate into the nucleus and lead to the phosphorylation-dependent acétylation of 
histone H3 at Ser'^, which is important in the activation o f NF-kB responsive gene 
expression (Yamamoto et a l, 2003). The role of IKKy is still relatively unclear however it 
is reported to translocate to the nucleus and compete with p65 for limiting amounts of the 
co-activator protein CBP, thereby leading to repression o f p65-dependent transcription 
(Verma et a l,  2004). The extra-nuclear role of some of the IKK components implies that 
there may be dynamic interactions occurring between individual IKK members. This
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suggests that one possible mechanism o f inhibition could be the impairment of IKK 
assembly necessary for IKK kinase activity. To identify if this is the case, confocal laser 
scanning microscopy using differently-tagged fluorescent IKKp and IKKy might be 
employed to study the dynamic interactions between different proteins.
One issue not fully addressed in this thesis is if  the AzAAR-mediated effects on NF-kB 
p65/p50 heterodimers can also be found for other NF-kB subunit combinations. The 
specific subunit composition of NF-kB is thought to be one mechanism o f determining the 
specificity of gene transcription for NF-kB responsive genes. Therefore it is possible that 
AzaAR expression can only inhibit the expression of a particular subset o f NF-kB 
responsive genes. To specifically identify which genes are regulated by which subunit, 
Kunsch et al., (1992) identified preferred DNA-binding motifs specific for p50, Rel A and 
c-Rel homo dimers. This specificity can be found in vivo, for example several genes have 
been reported to selectively bind Rel A homodimers (ICAM-1; Ledebur and Parks, 1995 
and IL-4; Casolaro et al., 1995). This degree of specificity may be relevant for other NF- 
KB-inducing stimuli, since in this investigation TN Fa and LPS only activate p50/p65 
heterodimers. Further analysis o f different NF-kB-regulated genes induced by various 
stimuli using EMSA and reporter gene assays would be useful in assessing the ability of 
the AzaAR to affect genes that are activated by different NF-kB subunits.
The multiple distinct mechanisms employed by the A zaA R  to inhibit NF-kB activity raise 
an important question, how does the A zaA R affeet NF-kB activity by differing 
mechanisms? One possibility is that AzaAR expression leads to the activation o f multiple 
distinct signalling molecules, which affect the NF-kB cascade by different mechanisms. 
One key feature o f the AzaAR is the long C-terminal tail, which plays a role in regulating 
the levels of constitutive activity o f the receptor (Klinger et a l,  2002). In addition it is 
reported to be involved in the formation of heterodimers with the dopamine Dz receptors 
within the rat striatum (Canals et a l, 2003), however it is not required for the formation of 
AzaAR homodimers (Canals et ah, 2004), therefore its precise role in the formation o f 
oligomers is still unclear at present. The presence o f several proline rich domains within 
the receptor, may represent SH3 domains which are important for protein-protein 
interactions suggesting the activation of other SH3 domain containing proteins may be 
important in mediating the downstream effects.
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The AzaAR couples predominantly to Gs although it is also reported to couple to Goif and 
Gi6 (Offernianns and Simon, 1995; Kull et aL, 2000). G-protein coupling leads to the 
activation o f adenylyl cyclase resulting in the generation of cAMP. cAMP has a clear role 
in the inhibition o f STAT activity as previously described (Section 5.3) however, its 
precise role in the modulation o f NF-icB-dependent responses is unclear. In addition to the 
inhibition of NF-kB-dependent responses via competition for limiting amounts o f CBP 
between eAMP-stimulated phospho-CREB and p65 (Parry and Mackman, 1997), cAMP 
can also inliibit TNFa-stimulated phosphoiylation of IicBa in human aortic endothelial 
cells pretreated with adiponectin (Ouchi et aL, 2000). Therefore, cAMP may regulate NF- 
icB-dependent responses by multiple mechanisms. In this investigation, AzaAR expression 
in C6 cells also inhibits the phosphorylation o f IicBa suggesting that at least in this model, 
cAMP may play a part although this was not tested. In contrast, AzaAR expression in 
HUVECs inhibited the nuclear transloeation o f p65 independent of IxB a degradation 
suggesting that this mechanism represents a novel pathway for the inhibition of NF-kB- 
dependent gene transcription.
In addition to the activation of adenylyl cyclase leading to the generation o f cAMP, AzaAR 
activation has also been reported to activate the pathway in a p2E^^-, M EKl-dependent 
manner independent o f its ability to stimulate Gg in FIUVECs. There are contrasting 
reports about the effect o f ERK activation on NF-icB dependent gene expression. 
Overexpression of either M EKl or ERK caused the constitutive nuclear transloeation of 
NF-kB to the nucleus in a lymphoblastoid cell line suggesting that ERK would increase 
NF-icB-dependent gene transcription (Briant et a l, 1998). In addition, ERK is also 
reported to enhance NF-icB-dependent IL-6 expression in response to okadaic acid in 
human monocytes (Tuyt et a l, 1999). In contrast, it has also been reported that 
constitutive activation of the MEK-ERK pathway negatively regulates NF-icB dependent 
gene expression. However, this is due to the inliibition of phosphorylation of TATA-box 
binding protein (TBP), an essential component o f the basal transcription machinery 
resulting in a reduced interaction with p65 (Carter and Hunninghake, 2000). Therefore, the 
precise role of ERK activity in the regulation of NF-kB-dependent gene transcription is 
still unclear. In the present study, PD98059 a M EKl inhibitor failed to decrease the
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expression o f the E-selectin when treated with TNFa. This suggests that AzAAR-mediated 
activation of ERK does not play any role in the NF-icB regulation o f E-selectin expression.
AzaAR activation has also been reported to activate PKCt^ in rat pheochroniocytoma cells 
leading to the down-regulation o f VEGF expression although the precise mechanism from 
receptor to PKCi^ is not precisely laiown (Gardner and Olah, 2003). PKCÇ activity can 
also directly phosphorylate p65 at Ser^^  ^ in response to T N Fa (Duran et aL, 2003). In 
addition, PKC^ activity is required for the transcription o f matrix-metalloproteinase-9 in 
C6 glioma cells when treated with TN Fa or IL-1 (Esteve et aL, 2002). Therefore it is 
possible that A zaA R  activation o f PKC<!^  may have a role in regulating the activity of NF- 
kB. However, in this study iK B a was not degraded and therefore p65 would remain bound 
to the complex suggesting that A zaA R  expression does not mimic PKC(Î  ^ in this fashion. 
However, future work using PKC inhibitors such as PKC^ pseudosubstrate could be used 
to clarify if  PKC plays any role in the A zaA R mediated response in C6 cells in this system.
The AzaAR displays two desirable features that would make it suitable to act as a brake of 
the inflammatory response. One important feature is the level of constitutive activity 
displayed by the receptor, which is associated with the C-terminal tail o f the receptor as its 
removal can inhibit the level o f constitutive activity (Klinger et a l, 2002). The 
constitutive activity o f the receptor would allow the receptor to mediate its anti­
inflammatory effects even in the absence of agonist as described in this thesis. The 
constitutive activity of the receptor suggests that regulation o f AzaAR expression would be 
critical in the inhibition o f inflammatoiy responses. Studies by Lukashev et al (2003) 
demonstrate that in AzaAR"'^" cells, there is no significant compensatory increase in the 
expression of any other AR suggesting that the anti-inflammatoiy events triggered by 
AzaAR expression are veiy specific for this receptor. In addition, the demonstration by 
Armstrong et a l, (2001) that there is no receptor reserve in murine T-cells, suggests that 
AzaA R  expression is tightly regulated. The regulation o f A zaA R  expression is supported 
by the reported alterations in expression in response to ThI cytokines (Nguyen et aL,
2003). In addition, in mature plasmacytoid dendritic cells, A zaA R s become up-regulated 
in response to CpG oligodeoxynucleotide activation of TLR-9 leading to a decrease in IL- 
6, IL-12 and IFN a (Schnurr et aL, 2004) production. Therefore, there is precedent for the
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regulation o f AzaAR  expression by different inflammatory stimuli resulting in the 
inhibition of inflammatoiy responses.
One final important issue raised in this thesis is the anti-inflammatory NF-kB independent 
effects of A zaAR expression. Results presented in this thesis suggest that in C6 cells, an 
NF-KB-independent mechanism accounts for -50%  of nitric oxide production in response 
to TNFa/LPS/IFNy. However, AzaAR expression can completely attenuate the expression 
of iNOS suggesting other AzAAR-mediated anti-inflammatory mechanisms regulate the 
expression o f iNOS. Analysis o f p38 and JNK activity, two important signalling cascades 
in inflammatory responses, reveals that AzaAR expression has minimal effects on either 
signalling mechanism, suggesting that neither plays a significant role in the A zaAR- 
mediated NF-KB-independent attenuation of iNOS expression. In contrast, A zaAR  
expression leads to the accelerated degradation of STATl. The JAK-STAT signalling 
cascade plays an important role in the activation of several different inflammatory genes 
including iNOS (Section 1.4.3). It is unclear at present how STATl degradation is 
accelerated although cAMP has been reported to inhibit STATl activation (Section 5.3; 
Sengupta et aL, 1996). In addition, STATl activation is negatively regulated by SOCS 
proteins. Thus, A zaAR expression may up-regulate SOCS expression leading to 
accelerated STATl degradation. SOCS proteins were originally identified as cytokine- 
inducible SH2-domain-containing proteins (CIS). They are known to inhibit STAT 
activation by at least two distinct mechanisms that differ between family members SOCS 1 
and S0CS3 (Fujimoto et a l , 2003). Expression o f SOCSl but not S0CS3 promotes the 
degradation o f ubiquitinylated JAK2 (Shuai and Liu, 2003) leading to the reduction of 
STAT activation. In addition, STATl is known to be regulated by phosphorylation- 
dependent polyubiquitination in response to IFNy (Kim and Maniatis, 1996). Given that 
SOCSl can promote the degradation o f JAK2, it is also possible that SOCSl can target the 
degradation of associated STATL Therefore A zaAR expression may negatively regulate 
STATl protein levels by increasing the levels of SOCSl expression. To further identify 
the precise role for AzAAR-mediated NF-icB-independent anti-inflammatory effects, 
immunoblotting using anti-SOCS antibodies could be used to determine the effects of the 
AzaA R  on SOCS expression. In addition, it would be interesting to determine if this 
represented a common mechanism of action. For example, STAT activation is also 
stimulated by other cytokines like IL-6 and IL-11, which utilise a common gpl30 receptor
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component. Similar analysis of STATl activation and SOCSl expression could be used to 
determine if  AzaAR  is important in this way.
While it is important to analyse the precise role of AzaAR regulation of NF-kB activity 
with respect to inflammation, NF-kB is also emerging as an important protein involved in 
cancer. This can partly be explained by its ability to regulate the expression of a number of 
genes which are involved in the regulation o f apoptosis ineluding cIAPs, caspase-8-FLICE 
inhibitory protein (c-FLIP), A20 and B c1-X l. The best studied NF-icB-induced anti- 
apoptotic proteins are the elAPs. These proteins directly bind to effector caspases such as 
caspase-3 and caspase-7 as well as inhibiting the activation o f pro-caspase-6 and caspase- 
9, which are activated in response to both intrinsic and extrinsic apoptotic pathways (Karin 
and Lin, 2002). Another example o f an anti-apoptotic protein that is regulated by NF-kB 
is c-FLIP. This was first identified as a cellular homolog of viral FLIP (Thome et aL, 
1997) and can inhibit apoptosis by directly binding to F ADD and pro-caspase-8 via the 
DED (Irmler et aL, 1997). Thus inhibition o f NF-kB by AzaAR activation would also 
possibly sensitise cells to apoptosis. Sensitisation to apoptosis would be of great benefit in 
treating tumours, however it could also lead to undesirable side effects such as premature 
apoptosis of immune cells leading to an immunocompromised situation. However, it is 
important to note that NF-kB has recently been reported to actively repress anti-apoptotic 
gene expression when activated by UV-C and chemotherapeutic drugs such as 
daunorubicin. This inhibition is mediated by the association o f p65 with HDAC and 
therefore indicates that NF-kB can act both as a transcriptional activator or repressor 
dependent upon the manner in which it is induced (Campbell et aL, 2004).
In conclusion, adenosine released in the cellular response to stress, acting at the AzaAR 
can dramatically inhibit the pro-inflammatory response o f NF-kB via the activation of a 
distinct signalling mechanism, which can inhibit the phosphorylation of IicBa and the 
nuclear transloeation of NF-kB. This leads to the decrease in monocyte recruitment to 
sites of inflammation and therefore to a reduced leukocyte infiltration. This suggests that 
the A zaA R  may represent a good therapeutic target for the inhibition o f chronic 
inflammation in vivo. Further investigation is required however to determine where 
exactly within the NF-kB signalling pathway the AzAAR-mediated response has its effect. 
Results presented in this study suggest that this occurs at least in two places, i.e. at the
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level of nuelear transloeation and at the level of IKK activation. The differences may be 
cell-type specific or stimulus dependent and therefore a rigorous investigation of the 
AzAAR-mediated effects in further cell-types and with the same stimuli might help clarify 
the role of the A zaAR. Further investigations may also centre upon if  this effect is specific 
to a particular Rel family member and which specific genes are therefore affected. Finally 
it will be essential to understand what the functional consequences o f this are, not only 
with respect to inflammation but also with respect to apoptosis as this could potentially 
lead to severe side effects for any potential therapy.
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Appendix I
Calculation o f adenovirus titre 
Readings from plate
Virus dilution No. o f positive wells
10-4 10/10
10-6 10/10
10-7 10/10
10-8 9/10
10-9 3/10
10-10 0/10
10-11 0/10
In order to calculate the titre, the above results are fitted into the equation below:
The proportionate distance =
 % positive above 50%- 50%________
%positive above 50%- % positive below 50%
90% -50% = 0.67
90%-30%
Now log IDso (infectivity dose) =
Log dilution above 50% + (proportionate distance x ~1) x dilution factor 
.'. log IDso = -8 + (0.67 X -1 ) -8.76
IDso=10‘" ‘^
Now TCID50 (Tissue culture infectivity dose 50) = ________1_____
1 0 - 8.76
.•.TCID50 = 10 '^^  ^/ 100 pi X dilution factor (10) 
.•.TCID5o/ml= 10 -^^ ^
= 4.67 X  10^
Now 1 TCÎD50 = 0.7 pfu .'. final titre = 0.7 x 4.67 x 10^
= 3.27 X  10^ pfii/ml
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Appendix 2
Sample calculation for Bmax :
Bniax= 0.2102 nM
Since Molarity = Moles
Volume
Moles = Molarity (M) x Volume (L)
Moles = (0.2102 x 10‘ )^ x (250 x lO'*^ )
= 52.55 fmol
Actual protein cone. = 1.303 mg/ml (from protein assay)
14.7 (Dilution factor)
= 88.6 pg/ml
Since 0.15 ml o f membrane prep, was added per tube this makes total protein concentration 
per tube:
-  88.6 mg/ml x 0.15 ml/tube 
= 13.29 pg protein/tube 
.*. 52.55 fmol in 13.29 pg of protein = 52.55
13.29
= 3.95 fmoVpg (= pmol/ mg)
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Appendix 3
The Cheng-Prusoff Equation
Ki =  EC50_
1 + [Ligand]
Kd
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